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Introduction
Tissue	engineering	 is	a	growing	area	of	research	aiming	to	creates	scaffolds	or	constructs	to	
replace/	repair	damaged	tissue	or	organs.	Tissue	is	basically	composed	of	cells	and	extracellular	
matrix.	The	cells	are	surrounded	by	extracellular	matrix	components,	which	provide	specific	
signals	to	the	cells	with	regard	to	cellular	processes,	like	proliferation,	differentiation,	migration	
and	cell-matrix	interactions1, 2.	Since	cells	behave	differently	on	various	surfaces,	one	can	use	the	
surrounding	matrix	to	guide	cells	towards	a	certain	phenotype3, 4. Among the most important 
extracellular	 matrix	 components	 are	 collagen	 fibrils,	 elastic	 fibers,	 glycosaminoglycans	 and	
growth factors.
Table 1; Characteristics of elastin, collagen and glycosaminoglycans.
*  With strong variation in molecular structure within one molecule (HS: heparan sulfate, DS: dermatan 
sulfate, CS: chondroitin sulfate)5.  
# With some variation in size6.
Collagen
Collagen is the most abundant protein in the body making up about 30% of the body’s dry 
weight.	Over	29	different	types	of	collagen	have	been	identified,	types	I-V	being	quantitatively	
the most important6.	 In	 all	 organs,	 collagen	 forms	 the	basic	matrix	material,	 type	 I	 collagen	
being	the	main	fibrillar	collagen	of	bone,	tendon	and	skin.	The	type	I	collagen	is	a	rod	(1.5	x	300	
nm) with a molecular mass of about 300 kDa, 90% of all collagen is type I. Collagen has adhesive 
properties	and	its	degradation	products	have	chemotactic	characteristics7. 
Elastin    
Elastin	 is	a	highly	hydrophobic	protein	which	provides	elasticity	to	tissues	 like	skin,	 lung	and	
blood vessels8.	Tropoelastin	molecules	and	microfibrils	are	crosslinked	to	each	other,	forming	
elastic	fibers	which	can	stretch	to	several	times	their	normal	length9. The hydrophobic nature 
and	the	high	degree	of	crosslinking	make	elastic	fibers	resistant	to	proteolytic	degradation.	The	
physiological	turnover	of	elastin-fibers	is	very	slow	(the	half	life	time	in	humans	is	approximately	
70	years).	Elastin	interacts	with	specific	cell	surface	receptors	and	elastin-derived	peptides	are	
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1chemotactic	for	cells10.	Elastin	fibers,	however,	are	not	easily	synthesised	during	wound	healing	
and	regeneration11, 12.	Elastin	is	a	protein	which	provides	elasticity	to	tissues	and	therefore	has	
a	high	potential	in	the	field	of	tissue	regeneration13, 14. 
Glycosaminoglycans 
Glycosaminoglycans	 (GAGs)	 are	 long,	 linear	 and	 highly	 negatively	 charged	 polysaccharides	
which	 are	 covalently	 bound	 to	 core	 proteins	 (proteoglycans)	 in	 the	 extracellular	matrix	 and	
cell surfaces15. Based on their backbone structure, four major classes of GAGs are formed, viz. 
heparan	sulfate/heparin,	dermatan/chondroitin	sulfate,	keratan	sulfate	and	hyaluronate.	GAGs	
mediate	many	biological	 functions,	 in	part	by	their	capacity	to	bind	and	modulate	a	number	
of	proteins	 including	growth	 factors,	 cytokines,	 extracellular	matrix	proteins	and	proteases/
anti-proteases16.	These	interactions	are	essential	for	basic	cellular	processes	like	cell	adhesion,	
growth,	differentiation	and	activation.	This	implicates	a	major	role	for	GAGs	in	wound	healing,	
inflammation,	tissue	morphogenesis	and	homeostasis.	The	bio-characteristics	of	GAGs	make	
them	valuable	molecules	to	be	incorporated	into	tissue	engineered	constructs17.  GAGs can be 
incorporated	in	constructs	by	crosslinking	and	their	significance	in	angiogenesis	and	the	wound	
healing has been demonstrated18-20.
Growth factors
Growth factors are signal molecules that regulate many aspects of cell behaviour like growth, 
differentiation	and	survival.	Growth	factors	can	enhance	biological	processes	like	the	formation	
of	blood	vessels	 (e.g.	by	VEGF	 (vascular	endothelial	 growth	 factor)),	 and	 the	proliferation	of	
certain	types	of	cells	like	keratinocytes	by	FGF-7	(keratinocyte	growth	factor)	and	fibroblasts	by	
FGF-2	(basic	fibroblast	growth	factor)21.	The	extracellular	matrix	serves	as	a	reservoir	for	growth	
factors	protecting	 them	against	proteolytic	degradation.	Growth	 factors	 are	able	 to	bind	 to	
glycosaminoglycans and a sustained release enhances biological processes. Growth factors 
such	as	FGF2	and	VEGF	can	be	used	in	tissue	engineered	constructs	to	enhance	angiogenesis	
and	tissue	formation22, 23.
Scaffolds with defined molecular composition: isolation procedures and construction
Complex	 scaffolds	with	 a	 predefined	 composition	 can	 be	 prepared	when	purified	 individual	
components	 are	 available.	 Only	 in	 this	 way,	 one	 can	 systematically	 study	 the	 effect	 of	 the	
single	components	on	tissue	response	 in vivo.	 Insoluble	type	I	collagen	fibrils	can	be	purified	
from	bovine	 achilles	 tendon	 using	 extractions	with	 diluted	 acetic	 acid,	 NaCl,	 urea,	 acetone,	
and demineralised water24.	 Insoluble	 elastin	 fibres	 can	 be	 isolated	 from	equine	 ligamentum	
nuchae	using	extractions	with	NaCl,	organic	 solvents,	CNBr	 in	 formic	acid,	urea	with	diluted	
2-mercaptoethanol,	and	a	trypsin	digestion25.	Purity	and	fibril/fibre	structure	is	analyzed	by	SDS-
PAGE,	amino	acid	analysis,	transmission	electron	microscopy	(TEM),	and	SEM.	Using	isolations	
procedures,	the	collagen	fibrils	still	possess	their	characteristic	striated	banding	pattern24, and 
elastin	fibres	are	intact	and	free	of	microfibrils25. 
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Glycosaminoglycans	 (heparan	 sulfate	 from	 bovine	 kidney	 and	 chondroitin	 sulfate	 from	
bovine	 trachea)	 can	 be	 purified	 using	 papain	 digestion,	 alkaline	 borohydride	 treatment,	
diethylaminoethyl	cellulose	(DEAE)	ion-exchange	chromatography,	and	glycosidase	digestion26. 
Isolated glycosaminoglycans are characterized by agarose gel electrophoresis27	and	quantified	
using	a	modified	Farndale	assay28.	Growth	factors	are	produced	in	milligram	quantities	using	
recombinant	DNA	technology	and	purified	using	affinity	chromatography,	as	demonstrated	e.g.	
for vascular endothelial growth factor (VEGF)29	and	fibroblast	growth	factor	2	(FGF2)23. 
Crosslinking and covalent attachment of glycosaminoglycans
Crosslinking	 of	 scaffolds	 will	 make	 them	more	 resistant	 to	 degradation	 and	 increases	 their	
mechanical stability. A commonly used crosslinker is 1-ethyl-3-(3-dimethyl aminopropyl) 
carbodiimide	(EDC)	in	combination	with	N-hydroxysuccinimide	(NHS),	which	creates	zero-length	
crosslinks	introducing	only	an	amide	bond.	The	strength	of	the	scaffold	and	the	biodegradation	
can	be	varied	by	the	crosslinking	condition26, 30.  Glycosaminoglycans can be bound to lyophilized 
scaffolds	 in	 the	 crosslinking	 step,	 thereby	 covalently	 attaching	 them	 to	 the	 scaffold26. When 
crosslinking	 glycosaminoglycans,	 such	 as	 chondroitin	 sulfate,	 to	 collagen	 scaffolds,	 growth	
factors can be bound and modulated23 and also the water-binding capacity increases over 50%19. 
Binding of growth factors
Binding	of	growth	factors	is	often	modulated	by	glycosaminoglycans,	and	the	intrinsic	properties	
of	glycosaminoglycans	to	bind,	for	example,	heparin-binding	growth	factors	to	scaffolds	can	be	
exploited	in	scaffolds	for	tissue	engineering.	A	wide	variety	of	heparin-binding	growth	factors	is	
known,	for	instance	fibroblast	growth	factors	(FGFs),	vascular	endothelial	growth	factor	(VEGF),	
heparin-binding epidermal growth factor (hbEGF), placental growth factor (PlGF)17. When 
growth	factors	are	bound	to	the	scaffold	by	glycosaminoglycans,	a	more	sustained	release	is	
found23. 
Scaffolds with a specific three-dimensional structure
Beside	 the	 molecular	 make-up	 of	 the	 scaffolds,	 the	 3-dimensional	 architecture	 is	 of	 great	
importance31.	Cells	in	a	porous	bioscaffold	synthesize	extracellular	matrix	molecules	aligning	the	
structure	of	the	presented	scaffold	31.	This	opens	the	opportunity	to	influence	the	orientation	of	
the	newly	formed	extracellular	matrix.	
Compact films
For	certain	applications,	like	structural	support	for	epithelial	cells	(e.g.,	keratinocytes,	urothelial	
cells),	a	two-dimensional	structure	is	sufficient.	Epithelia	are	generally	only	one	or	a	few	cell	
layers	thick,	the	tightly	packed	cells	resting	on	a	basement	membrane,	containing	mostly	type	
IV collagen, heparan sulfate proteoglycan, and laminins32.	Compact	collagen	films	(Fig.	1A)	can	
be	prepared	by	air-drying	a	homogenized	and	de-aerated	collagen	suspension	in	diluted	acetic	
acid.	 The	 concentration	 of	 the	 collagen	 suspension	 increases	 when	 the	 solvent	 evaporates	
11
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1and	after	evaporation	a	transparent	film	layer	of	collagen	remains.	The	film	appears	dense	by	
scanning	electron	microscopy	(Fig.	1C).	For	application	in	skin,	for	example,	films	are	preferred	
over	highly	porous	scaffolds,	since	cultured	keratinocytes	may	infiltrate	these	scaffolds,	instead	
of	forming	multiple	cell	layers	on	top31 .
Figure 1. Macroscopic (A, B) and scanning electron microscopical images (C, D) of dense films (A, C) and 
porous scaffolds (B, D). Bar is 1 cm in A, B, and 100 µm in C, D 33. Figure reproduced from 33 with permission. 
12
Ch
ap
te
r
1
Porous scaffolds
Porous	scaffolds	are	suitable	for	tissues	where	ingrowth	of	cells	is	important	(Fig.	1B,	D).	Porous	
collagen	or	collagen-elastin	scaffolds	can	be	prepared	by	freezing	and	subsequently	lyophilizing	
a	 suspension	of	 collagen	and	elastin19.	More	 specifically,	a	 collagen	 (with	or	without	elastin)	
suspension	 in	 diluted	 acetic	 acid	 is	 applied	 to	 a	mould,	 frozen	 and	 lyophilized,	 resulting	 in	
porous	 scaffolds.	 The	 pore	 structure	 observed	 after	 freeze-drying	 resembles	 the	 ice	 crystal	
network formed during the freezing process. By varying the freezing temperature, and hence 
the	velocity	of	freezing,	the	pore	size	of	the	scaffolds	can	be	varied	to	some	degree31, 34. With 
faster	freezing,	smaller	ice	crystals	are	formed,	leading	to	a	scaffold	with	a	smaller	average	pore	
diameter.	In	Fig.	2,	scanning	electron	micrographs	of	scaffolds	are	shown	which	were	frozen	at	
three	different	temperatures.	The	largest	and	most	honeycomb-like	pores	were	formed	when	
freezing at -20°C. 
Figure 2. Scanning electron micrographs of porous collagen scaffolds prepared by freezing and lyophilisation 
of an acidic collagen suspension. Pore size can be influenced by the freezing temperature. Use of relatively 
high freezing temperature (-20°C), resulted in larger ice crystals compared to those obtained with lower 
freezing temperatures (-80 or -196°C). The insets in B and C show lamellae with interconnecting struts. Bars 
are 100 µm, bars in inserts are 20 µm. Figure reproduced from Faraj et al. 200731 with permission.  
Scaffolds for skin tissue engineering
The	construction	of	scaffolds	with	a	defined	morphology	and	molecular	composition	allows	the	
preparation	of	constructs	that	mimic	the	micro-environment	of	normal	tissue.	These	constructs	
are designed in such a way that they give the correct signals to the cells to migrate into the 
scaffold	and	regenerate	the	desired	tissue.	Due	to	the	defined	morphology	and	composition	the	
contribution	of	each	component	can	be	evaluated	in vitro and in vivo.	The	knowledge	acquired	
with this approach makes it possible to design and develop constructs to replace and/or repair 
tissue.	One	application	is	skin.
The skin, the largest organ of the body, is composed of two anatomical layers, each with a 
distinct	function.	The	upper	epidermal	layer	is	a	defence	against	bacteria	and	water	loss.	The	
dermal	layer	provides	protection	against	mechanical	trauma	and	gives	strength	and	elasticity	
to	the	skin.	Blood	vessels	in	the	dermal	layer	provide	nutrition	for	the	epidermis35.	After	skin	
damage	(like	a	trauma	or	burn	wound),	the	barrier	against	infection	and	fluid	loss	is	lost.	Any	
loss	of	 full-thickness	skin	of	more	than	4	cm	in	diameter	will	not	heal	well	without	a	graft36. 
13
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1Regeneration	 of	 the	 epidermis	 starts	 at	 the	 wound	 edges	 and	 from	 the	 remaining	 dermal	
appendages37.	In	full-thickness	wounds,	the	entire	epidermis	and	dermis	are	destructed,	leaving	
no residual epidermal cells for wound closure from underneath.
The	golden	standard	to	close	large	burn	wounds	is	still	transplantation	of	autologous	split	skin,	
i.e. the epidermal layer and the upper part of the dermis. However, this procedure has a number 
of	serious	drawbacks	including	the	limited	availability	of	donor	tissue	and	scarring	at	grafted	and	
donor	sites.	 Infection	is	also	a	complication,	whereas	contractures	and	hypertrophic	scarring	
cause	problems	after	healing38.	There	is	a	clear	need	for	new	strategies	to	treat	patients	with	
skin	damage.	Tissue	engineering/regenerative	medicine	may	offer	this	alternative.
Most	techniques	of	skin	tissue	engineering	rely	on	biocompatible	scaffolds	with	or	without	cells	
to	achieve	tissue	formation.	Ideally,	scaffolds	should	guide	the	cells	to	initiate	the	restoration	of	
essential	functions	of	the	damaged	tissue,	which	may	be	achieved	by	signals	that	sustain	cellular	
growth,	migration	and	differentiation39, 40.	Current	biomaterials	are	not	optimal,	because	they	
often	need	a	 two	 stage	operation	procedure	 (e.g.	 IntegraDRT)41, 42	 and	 still	 result	 in	 scarring	
and	contractures.	 In	addition,	they	are	poorly	characterised	with	respect	to	the	components	
present,	 and	 this	 seriously	 hinders	 the	 identification	of	 the	 biological	 relevant	molecules	 to	
achieve good wound healing.
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Aim and outline of this thesis
The	ultimate	goal	in	tissue	engineering	is	to	make	constructs	that	mimick	healthy	tissue	or	can	
induce	cells	to	make	functional	tissue.	The	aim	of	this	thesis	is	to	develop,	prepare	and	evaluate	
a	new	molecularly-defined	skin	construct	that	mimicks	the	micro-environment.	It	is	important	
to	 use	 highly	 purified	 components	 to	 reduce	 the	 foreign	 body	 reaction	 and	 control	 the	
regeneration	process.	From	the	basic	components,	type	I	collagen,	elastin,	glycosaminoglycans	
and	growth	factors,	tailor-made	biomaterials	can	be	produced.	In	this	thesis,	a	highly	complex	
skin	scaffold	for	full-thickness	wounds	was	developed,	analyzed	and	evaluated.	
In	chapter	1,	the	concept	of	molecularly-defined	scaffolds	mimicking	the	micro-environment	is	
introduced.	In	chapter	2,	the	expression,	purification	and	analysis	of	the	biological	activity	of	
recombinant rat VEGF-164 is shown, as produced by Pichia pastoris in a fermentor. Using the 
fermentor	procedure,	it	is	possible	to	produce	large	amounts	of	VEGF-164.	The	tissue	response	
of	scaffolds	composed	of	type	I	collagen-insoluble	elastin	fibers	and	type	I	collagen-solubilised	
elastin	in	an	subcutaneous	rat	model	are	described	in	chapter	3	and	4,	respectively.	In	chapter	
5,	type	I	collagen	and	type	I	collagen-heparin	scaffolds	with	or	without	FGF-2	and/or	VEGF	were	
assessed	 in	a	subcutaneous	rat	model	with	specific	 focus	on	blood	vessel	 formation.	Finally,	
results from this research were combined to design and create a double-layered skin construct 
of	type	I	collagen,	solubilised	elastin,	heparin,	dermatan	sulfate,	FGF-7,	FGF-2	and	VEGF.	This	
complex	scaffold	was	analyzed	in	a	rat	acute	wound	model	and	compared	to	no	treatment	and	
the	commercial	IntegraDRT	(chapter	6).	Finally,	a	summary	of	the	studies	and	future	directions	
are given in chapter 7.
15
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Abstract
Large-scale	 production	of	 recombinant	 rat	 vascular	 endothelial	 growth	 factor	 (rrVEGF-164)	 is	 
desirable	 for	 angiogenic	 studies.	 In	 this	 study,	 biologically	 active	 recombinant	 rat	 vascular	 
endothelial	growth	factor	(rrVEGF-164)	was	cloned	and	expressed	in	the	yeast	Pichia	pastoris,	and	
large-scale	production	was	performed	by	fermentation.	cDNA	encoding	VEGF-164	was	prepared	
from	embryonic	rat	tissue	RNA,	and	a	recombinant	pPIC9HV/rVEGF-164	plasmid,	containing	an	
AOX1	promoter,	was	 constructed.	 The	methylotrophic	 P.	 pastoris	was	 used	 as	 the	 eukaryotic	 
expression	 system.	 After	 transformation,	 rrVEGF-	 164	 was	 produced	 by	 fermentation	 (≈124	
mg/L)	and	purified	by	heparin	affinity	chromatography.	SDS–PAGE	indicated	that	rrVEGF-164	was	
produced	as	a	disulphide-bridged	dimer	of	48	kDa	which	was	purified	 to	near	homogeneity	by	 
heparin	 affinity	 chromatography	 in	 a	 large	 quantity.	 A	 bioassay	 indicated	 a	 three-	 to	 fivefold	 
increase	 in	 endothelial	 cell	 proliferation	 after	 3	 days,	 due	 to	 the	 addition	 of	 the	 produced	
rrVEGF-164.	The	produced	rrVEGF-164	showed	a	higher	biological	activity	than	a	commercially	
available,	mouse	cell	 line-based,	growth	 factor.	 In	conclusion,	using	 the	P.	pastoris	expression	
system	we	were	able	to	produce	biologically	active	rat	VEGF-164	in	high	quantities	and	this	may	
provide a powerful tool for basic and applied life sciences.
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Introduction
Vascular endothelial growth factor (VEGF)2 is one of the most celebrated mediators in the 
process	of	angiogenesis.	VEGF	 is	a	hypoxia-	 inducible	protein	 that	promotes	 the	proliferation	
and survival of vascular endothelial cells1.	At	 least	five	different	rat	VEGF	alternatively	spliced	 
isoforms	have	been	identified	originating	from	a	single	VEGF	pre-mRNA:	VEGF-120,	-144,	-164,	
-188 and -2052–4. These isoforms resemble the human VEGF isoforms (VEGF-121, - 145, -165, 
-189	and	-206)	and	differ	in	length	from	them	by	one	amino	acid.	VEGF	is	only	active	in	its	dimeric	
form5,6.	All	rat	VEGF	isoforms	are	mitogenic	to	vascular	endothelial	cells	and	induce	permeabilisation	
of blood vessels7. VEGF-164, VEGF-188 and VEGF- 205 are able to bind heparin7–9. VEGF-164 
binds	to	the	VEGF	receptor	(VEGFR)	present	on	endothelial	cells,	stimulating	the	production	of	
matrix	metalloproteinases	(MMPs).	MMPs	degrade	the	basement	membrane,	allowing	proliferation	
and	migration	of	endothelial	cells	towards	the	interstitium,	so-called	sprouting.	Subsequently,	peri-
cytes	proliferate	and	migrate	towards	the	newly	formed	sprouts	and	induce	maturation	by	forming	
a layer around the sprout10,11.	Large-scale	production	and	purification	of	rat	VEGF-164	is	desirable	
for	angiogenic	studies	in	vitro	and	in	vivo,	especially	in	rat	animal	models	for	tissue	engineering	
in which enhanced angiogenesis is an issue. Since the source of natural (rat) growth factors is 
limited,	attempts	have	been	made	to	produce	growth	factors	on		a	large-scale	by	recombinant	
DNA technology. Growth factors have been produced in Escherichia coli and have played an impor-
tant role in basic research of rat angiogenesis12,13.	E.	coli	is	a	prokaryote	and	its	intrinsic	characteristics	 
such	 as	 protein	 processing,	 protein	 folding,	 and	 post	 translational	modifications,	 differ	 from	
those of eukaryotes. In E. coli, dimeric growth factors such as VEGF are produced as a monomer 
and	need	to	be	dimerised	after	production.	The	Pichia	pastoris	yeast	expression	system	allows	
correct		folding	of	dimeric	proteins	in	addition	to	efficient	expression,	intact	secretion,	large-scale	
production,	and	stable	genetics14,15.	Human	VEGF	has	been	efficiently	expressed	in	P.	pastoris16. 
Expression	of	biologically	active	rat	VEGF	in	P.	pastoris,	however,	has	–	to	our	knowledge	–	never	
been published. 
In	this	study,	rrVEGF-164	was	inserted	into	the	pPIC9HV	expression	vector	and	transfected	into	
the	P.	pastoris	yeast	cells.	 rrVEGF-164	was	secreted	 in	 large	quantities,	purified	using	heparin	 
affinity	chromatography,	and	 its	biological	activity	was	studied	 in	vitro	using	human	umbilical	
vein endothelial cell (HUVECs).
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Materials and Methods
Materials
Unless stated otherwise, all materials were from Merck (Darmstadt, Germany). The VEGF 
upstream (50-GTA GAA TTC GCA CCC ACG ACA GAA GG-30) and VEGF downstream (50-TAT GCG 
GCC	GCT	CAC	CGC	CTT	GGC	TTG	T-30)	primer	containing	EcoRI	and	NotI	restriction	sites	were	
synthesised	by	 Isogen	Biosciences	BV	 (Maarssen,The	Netherlands).	 The	P.	pastoris	 expression	
vector pPIC9 and P. pastoris host strain GS115 were purchased from Invitrogen Corp. (Carlsbad, 
CA,	USA).	The	commercial	rrVEGF-164,	produced	in	a	mouse	myeloma	cell	 line	(R&D	Systems,	
Minneapolis,	MN,	USA)	was	used	as	a	positive	control	and	for	reference.	
LB-medium	consisted	per	litre	of:	10	g	NaCl,	10	g	peptone	(Gibco	BRL),	5	g	yeast	extract	(Difco	
Laboratories, Detroit, MI, USA), containing 10 g glucose and 0.1 g ampicillin (Sigma Chemical Co., 
St.	Louis,	MO,	USA).
Buffered Glycerol-complex Medium (BMGY) containing glycerol as the carbon source, consisted 
per	litre	of:	10	g	yeast	extract,	20	g	peptone,	21.2	g	potassium	sulphate	(pH	6.0),	13.4	g	yeast	
nitrogen	base	(YNB)	(Sigma),	0.4	mg	biotin	and	10	ml	glycerol.
Buffered Methanol-complex Medium (BMMY)	 is	 similar	 to	 BMGY,	 but	 with	 5	 ml	 methanol	 
instead of glycerol. Basal saltsmedium(BSM) consisted per litre of: 26.7mL phosphoric acid, 
1.18	g	calcium	sulphate•2H2O,	18.2	g	potassium	sulphate,	14.9	g	magnesium	sulphate•7H2O,	
4.1	g	potassium	hydroxide	and	40	ml	glycerol.
PTM1 trace salts (Invitrogen)	consisted	per	litre	of:	5	ml	sulphuric	acid,	6	g	cupric	sulphate•5H2O,	
0.08	g	sodium	iodide,	3	g	manganese	sulphate•H2O,	0.2	g	sodium	molybdate•2H2O,	0.02	g	boric	
acid,	0.5	g	cobalt	chloride,	20	g	zinc	chloride,	65	g	ferrous	sulphate	•7H2O,	and	0.2	g	biotin.
YPD-medium	consisted	per	litre	of:	10	g	yeast	extract,	20	g	peptone,	20	g	D-glucose,	with	100,000	
U penicillin and 0.1 g streptomycin (Gibco BRL, Carlsbad, Ca, USA).
YNB dropout plates	 consisted	per	 litre	of:	6.7	g	YNB,	1.92	g	 yeast	 synthetic	dropout	medium	
supplement (Sigma), 20 g glucose and 20 g agar (Gibco BRL).
TYE agar plates	consisted	per	litre	of:	8	g	NaCl,	10	g	peptone,	5	g	yeast	extract,	15	g	agar	(Gibco	
BRL), 10 g glucose and 100 g ampicillin (Sigma).
Preparation of rat VEGF-164 cDNA
Total	RNA	was	isolated	from	Rattus	norvegicus	embryonic	tissue	(17	days	post-conception)	using	
the	SV	Total	RNA	Isolation	System	(Promega,	Madison,	WI,	USA).	After	denaturation	(10	min	at	
65 °C)	of	the	total	RNA	(≈0.5	µg),	cDNA	(≈0.4	µg)	was	synthesised	using	hexanucleotide	primers.	
A	reverse	transcriptase	reaction	was	performed	for	90	min	at	37	oC	using	the	following	reaction	
mixture;	200	U	reverse	transcriptase	(Promega)	in	50	mM	Tris–HCl	(pH	8.3)	containing	75	mM	
KCl,	3	mM	MgCl2	[M-MLV	Reversed	Transcriptase	buffer	(Gibco	BRL,	Gaithersburg,	MD,	USA)],	
1	mM	deoxynucleoside	 triphosphates	 (dNTPs)	and	10	mM	DTT	 (Gibco	BRL)	 in	a	 total	 volume	
of 20 µL.	PCR	fragments	of	the	full-length	cDNA	were	prepared	with	10	mM	Tris–HCl	(pH	8.3)	
containing 50 mM KCl, 1.5 mM MgCl2, 100 µM dNTPs, 20 µM	rrVEGF-164	primers	and	1	U	Taq	
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polymerase (Promega) in a total volume of 50 µL.	The	PCR	was	performed	on	a	Peltier	Thermal	
Cycler (PTC-200; MJ Research and Biozym, Landgraaf, The Netherlands), with a 30 cycles program 
(95 °C for 60 s, 65 °C for 60 s, 72 °C	for	90	s	and	extension	at	72	°C for 5 min). The rrVEGF-164 
cDNA	was	isolated	from	a	2%	(w/v)	agarose	gel	and	purified	with	a	QIAEX	II	gel	extraction	system	
(QIAGEN, Hilden, Germany). The SMART-ladder marker (Eurogentec Seraing, Belgium) was used 
to	estimate	the	sizes	of	the	PCR	products.
Construction of expression vector
The	purified	cDNA	was	subcloned	into	the	vector	pPIC9HV	(J.M.H.	Raats,	Dept.	of	Biochemical	
Chemistry, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, unpub-
lished	data	(pPIC9	expression	plasmid	was	obtained	from	Invitrogen))	after	digestion	with	EcoRI	
and	NotI	 (Invitrogen)	 in	 the	presence	of	1x	React®	3	buffer	 (Gibco	BRL)	 for	1	h	at	37	°C. The 
pPIC9HV is similar to the original pPIC9 vector17,18,	but	contains	a	polyhistidine	and	VSV	tag	for	
detection	and		purification.	The	rrVEGF-164	insert	was	ligated	into	pPIC9HV	vector	DNA	using	T4	
ligase	(Gibco	BRL)	in	T4	ligase	buffer	(Gibco	BRL)	for	24	h	at	16	°C. The host strain E. coli (supE44 
DlacU169 (a80lacZDM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1) was transformed with the 
expression	vector	by	heat-shock	(45	s	at	42	°C). The E. coli cells were incubated for 1 h at 37 °C 
in	LB-medium.	After	1	min	of	centrifugation	at	14,000g,	the	transformed	E.	coli	cells	were	ap-
plied	to	a	TYE	agar	plates	and	incubated	for	24	h	at	37	°C.	The	rrVEGF-164	positive	transformants	
were	selected	by	means	of	ampicillin	antibiotic	resistance	due	to	the	presence	of	ampicillin	resis-
tance	gene	(AMP)	in	the	Pichia	expression	vector.	Ampicillin	resistant	E.	coli	ransformants	were	
selected	and	suspended	in	LB-medium.	After	24	h	incubation	at	37	°C at 200 rpm in an orbital 
shaker, the suspension was centrifuged for 1 min at 14,000g. Plasmid DNA was isolated using the 
QIAprep	spin	miniprep	kit	(QIAGEN)	according	to	the	manufacturer’s	instructions,	and	positive	
transformants	were	 identified	by	automated	 sequencing	using	 an	a-factor	primer	 (50-ACTAC-
TATTGCCAGCATTGCTGCT-30)	at	the	DNA	Sequencing	Facility,	Dept.	of	Human	Genetics,	Radboud	
University Nijmegen Medical Centre, The Netherlands.
Transformation into P. pastoris yeast cells
Pichia	pastoris	GS115	cells	were	grown	in	100	ml	YPD-medium	overnight	at	30	°C at 200 rpm in 
an	orbital	shaker,	until	an	OD600	of	1.5	was	reached,	which	corresponds	to	a	cell	density	of	ap-
proximately	109	cells/ml.	Competent	GS115	cells	were	freshly	prepared	before	transformation	
by	 consecutive	washings	with	 ice-cold	 sterile	MilliQ	water	 and	1	M	 sorbitol	 according	 to	 the	
Invitrogen	manual.	The	DNA	was	linearised	by	digesting	10	µg of plasmid DNA with SalI. Subse-
quently,	the	linearised	DNA	was	purified	using	the	QIAGEN	PCR	cleanup	kit.	To	transform	the	P.	
pastoris	yeast	cells	with	the	expression	vector,	cells	were	resuspended	in	1	M	sorbitol	on	ice,	and	
80 µL of competent cells were electroporated by means of pulse discharges (1.5 kV, 25 µF,	400	X,	
Bio-Rad Gene Pulser, CA, USA) for 9 ms in the presence of 10 µg linearised plasmid DNA (20 µL). 
After		electroporation,	cells	were	put	on	ice	for	5	min,	10x	diluted	in	1	M	sorbitol	and	incubated	for	
1 h at 30 °C	(without	shaking).	Cells	were	spread	on	YNB	dropout	plates	and	incubated	at	30	°C. 
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The	plasmid	contains	the	His4	gene	(encoding	histidinol	dehydrogenase)	which	initiates	the	yeast	
cell	to	synthesise	histidine	(His+).	Therefore,	only	positive	transformants	can	grow	on	the	histidine	
deficient	plates	(YNB	dropout	plates),	which	can	be	used	for	positive	clone	selection19.	After	2	
days	of	culturing,	the	positive	transformants	were	counted,	picked,	and	streaked	on	new	dropout	
plates.	After	a	45	h	incubation	at	30	°C,	single	colonies	were	picked	and	cultured	in	a	baffled	flask	
containing	25	ml	BMGY-medium	for	an	overnight	period	at	30	°C at 200 rpm in an orbital shaker. 
To store the cultures, frozen stocks were prepared by adding 60% (v/v) glycerol (0.5 ml) to the 
P.	pastoris	recombinants	in	YPD-medium	(0.5	ml)	and	freezing	at		-80	°C.
Expression screening of rrVEGF-164
To	 analyse	 the	 expression	 levels	 of	 the	 constructed	 transformants,	 a	 small-scale	 expression	
screening	was	performed	using	a	fast	induction	method	with	methanol.	His+	transformants	were	
picked	and	added	to	15	ml	BMGY-medium,	and	cultured	 in	200	ml	baffled	flasks	overnight	at	
30 °C,	200	rpm	in	an	orbital	shaker.	To	induce	production	of	rrVEGF-164,	cells	were	centrifuged	
(1500g, 4 °C,	 10	min)	 and	 resuspended	 in	 BMMY-medium	 containing	 25%	 (v/v)	methanol	 as	
the major carbon source. Cells were incubated for 2 days at 30 °C, 200 rpm in an orbital shaker. 
After	centrifugation	(1500g,	4	°C, 10 min), the secreted rrVEGF-164 was concentrated from the 
supernatant by adding 50 µl heparin-acryl beads (Sigma Chemical Co.) to 1 ml supernatant, 
and	incubation	for	1	h	at	21	°C	under	rotating	conditions.	Heparin	beads	were	concentrated	by	 
centrifugation	(1500g,	4	°C,	10	min)	and	analysed	using	SDS–PAGE	and	Western	blotting	analysis	
as described below. 
Large-scale production of rrVEGF-164
For	large-scale	rrVEGF-164	production,	a	1	L	baffled	flask	with	200	ml	YNB-medium	was	inoculated	
with	 1	ml	 thawed	P.	 pastoris	 host	 strain	GS115	 containing	 the	 rrVEGF-164	expression	 vector.	
An overnight culture was incubated at 30 °C	at	200	rpm	in	an	orbital	shaker	until	an	OD600	of	 
approximately	6	was	reached.	The	Bioflo®3000	fermentor	(New	Brunswick	Scientific,	Edison,	NJ,	
USA), containing 2 L of basal salts medium, was sterilised by autoclaving for 45 min at 121 °C. 
After	 autoclaving,	 4.35	 ml/L	 PTM1	 trace	 salts	 (Sigma)	 were	 added	 aseptically	 to	 the	 initial	 
fermentation	volume.	Ammonium	hydroxide	(28%	(w/v),	Sigma)	was	used	as	a	nitrogen	source	
and	to	increase	the	pH	during	the	fermentation	process.	The	200	ml	inoculum	was	transferred	
into	 the	 fermentor	 after	 setting	 the	 dissolved	 oxygen	 (DO)	 at	 100%,	 the	 pH	 at	 6.0	 and	 the	 
temperature at 30 °C.	Anti-foam	solution	289	(Sigma)	diluted	1:500	in	MilliQ	water	was	used	to	
reduce	foam	production	during	fermentation.	Yeast	cells	use	oxygen	for	oxidative	metabolism	of	
glycerol.	When	glycerol	is	consumed	the	need	for	oxygen	declines	and	as	a	consequence	the	DO	
rises.	After	approximately	24	h	of	batch	culture,	the	glycerol	was	completely	consumed	which	
was	indicated	by	a	sharp	rise	in	DO	(up	to	70%,	see	Fig.	4).	The	5	h	glycerol	fedbatch	was	started	
by feeding 50% (v/v) glycerol containing  12 ml/L PTM1 trace salts with feed rate of 18.15 ml/L/h. 
After	the	glycerol	was	used	(DO	of	≈100%),	the	methanol	feed	(100%	(v/v)	methanol	(Labscan)	
with	12	ml/L	PTM1	trace	salts)	was	started	to	fully	induce	the	AOX1	promoter	of	the	expression	
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system.	During	the	methanol	feed,	DO	decreased	rapidly	from	≈100%	to	30%	and	was	continued	
at 30% for another 30 h. The culture was then harvested and centrifuged (20 min at 5000g). 
The	supernatant	was	filtered	using	a	0.45	lm	cellulose	acetate	membrane	filter	(Schleicher	and	
Schuell,	Dassel,	Germany)	and	dialysed	against	10	mM	phosphate	buffered	saline	(pH	7.4).	
Purification and identification of rrVEGF-164 
For	purification	of	rrVEGF-164,	the	dialysed	supernatant	(300	ml)	was	1:1	diluted	with	10	mM	
phosphate	buffer	(PB)	containing	0.2	M	NaCl	and	adjusted	to	pH	7.0	with	1	M	Na2HPO4.	The	so-
lution	was	subjected	to	fast	protein	liquid	chromatography	(FPLC),	using	a	5	ml	heparin-Sepharose	
HiTrapTM column (Amersham Biosciences, Stockholm, Sweden). The rrVEGF-164 was eluted 
with 1 M NaCl in 10 mM PB (pH 7.0) for 20 min, followed by 2 M NaCl in 10 mM PB (pH 7.0) for 
20	min	at	2.5	ml/min	for	both	solutions	(see	Fig.	5).	Five	fractions	(2.5	ml/fraction)	with	highest	
A280 absorbance were collected, pooled and directly frozen at -80 °C. 
Purity	 and	 dimer	 formation	 were	 evaluated	 by	 sodium	 dodecyl	 sulphate	 polyacrylamide	 gel	 
electrophoresis	(SDS–PAGE;	15%	(w/v);	Serva	GmbH,	Frankfurt,	Germany)20.
Briefly,	the	supernatant	was	diluted	1:1	with	sample	buffer	with		and	without	5%	(v/v)	b-mer-
captoethanol	(with	and	without	reducing	conditions)	and	denatured	for	5	min	at	95	°C. Then 10 
µl (±0.6 µg) of denatured rrVEGF-164 was loaded on the gel and was visualised by Coomassie 
brilliant	blue	(0.1%	(w/v))	staining	or	further	identified	by	Western	blotting	using	goat	anti-rat	
VEGF	antibody	(1:1000)	(R&D	Systems)21.	The	amount	of	purified	rrVEGF-164	was	determined	by	
a Lowry analysis using bovine serum albumin (BSA) as a standard22.
Biological activity of produced rrVEGF-164 
Human umbilical vein endothelial cells (HUVECs, ATCC, CRL- 1730, Rockville, MD, USA) were 
grown in F12K medium (Gibco BRL) with 20% (v/v) fetal calf serum (FCS), 1.5 % (w/v) calf brain 
extract	 (as	 a	 source	 for	 endothelial	 cell	 growth	 factor	 (ECGF)),	 0.14	mg/ml	heparin,	 200	mM	
L-glutamine, 100 U/ml penicillin and 100 µg/ml	 streptomycin	 (Gibco	 BRL).	 After	 coating	 the	 
96-	wells	plate	with	1%	(v/v)	gelatine,	4000	cells	were	seeded	per	well	and	these	were	left	to	
attach	overnight	in	the	medium	mentioned	above	without	ECGF.	Next,	medium	was	replaced	by	
F12K	medium	without	ECGF	and	0–100	ng/ml	rrVEGF-164	was	added.	A	cell	proliferation	assay	
(WST-1,	Roche,	Mannheim,	Germany),	based	on	the	reduction	of	a	tetrazolium	salt	to	formazan	
by	mitochondrial	dehydrogenases	in	viable	cells,	was	used	to	determine	the	relative	number	of	
cells at day 1 and 323.	Proliferation	of	cells	in	medium	without	VEGF	was	set	to	100%.	A	Student’s	
t-test	was	used	for	statistical	analyses	and	p	<	0.05	was	considered	statistically	significant.
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Fig. 1. Agarose gel electrophoresis of PCR products. (A) Ethidium bromide-stained agarose gel shows in lane 1: 
DNA marker, lane 2: PCR products after amplification using VEGF specific primers, indicating three VEGF splice 
variants, VEGF-188 (564 bp), VEGF-164 (492 bp) and VEGF-120 (360 bp). (B) Lane 1: DNA marker, lane 2: the 
rrVEGF-164 insert (492 bp) and in lane 3 the pPIC9HV vector (8580 bp). 
Fig. 2. Map of the rrVEGF-164 expression vector based on the pPIC9HV vector. MCS: multiple cloning site. The 
a-factor directs VEGF to the secretory pathway. EcoRI and NotI restriction sites were used to insert rrVEGF-164 
into the multiple cloning site. The ampicillin resistance gene (AMP) was used for E. coli transformant selection. 
The histidine independent gene (His4) allows growth in the absence of histidine, and was used for P. pastoris 
transformant selection. The SalI restriction site was used to inactivate the His4 gene and only a successful ligation 
results in an intact His4 gene.
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Fig. 3. Nucleotide sequence and the deduced amino acid sequence of the relevant part of P. pastoris rrVEGF-164 
expression vector, indicating a-Factor Signal Sequence, the EcoRI restriction site, the rVEGF-164 insert, the NotI 
restriction site and the polyhistidine-VSV tag. A stop codon was positioned between rVEGF-164 and NotI in order 
to produce VEGF without tags. The a-factor signal, the rVEGF-164, and the His/VSV tag are indicated by boxes. 
The a-factor primer is also indicated.
Results and discussion
Preparation of rat VEGF-164 cDNA
Total	RNA	was	 isolated	 from	embryonic	R.	norvegicus	tissue	and	 transcribed	 into	cDNA	using	
random	hexanucleotide	primers.	After	amplification	with	VEGF	specific	primers,	PCR	products	
were separated on agarose gel, and three VEGF splice variants (VEGF-188 (564 bp), VEGF-
164	(492	bp)	and	VEGF-120	(360	bp))	could	be	identified	on	the	basis	of	their	molecular	mass	 
(Fig.	1A).	The	492	bp	fragment	was	extracted	from	the	gel,	and	reamplified.	This	fragment	and	
the	pPIC9HV	vector	were	cut	with	EcoRI	and	NotI	and	put	on	an	agarose	gel	for	isolation	and	for	
further	ligation		(Fig.	1B).
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Construction of expression vector
After	 EcoRI	 and	 NotI	 digestion,	 purification	 and	 ligation,	 the	 resulting	 pPIC9HV-rrVEGF-164	 
expression	vector	(Fig.	2)	was	transformed	into	E.	coli.	Positive	clones	were	selected	by	means		of	
ampicillin	resistance.	Eight	of	64	colonies	able	to	grow	on	ampicillin	plates	were	sequenced.	After	
verifying	the	nucleotide	sequence	of	the	insert	using	DNA	sequencing	(Fig.	3)	and	a	subsequent	
BLAST	search,	one	colony	was	found	identical	with	seven	rrVEGF-164	sequences	published.	The	
nucleotide	sequence	encoding	the	rrVEGF-164	(Genbank	reference	GQ423618)	showed	a	100%	
homology	with	 the	 nucleotide	 sequence	 of	 rrVEGF-164	 published	 by	 Conn	 et	 al.24 (Genbank 
reference AAA41211) and Strausberg et al.25	(Genbank	reference	AAI68708).	Cloning	and	production	
of	rat	VEGF-164	After	isolation	and	linearisation	of	the	plasmid	DNA	of	the	positive	clone	with	
SalI, the competent P. pastoris GS115 cells were transformed with plasmid DNA by means of 
electroporation.	The	transformants	were	cultured	 in	 the	absence	of	histidine	and	six	colonies	
were	picked	and	examined	for	rrVEGF-164	production.	Western	blot	analyses	indicated	that	four	
of	the	six	clones	produced	rrVEGF-164	(data	not	shown).
Fig. 4. Profile of fermentation process describing the % methanol feed, pH, % dissolved oxygen level and % 
glycerol feed in time (hours). In the culture phase a biomass of yeast cells was formed. In the fed-batch phase 
glycerol was accumulated in the yeast cells as a major carbon source. In the induction phase the VEGF-164 
production was induced with methanol. 
Purification and identification of rrVEGF-164
From	the	small	production	screening	one	clone	with	a	strong	band	on	Western	blot	was	selected	 
and	used	 for	 large-scale	production.	After	 the	 fermentor	 run,	 the	bulk	cell	mass	was	separated	
from	 the	 supernatant	 and	 the	 expressed	 rrVEGF-164	 was	 purified	 from	 the	 supernatant.	 
Because	rrVEGF-164	is	a	heparin-binding		protein,	the	expressed	product	was	purified	with	a	hep-
arin	column.	The	rrVEGF-164	was	present	in	the	1	M	NaCl	elution	peak	(Fig.	5).	The	rrVEGF-164	 
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content	 in	the	pooled	peak	fractions	was	≈124	mg/L	as	determined	by	Lowry	protein	assay22. 
Using	non-reducing	 conditions,	 SDS–PAGE	 showed	one	broad	band	of	 about	 48	 kDa	 (dimer),	
whereas	under	reducing	conditions	a	main	band	of	about	24	kDa	band	(monomer)	was	observed	
(Fig.	 6A).	 It	was	 to	be	expected	 that	on	a	 SDS–PAGE	gel	 dimeric	 and	monomeric	 rrVEGF-164	
migrate	at	45	kDa	and	23	kDa,	respectively26.	Western	blot	analysis	using	an	anti-rat	VEGF-164	
antibody	 further	 indicated	 that	 the	 protein	 was	 rat	 VEGF-164	 (Fig.	 6B).	 Under	 non-reducing	 
conditions,	 the	expressed	 rrVEGF-164	existed	 in	 the	biologically	active	 form	of	a	homodimer.	
Dimers	of	VEGF	are	disulphide-bridged,	which	is	essential	for	the	biological	activity	of	VEGF-1645. 
These data indicate that rrVEGF-164 is produced as a disulphide-bridged dimer which can be 
purified	to	near	homogeneity	by	heparin	affinity	chromatography.
Fig. 5. FPLC flow chart of the 
purification of rrVEGF-164 by 
heparin affinity chromatography. 
In green the elution buffers are 
indicated; viz. 10 mM phosphate 
buffer (pH 7.0) containing 1 M 
NaCl or 2 M NaCl. The Y-axis 
indicates absorbance λ = 280 
nm expressed in arbitrary units 
(AU). On the X-axis, the collected 
fractions (each containing 2 ml) 
are represented by the vertical 
dashed lines. (For interpretation 
of the references to colour in 
this figure legend, the reader is 
referred to the web version).
Biological activity of produced rrVEGF-164
The	biological	activity	of	the	purified	rrVEGF-164	was	determined	by	a	WST-1	proliferation	assay	
using	human	endothelial	cells	(HUVECs).	HUVECs	are	generally	used	to	evaluate	the	activity	of	
VEGF from various species16,27.	Already	after	1	day,	the	25	ng/ml	content	resulted	in	a	threefold	
increase	in	proliferation	compared	to	medium	without	added	VEGF	(Fig.	7A).	After	3	days,	the	
amount	of	proliferation	at	content	of	12.5–25	ng/ml	showed	a	three-	to	fivefold	increase	(Fig.	7B).	
We also compared our produced Pichia VEGF with commercial rrVEGF-164 which is produced in 
a	mouse	myeloma	cell	line.	At	amounts	of	12.5–100	ng/ml,	the	produced	rrVEGF-164	showed	
a	significantly	higher	proliferation	than	the	commercial	batch	of	rrVEGF-164	(p	<	0.05;	Fig.	7A	
and	B).	The	difference	in	activity	for	the	commercial	VEGF	and	our	Pichia-derived	VEGF	might	be	
due	to	the	presence	of	inactive	forms	as	influenced	by	the	production	method.	Until	now,	both	
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Fig. 6. Analysis of produced 
rrVEGF-164 by SDS–PAGE 
and Western blot analysis. 
(A) Coomassie brilliant blue 
staining; lane 1: markers; 
lane 2: rrVEGF-164 under 
non-reducing conditions 
(about 48 kDa); lane 3: 
rrVEGF-164 under reducing 
conditions (about 24 kDa). (B) 
Western blot analysis of the 
produced rrVEGF-164; lane 1: 
markers; lane 2: rrVEGF-164 
under non-reducing condi-
tions (about 48 kDa); lane 3: 
rrVEGF-164 under reducing 
conditions (about 24 kDa). 
(A) and (B) are both com-
posite images of VEGF-164 
monomer and dimer prod-
ucts, taken from separate 
reducing and non-reducing 
gels, respectively.
Fig. 7. Biological activity of the produced 
rrVEGF-164 and commercially available 
rrVEGF-164 analysed using a WST-1 assay. 
(A) Proliferation after 1 day of culture. (B) 
Proliferation after 3 days of culture. The 
proliferation without added VEGF was set 
to 100%. Results are means ± SD for three 
separate experiments. All values were 
significantly increased compared to the 
control values. * indicates p < 0.05 when 
comparing produced and commercial 
rrVEGF-164.
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mouse myeloma cell lines and E. coli have been used to produce rrVEGF- 164 commercially. The 
myeloma	and	E.	coli	production	methods	can	result	in	heterogeneity	of	molecules	with	variable	
biological	 activities28.	 Additionally,	 for	 E.	 coli	 the	 expressed	 product	 is	 present	 in	 inclusion	
bodies	 and	 in	 order	 to	 be	 active	 the	 protein	must	 be	 refolded	 (dimerised)	 after	 purification.	
For rrVEGF-164 produced in P. pastoris, the protein has already been processed, including 
disulphide-linked	dimers,	before	secretion	into	the	cell	medium.	This	preprocessing	can	result	in	
a	potentially	more	homogeneous,	more	highly	active	population	of	the	product.	
Conclusions
In	this	study,	we	have	cloned	and	expressed	biologically	active	recombinant	rat	vascular	 
endothelial growth factor (rrVEGF-164) in the yeast P. pastoris. Recombinant rat VEGF-164 was 
successfully	produced	as	an	active	dimer	in	a	large	quantity.	The	produced	rrVEGF-164	had	a	
higher	biological	activity	than	commercially	available	growth	factor	(produced	in	a	mouse	
myeloma	cell	line).	The	high	level	expression	of	biologically	active	recombinant	rat	VEGF-164	
provides a useful tool for basic and applied research. 
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Abstract
Collagen–elastin	scaffolds	may	be	valuable	biomaterials	for	tissue	engineering	because	they	combine	
tensile	strength	with		elasticity.	In	this	study,	the	tissue	response	to	and	the	calcification	of	these	
scaffolds	were	evaluated.	In	particular,	the	hypothesis	was	tested	that	calcification,	a	common	
phenomenon	in	biomaterials,	may	be	due	to	microfibrils	within	the	elastic	fibre,	and	that	these	
microfibrils	might	generate	a	tissue	response.	Four	scaffolds	were	subcutaneously	implanted,	viz.	
collagen,	collagen+pure	elastin,	collagen+microfibril-containing,	and	collagen+pulverised	elastic	
ligament	(the	source	for	elastin).	Explants	were	evaluated	at	day	3,	7	and	21.
In	young	Sprague	Dawley	rats,	collagen+ligament	calcified	substantially,	whereas	collagen+elastin	
(with	and	without	microfibrils)	calcified	less,	and	collagen	did	not.	Calcification	started	at	elastic	
fibres.	 In	bothSprague	Dawley	and	Wistar	adult	 rats,	however,	none	of	 the	scaffolds	calcified.	
Mononuclear	cell	 infiltration	was	prominent	 in	young	and	adult	Sprague	Dawley	rats.	 In	adult	
Wistar	rats,	this	infiltration	was	associated	with	the	presence	of	microfibrils.	Degradation	of	scaffolds	
and	new	matrix	formation	were	related	with	cellular	influx	and	degree	of	vascularisation.
In	 conclusion,	 absence	 of	microfibrils	 from	 the	 elastic	 fibre	 does	 not	 prevent	 calcification	 in	
young	Sprague	Dawley	rats,	but	does	reduce	the	tissue	response	 in	adult	Wistar	rats.	Cellular	
response	and	calcification	differs	with	age	and	strain	and	therefore	the	choice	of	animal	model	is	
of	key	importance	in	biomaterial	evaluation.
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3Introduction
Tissue	 engineering	 involves	 the	 development	 of	 innovative	 biomaterials	 to	 replace	 or	 repair	
damaged	 and	 defective	 tissue.	 Type	 I	 collagen	 and	 elastin	 are	 structural	 extracellular	matrix	 
proteins	that	are	abundantly	present	in	human	tissues	and	form	natural	scaffolds	in	the	body.	
Collagen	provides	tensile	strength	and	is	widely	used	as	a	biomaterial,	e.g.	in	skin	substitutes,	
vascular	 grafts,	 scaffolds	 for	 cartilage	 repair,	 and	 bone	 implants1–3.	 Elastin	 provides	 elasticity	
to	tissues.	This,	together	with	its	stability	due	to	specific	interchain	crosslinks,	makes	elastin	a	 
desirable	protein	 for	tissue	engineering4.	 Recently,	 it	 has	been	demonstrated	 that	 the	elastin	
is	capable	of	regulating	proliferation,	migration	and	differentiation	of	vascular	smooth	muscle	
cells,	and	that	it	reduces	the	vascular	proliferative	response	to	arterial	injury	in	vivo5. This makes 
the	 application	 of	 elastin	 in	 tissue	 engineering	 even	more	 significant.	 However,	 unlike	 type	 I	 
collagen,	elastin	has	found	little	use	as	a	biomaterial6–8.	One	reason	is	that	the	elastin	preparations	
have	a	strong	tendency	to	calcify	upon	implantation9.	Another	is	that	the	purification	of	elastin	
is	complex10.	Calcification	may	be	due	to	microfibrillar	components	within	the	elastic	fibre	that	
are	difficult	to	remove.	A	major	component	in	this	respect	is	fibrillin,	which	binds	calcium	due	
to its many calcium-binding EGF domains11.	In	dystrophic	calcinosis	cutis,	mineralisation	of	the	
elastic	fibre	has	been	shown	to	start	at	microfibrils	present	within	and	surrounding	the	elastic	 
fibre12.	In	general,	calcification	is	a	major,	not	well-understood	problem	in	biomaterial	application.	 
Especially	 cardiovascular	prosthetic	 implants	 such	as	bioprosthetic	heart	valves,	aortic	homo-
grafts	and	trileaflet	polymeric	valve	prostheses	are	prone	to	calcify.	Crosslinked	cellular	debris,	
collagen	 and	 elastin	 have	 been	 suggested	 as	 the	 onsets	 for	 calcification13–15. We previously 
described	the	preparation	and	biochemical,	biomechanical,	 immunohistochemical	and	in	vitro	
evaluation	 of	 collagen–	 elastin–glycosaminoglycan	 scaffolds16.	 In	 this	 study,	 we	 investigated	
whether	purification	of	elastin,	 i.e.	 removal	of	microfibrils,	can	(partially)	prevent	calcification	
and	may	influence	the	tissue	response	such	as	cellular	events	and	matrix	remodelling.	For	this	
reason,	 we	 prepared	 four	 different	 scaffolds	 using	 purified	 collagen,	 purified	 elastin,	 partly	 
purified	elastin	(i.e.	withmicrofibrils)	and	elastic	ligament	(the	source	for	elastin),	and	implanted	
these	subcutaneously	in	rats.	Different	rat	models	were	used	to	monitor	variations	between	rat	
strain	and	age	on	the	outcome	of	the	experiment.
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Materials and methods
Materials
Four	 different	 biomaterials	were	 prepared:	 (1)	 purified	 type	 I	 collagen,	 (2)	 purified	 insoluble	
elastin,	(3)	partly	purified	insoluble	elastin,	still	containing	microfibrils	and	some	collagen,	and	
(4)	pulverised	ligamentum	nuchae,	the	source	for	elastin.	Insoluble	type	I	collagen	was	purified	
from	bovine	achilles	 tendon	using	diluted	acetic	acid,	NaCl,	 urea,	 and	acetone	extractions	as	
described17.	 Insoluble	 elastin	was	 isolated	 from	equine	 ligamentum	nuchae	 using	 extractions	
with NaCl, organic solvents, CNBr in formic acid, urea withdiluted 2-mercaptoethanol, and diges-
tion	 with	 trypsin,	 essentially	 as	 described,	 but	 withomis	 sion	 of	 the	 collagenase	 digestion10. 
Microfibril-containing	insoluble	elastin	was	prepared	using	only	one	NaCl	extraction,	organic	sol-
vents	extractions	and	CNBr	in	formic	acid	treatment.	Pulverised	equine	ligamentum	nuchae	was	
prepared	using	a	FritschPulveri	 sette	19	witha	1mm	sieve	 (Idar-	Oberstein,	Germany).	Mouse	
anti-bovine	 elastin	 IgG	 (clone	 BA-4)	 was	 purchased	 from	 Sigma	 Chemical	 Co.	 (St	 Louis,	MO,	
USA).	Rabbit	anti-bovine	type	I	collagen,	rabbit	antirat	type	I	collagen,	and	rabbit	anti-rat	type	III	 
collagen	 IgGs	 were	 from	 Chemicon	 (Temecula,	 CA,	 USA).	 Goat	 anti-human	 type	 IV	 collagen	
IgG	 was	 from	 Southern	 Biotechnology	 Inc.	 (Birmingham,	 AL,	 USA).	 Alexa	 488-	 labelled	 goat	 
anti-mouse	IgG,	Alexa	488-labelled	goat	anti-rabbit	IgG,	and	Alexa	488-labelled	donkey	antigoat	
IgG were from Molecular Probes Europe (Leiden, The Netherlands).
Preparation of scaffolds
Four	 different	 scaffolds	 were	 prepared	 composed	 of	 purified	 collagen	 (COL),	 purified	
collagen+purified	 elastin	 in	 a	 1:1	 ratio	 (COL-EL),	 purified	 collagen+microfibril-containing	 elas-
tin	 in	 a	 1:1	 ratio	 (COL-mfEL),	 and	 purified	 collagen+pulverised	 elastic	 ligament	 in	 a	 1:1	 ratio	 
(COL–Ligament).	 Collagen	 was	 incorporated	 into	 all	 scaffolds,	 because	 we	 were	 unable	 to	 
prepare	coherent	scaffolds	of	elastin	only.	Scaffolds	were	prepared	by	lyophilising	an	acidic	1%	
suspension	of	the	various	preparations.	All	scaffolds	were	chemically	crosslinked	for	4h	with	33	
mm	 1-ethyl-3-(3-dimethyl	 aminopropyl)carbodiimide	 (EDC)	 and	 6mm	 N-hydroxysuccinimide	
(NHS) in 50mm 2-morpholinoethane sulphonic acid (MES) (pH 5.5) in the presence of 40% (v/v) 
ethanol.	After	reaction,	the	scaffolds	were	washed	in	0.1	m	Na2HPO4	(pH	9.1),	1	m	NaCl,	2	m	
NaCl, and demineralised water16,17.
Characterisation of elastin-containing preparations and scaffolds Sodium dodecyl sulphate poly-
acrylamide gel electrophoresis
(SDS-PAGE):	Purified	elastin,	microfibril-containing	elastin,	and	pulverised	 ligamentum	nuchae	
preparations	were	incubated	at	95oC	for	10	min	under	reducing	conditions	(5%	(v/v)	2-mercap-
toethanol)	and	analysed	on	a	10%	(w/v)	gel.	Non-elastin	components	will	penetrate	the	gel	and	
are	visualised	by	a	Coomassie	Brilliant	Blue	solution	(0.1%	(w/v)18. 
Transmission electron microscopy (TEM): TEM was used to analyse the presence/absence of mi-
crofibrils	and	other	(extra)cellular	components.	Purified	elastin,	microfibril-	containing	elastin,	
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3and	pulverised	ligamentum	nuchae	preparations	were	embedded	in	1.5%	(w/v)	agarose,	fixed	in	
2%	(v/v)	glutaraldehyde	in	0.1	m	phosphate	buffer	(pH	7.4)	for	12	h	at	4oC,	and	post	fixed	with1%	
(w/v)	osmium	tetroxide	in	0.1	m	phosphate	buffer	(pH	7.4)	for	1	h.	After	a	rinsing	period	of	3	h	
with	0.1	m	phosphate	buffer	(pH	7.4),	the	samples	were	dehydrated	in	an	ascending	series	of	
ethanols	and	embedded	 in	Epon	812.	Ultrathin	sections	 (60	nm)	were	picked	up	on	 formvar-
coated	grids,	post	 stained	with	 lead	citrate	and	uranyl	acetate,	and	examined	 in	a	 JEOL	1010	
electron microscope.
Scanning electron microscopy (SEM):	SEM	was	used	to	analyse	the	morphology	of	the	scaffolds.
Scaffolds	were	mounted	on	stubs	and	sputtered	with	an	ultrathin	layer	of	gold	in	a	Polaron	E5100	
SEM	coating	system.	The	specimens	were	studied	with	a	JEOL	JSM-6310	SEM	apparatus	with	an	
accelerating	voltage	of	15	kV.
Amine group content:	The	amine	group	content	of	scaffolds	was	determined	spectrophotometrically	
after	reaction	with2,4,6-t	rinitrobenzene	sulfonic	acid19.
Implantation of scaffolds
NIH	guidelines	for	the	care	and	use	of	laboratory	animals	(NIH	publication	85-23	Rev.	1985)	were	
observed.	 The	 study	was	 approved	 by	 the	 Ethical	 Committee	 of	 the	University	 of	 Nijmegen.	
Sprague-Dawley rats (male, 21 days old and 3 months old) and Wistar rats (male, 3 months old) 
were	purchased	from	Harlan	(Zeist,	The	Netherlands).	Young	rats	were	housed	per	3,	and	adult	
rats	per	2.	The	animals	were	fed	pelleted	diet	(RMH-B	10	mm)	and	water	ad	libitum.	Scaffolds	
were	washed	in	70%	(v/v)	ethanol	(4x30	min)	and	sterile	phosphate-buffered	saline	(PBS)	(pH	
7.2)	 (8x30	min)	at	22°C.	Rats	were	anaesthetised	with	 isoflurane.	After	disinfection,	 subcuta-
neous	pockets	were	made	to	the	right	and	 left	of	two	midline	 incisions	on	the	back.	Punches	 
(≈6	mm)	of	the	scaffolds	were	implanted	in	the	pockets	at	a	distance	of	about	1	cm	from	the	 
incisions	(4	implants/rat).	For	each	implantation	time,	two	rats	received	two	punches	of	the	same	
scaffold	on	one	side	of	 the	midline	 incision.	 Implants	with	surrounding	tissue	were	harvested	
from	Sprague	Dawley	rats	at	3,	7	and	21	days	after	implantation,	from	Wistar	rats	at	21	days	only.	
Processing of explants
Immediately	after	explantation,	scaffolds	were	divided	in	two	halves.	One	half	was	processed	for	
conventional	light	microscopy,	the	other	half	for	immunohistochemistry.	
Conventional histology
Scaffolds	and	surrounding	tissue	were	fixed	in	4%	(v/v)	formaldehyde	in	phosphate	buffer	(pH	
7.2)	 Immediately	A.	Explantation	scaffolds	 for	at	 least	24	hat	4°C,	and	embedded	 in	paraffin.	
Consecutive	sections	of	5	mm	were	mounted	onto	glass	slides,	dewaxed	in	xylol	and	hydrated	
through	a	graded	series	of	ethanol.	Sections	were	routinely	haematoxylin–eosin	stained.	Elastin	
and	 collagen	were	 stained	according	 to	Elastin	Van	Gieson	 (EVG),	 and	 calcium	deposits	were	
visualised by Von Kossa staining20.	The	sections	of	the	explants	were	semi-quantitatively	scored	
independently	by	at	least	two		experienced	investigators.
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Immunohistochemistry
Immunofluorescence	microscopy	was	 used	 to	 study	 the	 biodegradation	 of	 scaffold	 collagen	 and	
elastin,	and	 the	 formation	of	new	collagens	by	 the	host.	Scaffolds	were	 frozen	 in	 liquid	nitrogen.	
Cryosections	 were	 mounted	 onto	 glass	 slides.	 After	 blocking	 with	 1%	 (w/v)	 bovine	 serum	 
albumin	(BSA)	in	PBS,	sections	were	incubated	with	mouse	anti-bovine	elastin	(1:1000),	rabbit	
anti-bovine	 type	 I	 collagen,	 rabbit	 anti-rat	 type	 I	 collagen,	 rabbit	 anti-rat	 type	 III	 collagen	 (all	
1:100),	or	goat	anti-human	type	IV	collagen	(1:50)	for	90	min,	washed	with	PBS,	followed	by	a	1	
h	incubation	with	Alexa	488-labelled	secondary	antibodies	(1:100).	All	antibodies	were	diluted	
in	PBS	containing	1%	(w/v)	BSA.	Sections	were	washed	and	mounted	in	mowiol.	The	antibody	to	
bovine	elastin	also	reacts	with	equine	elastin;	the	antibody	to	human	type	IV	collagen	crossreacts	
with	rat	type	IV	collagen;	the	antibody	to	bovine	type	I	collagen	does	not	substantially	cross-react	
with rat type I collagen or vice versa.
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3Results
Characteristics of elastin preparations
Elastin	preparations	were	studied	using	SDS-PAGE	and	TEM.	SDS-PAGE	of	the	elastin	preparations	
indicated	no	contamination	with	other	proteins	in	purified	elastin,	whereas	microfibril-containing	
elastin	and	pulverised	elastic	ligament	contained	a	large	number	of	additional	proteins	(Fig.	1A).	
TEM	indicated	that	the	purified	elastin	fibres	were	free	of	microfibrils	and	no	other	structural	 
elements	could	be	detected	(Fig.	1B).	In	microfibril-containing	elastin,	microfibrils	could	be	easily	
observed	as	well	as	some	residual	collagen	fibrils,	but	without	any	other	contaminations	(Fig.	
1C).	Pulverised	elastic	ligament	contained	all	tissue	elements,	including	damaged	cells	(Fig.	1D).
Fig. 1. (A) SDS-PAGE gel of highly purified elastin (EL; 0.5 mg), microfibril-containing elastin (mfEL; 0.5 mg) and 
pulverised ligament (0.1 mg). Only soluble contaminants and/or elastin breakdown products will enter the gel; 
insoluble elastin, which represents the vast majority of the preparations, does not. (B–D) Transmission electron 
micrographs of highly purified elastin (B), partly purified microfibril-containing elastin (C), and pulverised elastic 
ligament (D). C=collagen; E=elastin; N=nucleus of fibroblast; arrows indicate microfibrils. Bar is 0.5 mm.
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Characteristics of scaffolds
The	3D	morphology	of	 the	scaffolds	was	analysed	with	SEM	(Fig.	2).	Collagen	was	present	as	
fine	fibrillar	and	sheet-like	structures,	whereas	elastin	was	observed	as	thick	fibres.	Pulverised	
ligament	showed	bundles	of	elastic	fibres,	since	the	collagenous	meshwork	between	individual	
elastic	fibres	was	not	removed.	The	amine	group	content	was	measured	to	investigate	the	extent	
of	 EDC/NHS	 crosslinking.	 In	 all	 scaffolds,	 35–40%	of	 amine	 groups	were	 used	 in	 crosslinking.	 
Collagen	possesses	a	larger	amount	of	amine	groups	than	elastin,	which	explains	the	absolute	
values	for	the	different	preparations	(Table	1).
Fig. 2. Scanning electron micrographs of the crosslinked scaffolds. (A) COL, (B) COL-EL, (C), COL-mfEL, and (D) COL-liga-
ment. Collagen is present as thin fibrils and sheets, elastin as thick fibres. Arrows indicate elastic fibres. Bar is 10 mm.
Table 1; Amine group content of various scaffolds
COL: scaffold composed of colla-
gen only; COL-EL: scaffold com-
posed of equal amounts of col-
lagen and highly purified elastin;
COL-mfEL: scaffold composed of 
equal amounts of collagen and 
microfibril-containing elastin; 
COL-ligament: scaffold com-
posed of equal amounts of colla-
gen and pulverised ligamentum 
nuchae. Results are mean±SD of 
three individual experiments.
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3Calcification of scaffolds
All	animals	remained	in	good	condition	and	no	infectious	problems	occurred.	Macroscopically,	
a	 thin	 capsule	was	 observed	 around	 the	 scaffolds	 at	 explantation.	 In	 Table	 2	 an	 overview	of	
calcification	behaviour	and	cellular	response	is	given.	
Young	Sprague	Dawley	rats:	COL	did	not	calcify	in	young	Sprague	Dawley	rats	except	one	(out	of	
4)	at	day	21	as	was	assessed	by	Von	Kossa	staining.	At	day	3,	some	calcification	could	be	observed	
in	COL-ligament	where	it	was	present	within	the	elastic	fibres.	Calcification	did	not	seem	to	be	
dependent	on	local	cell	infiltration,	since	calcification	developed	in	cell-free	as	well	as	cell-dense	
areas.	All	other	scaffolds	showed	no	calcification	at	this	time	point.	At	day	7,	all	of	the	composite	
scaffolds	(COL-EL,	COL-mfEL,	COL-ligament)	showed	calcification	to	some	extent.	COLligament
showed	intensive	calcification	at	elastic	fibres	only.	At	day	21,	calcification	of	COL-EL,	COL-mfEL,
and	 COL-ligament	 had	 increased	 (Fig.	 3).	 COL-EL	 and	 COL-mfEL	 calcified	 to	 about	 the	 same	 
extent.	In	COLligament,	calcification	had	extended	to	collagen.
Adult	Sprague	Dawley	rats	and	Adult	Wistar	 rats:	All	 scaffolds	 implanted	 in	adult	 rats	did	not	
show	any	calcification	up	to	day	21.	
Fig. 3. Light microscopical evaluation of the calcification of scaffolds, 21 days after implantation in young Sprague 
Dawley rats. (A) COL, (B) COLEL, (C), COL-mfEL, and (D) COL-ligament. Calcium deposits have an intense black colour 
due to Von Kossa staining. Arrows indicate elastic fibres. Bar is 50 mm.
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Tissue response to scaffolds
Figs.	4	and	5	show	some	representative	examples	of	the	tissue	response	to	scaffolds	in	young	and	
adult	Sprague	Dawley	rats	and	adult	Wistar	rats	at	different	time	points	(see	Table	2).	
Table 2; General overview of 
calcification and cellular events 
after subcutaneous implanta-
tion of the scaffolds in rats.
COL:	crosslinked	collagen	scaffold;	COL-EL:	crosslinked	scaffold	composed	of	equal	amounts	of	collagen	and	highly	
purified	elastin;	COL-mfEL:	crosslinked	scaffold	composed	of	equal	amounts	of	collagen	and	microfibril-containing	
elastin;	COL-ligament:	crosslinked	scaffold	composed	of	equal	amounts	of	collagen	and	pulverised	ligamentum	nu-
chae.	PMNs=	polymorphic	nuclear	cells,	i.e.	granulocytes;	phagocytic	cells	include	monocyte-derived	macrophages	
and	monocytes;	non-phagocytic	cells	include	lymphocytes,	plasma	cells	and	mast	cells.
Events	were	scored	ranging	from	sporadic	(sp)	to	severe	(++++),-:	not	present.
a		Absolute	numbers	of	non-phagocytic	cells	were	lower	than	of	phagocytic	and	giant	cells,	e.g.	++	for	phagocytic	
and	giant	cells	refers	to	more	cells	than	++	for	non-phagocytic	cells.
b  Blood vessels were assessed by immunostaining for rat type IV collagen, present in vascular basement mem-
branes.
c		One	out	of	four	implanted	collagen	scaffolds	showed	moderate	calcification	at	this	time	point.
Young Sprague Dawley rats
At day 3, several macrophages and some polymorphic nuclear granulocytes (PMNs) were present, 
mostly	at	the	periphery	of	the	scaffold.	More	PMNs	were	present	near	elastic	ﬁbres than near 
collagen,	 especially	 in	COL-ligament	and	COL-mfEL.	At	day	7,	 a	ﬁbrous capsule was observed 
around	the	scaffolds.	Some	capillaries	were	located	in	the	capsule	and	at	the	periphery	of	the	
scaffolds.	At	this	time,	PMNs	were	only	sporadically	present,	while	early	events	of	mononuclear	
cell inﬁltra	tions	were	found.	Mononuclear	cells	include	phagocytic	cells	like	active	monocyte-
derived	macrophages,	monocytes	as	well	as	non-phagocytic	cells	such	as	lymphocytes,	plasma	
cells	 and	mast	 cells.	 Foreign	 body	 giant	 cells	 (fused	macrophages	with	multiple	 nuclei)	were	
encountered in variable amount. At day 21, capillaries were present in between the ﬁbres of the 
scaffolds.	Phagocytic	cells	dominated	 the	 scaffolds,	while	 the	amount	of	non-phagocytic	cells	
increased	at	the	periphery,	especially	near	COL-ligament	and	COLmfEL	(Fig.	4).	
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Fig. 4. Light microscopical overview of the cellular response to scaffolds at day 21 in young Sprague Dawley rats. 
(A) COL, (B) COL-EL, (C), COLmfEL, and (D) COL-ligament. Note the increased amount of mononuclear cell infiltra-
tion, especially in COL-Ligament scaffolds. Sections were HE stained. C=capsule; G=giant cell; arrows indicate elastic 
fibres. Bar is 50 mm.
Adult Sprague Dawley rats
At	 day	 3,	 all	 implants	were	 encapsulated	with	 a	 fibrous	 capsule.	 Some	 PMNs	 had	 infiltrated	
mainly	COL-mfEL	and	COL-ligament	(Fig.	5A	and	B),	while	more	phagocytic	cells	infiltrated	COL	
and	COL-EL.	At	day	7,	PMNs	were	only	sporadically	found.	Increased	fibrous	encapsulation	was	
commonly	present	with	 capillaries	both	 intracapsularly	and	at	 the	periphery	of	 the	 scaffolds.	
Phagocytic	cells	accumulated	both	at	the	periphery	and	to	less	extent	in	the	scaffold.	Most	of	
these	cells	were	present	in	COL-ligament,	less	in	COLmfEL	and	COL-EL,	and	only	at	the	periphery	
of	COL.	(Fig.	5C	and	D).	At	day	21,	capillaries	were	found	throughout	COL-ligament,	COL-mfEL	
and	COL-EL	and	these	scaffolds	were	almost	completely	infiltrated	withphagocytic	cells,	but	to	
less	extent	in	COL.	
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Fig. 5. Light microscopical evaluation of the cellular response to scaffolds implanted in adult Sprague Dawley rats 
(A–D) and adult Wistar rats (E–F). (A) COL-EL and (B) COL-mfEL 3 days after implantation. Note that more PMN’s 
(neutrophiles) are present in COL-mfEL than in COLEL. (C) COL-EL and (D) COL 7 days after implantation. In COL, an 
increase of mononuclear cells, especially non-phagocytic cells, was found at the periphery of the scaffold. (E) COL-
EL and (F) COL-mfEL 21 days after implantation. In COL-mfEL, locally an increase of mononuclear cells was found. 
Sections were HE stained. C=capsule; G=giant cell; arrow heads indicate neutrophiles; arrows indicate elastic fibres. 
Bar is 50 mm.
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Scaffolds	from	adult	Wistar	rats	were	only	explanted	at	day	21	(Fig.	5E	and	F).	At	this	time,	a	
fibrous	capsule	was	formed	around	all	scaffolds.	In	general,	the	tissue	response	of	adult	Wistar	
rats	to	implanted	scaffolds	was	distinctly	milder	compared	to	Sprague	Dawley	rats.	Few	cells	had	
infiltrated	the	scaffolds.	COL	and	COL-EL	showed	few	mononuclear	and	giant	cells	at	the	periph-
ery.	In	COL-mfEL	and	COL-ligament,	these	cells	had	infiltrated	deeper	into	the	scaffolds.	
Vascularisation of the scaffolds
Young	Sprague	Dawley	rats:	Few	small	blood	vessels,	visualised	by	immunostaining	for	type	IV	
collagen present in endothelial basement membranes, were found at day 7 at the periphery of 
the	scaffolds.	At	day	21,	some	blood	vessels	were	found	at	the	periphery	of	COL,	while	other	scaf-
folds	showed	more	vascularisation	at	that	time,	both	at	the	periphery	and	within	the	scaffolds.	
Adult	Sprague	Dawley	rats:	Vascularisation	 increased	over	time.	 In	general,	COL-EL,	COL-mfEL	
and	COL-ligament	contained	more	blood	vessels	than	COL.	At	day	7,	vascularisation	of	COL-EL,	
COL-mfEL	and	COL-ligament	was	mainly	in	the	capsule	and	at	the	periphery	of	the	scaffolds;	at	
day	21	it	was	also	within	the	scaffold	(Fig.	6A	and	Fig.	6B).	
Adult	Wistar	rats:	Few	blood	vessels	were	only	 found	at	 the	periphery	of	COL-mfEL	and	COL-
ligament. 
Fig. 6. Immunostaining of COL-EL scaffolds for types IV and III collagen as indicators of vascularisation and matrix 
production after subcutaneous implantation in adult Sprague Dawley rats. (A) COL-EL after 7 and (B) after 21 days 
immunostained for type IV collagen. At day 7, type IV collagen staining is mainly present at the periphery, at day 
21 in the whole scaffold. (C) COL-EL after 7 days and (D) after 21 days immunostained for type III collagen. At day 
7, type III collagen staining is mainly present at the scaffold periphery, at day 21 it is found throughout the scaffold. 
C=capsule; S=scaffold. Bar is 50 mm.
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Scaffold degradation and new matrix synthesis
Table	3	gives	an	overview	of	the	immunofluorescence	staining	for	scaffold	components	and	for	
newly	formed	extracellular	matrix	molecules	at	different	time	points.
Table 3; Overview of immunostaining results of explants for scaffold and rat extracellular matrix components
COL: crosslinked collagen scaffold; COL-EL: crosslinked scaffold composed of equal amounts of collagen and highly 
purified elastin; COL-mfEL: crosslinked scaffold composed of equal amounts of collagen and microfibril-containing 
elastin; COL-ligament: crosslinked scaffold composed of equal amounts of collagen and pulverised ligamentum 
nuchae.
Events were scored ranging from sporadic (sp) to abundant (++). -: not present.
Scaffold degradation
Young	Sprague	Dawley	rats:	Conventional	histology	showed	small	amounts	of	degraded	collagen	
which were locally visible from day 7 on at the periphery. At day 21, degraded collagen was also 
found	deeper	within	the	scaffolds,	but	especially	centrally	a	large	amount	of	intact	scaffold	col-
lagen	remained	present.	 Immunostaining	 for	bovine	type	 I	collagen	supported	these	findings.	
At day 21, the presence of thin and fragmented collagen structures were most profound at the 
scaffold	periphery.	Locally,	fragmented	elastin	in	COL-EL,	COL-mfEL	and	COL-ligament	was	found	
from	day	7	on.	At	day	21,	the	total	amount	of	elastic	fibres	was	decreased	and	more	fragmented	
elastic	fibres	were	observed,	suggesting	resorption	and	degradation	of	the	fibres.	Both	calcified	
elastin/elastic	fibres	and	non-calcified	elastin/elastic	fibres	were	found	within	macrophages	and	
giant	cells.	Immunofluorescence	results	showed	that	staining	for	elastin	gave	the	best	signal	for	
COL-EL,	most	likely	due	to	unmasking	of	the	epitope	during	purification.	Calcified	elastin	could	
also	be	visualised	with	the	antibody.	The	fragments	of	elastin	(smaller	than	elastic	fibres)	were	
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Adult Sprague Dawley rats: Degraded collagen was visible at the periphery at day 7. Fragmented 
elastin	(bothEL	and	mfEL)	was	visible	locally	from	day	7	on.	Especially	in	COL-ligament	scaffolds,	
severely	 fragmented	 elastic	 fibres	were	 present	 at	 day	 21,	 suggesting	 fastest	 degradation	 of	
these	scaffolds.
Adult	Wistar	rats:	At	day	21,	a	large	amount	of	scaffold	collagen	and	elastin	was	still	present	in	
adult	Wistar	rats,	implying	the	lowest	degradation	rate	of	scaffolds	in	all	rat	models	used.	Only	lo-
cally,	degraded	collagen	fibrils	and	elastic	fibres	were	observed	at	the	periphery	for	all	scaffolds.
Matrix synthesis
Young	Sprague	Dawley	rats:	Newly	formed	rat	type	I	collagen	was	generally	found	in	the	fibrous	
capsule	 surrounding	 the	 implant	 and	 aligning	with	 the	 collagen	 fibrils	 in	 the	 scaffold.	 At	 day	
21,	young	Sprague	Dawley	rats	showed	more	staining	 for	type	 I	collagen	 in	elastin	containing	
scaffolds	than	in	collagen	scaffolds.	From	day	7	on,	type	III	collagen	could	be	clearly	observed	
in	the	fibrous	capsule	and	at	the	periphery	of	the	scaffolds.	At	day	21,	type	III	collagen	was	pres-
ent	throughout	the	scaffolds,	aligning	with	the	collagenous	and	elastinous	scaffold	components.	
Staining	for	type	III	collagen	in	COL	was	less	intense	than	in	the	other	scaffolds.	Adult	Sprague	
Dawley rats: In adult Sprague Dawley rats, staining for rat type I and III collagen was similar to 
staining in young Sprague Dawley rats. Whereas at day 7 type III collagen was mainly present 
in	the	capsule	and	the	outer	part	of	the	scaffolds,	at	day	21	it	was	found	throughout	the	scaf-
fold	(Fig.	6C	and	D).	Adult	Wistar	rats:	At	day	21,	minor	amounts	of	new	matrix	collagens	were	
observed	in	scaffolds	implanted	in	adult	Wistar	rats.	Type	I	collagen	was	sporadically	found	in	all	
scaffolds,	more	type	III	collagen	was	found	in	COL-mfEL	and	COL-ligament	scaffolds	than	in	COL	
and	COL-EL.
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Discussion
Tissue	response	to	new	biomaterials	has	to	be	evaluated	before	their	use	in	tissue	engineering	
for	clinical	purpose.	Here,	we	studied	the	tissue	response	and	calcification	of	subcutaneous	im-
planted	porous	biomaterials	composed	of	either	collagen	only	(COL),	collagen+highly	purified	in-
soluble	elastin	in	a	1:1	ratio	(COL-EL),	collagen+microfibril-containing	(i.e.	partly	purified)	elastin	
in	a	1:1	ratio	(COL-mfEL),	and	collagen+pulverised	ligament	in	a	1:1	ratio	(COLligament).	Young	
and adult Sprague Dawley rats and adult Wistar rats were used as animal models. The juvenile rat 
is	widely	accepted	as	a	sensitive	model	to	evaluate	calcification9,13,21,22.	In	our	experiment,	calcifi-
cation	only	occurred	when	elastin-containing	scaffolds	were	implanted	in	young	Sprague	Dawley	
rats	(3	weeks	old	at	implantation),	but	no	calcification	was	found	when	scaffolds	were	implanted	
in	adult	Sprague	Dawley	or	Wistar	rats	(3	months	old).	Calcification	of	implanted	biomaterials	
depends	on	many	variables.	One	of	them	is	the	animal’s	age.	Nimni	et	al.	already	found	that	after	
2	weeks	skin	collagen	subcutaneously	implanted	in	young	Long	Evans	rats	(1	month	old)	calcified	
much more than in older ones (8 months old)23.	Another	parameter	for	calcification	may	be	the	
purity	of	the	material.	In	our	experiment,	collagen	scaffolds	did	not	give	rise	to	calcification	in	
young	rats	(only	1	out	of	12	showed	calcification).	Using	a	purified	acellular	intestinal	collagen	
layer,	Abraham	et	al.	did	not	find	calcification	either24.	Withless	–defined	collagen	preparations,	
calcium	deposits	are	formed	indicating	that	contaminants	may	trigger	calcification14,23,25. This par-
tially	applies	to	elastin	as	well.	Calcification	started	within	the	elastic	fibre15.	Calcification	was	
seen	from	day	3	for	COL-ligament	scaffolds,	and	from	day	7	for	COL-mfEL	and	COL-EL	scaffolds.	
Although	absence	of	microfibrils	from	the	elastic	fibre	did	not	result	in	a	decrease	of	calcifica-
tion,	calcification	was	more	severe	if	an	impure	preparation	(i.e.	pulverised	ligament)	was	used.	
Our	hypothesis	 that	calcification	may	be	partly	due	to	the	presence	of	microfibrils	within	 the	
elastic	fibre	could	be	rejected	in	this	study.	Another	calcification	variable	might	be	imputed	to	the	
intactness	of	the	elastic	fibre.	Bailey	et	al.	recently	found	that	fragmented	and	damaged	aortic
elastic	fibres	are	associated	withmore	severe	calcification	than	intact	ones26.	Our	purified	elastic	
fibres	are	still	intact,	though.	Calcification	may	be	genetically	controlled	by	molecules	that	active-
ly	inhibit	calcification	and	may	occur	passively	when	these	inhibitors	are	absent27.	Other	possible	
solutions	to	prevent	calcification	are	aluminium	chloride	treatment9, ethanol/ EDTA treatment28, 
and	attachment	of	glycosaminoglycans29,30. This study underlines that young Sprague Dawley rats
are	a	sensitive	model	to	study	calcification.	Apart	from	that,	an	accompanying	strong	tissue	re-
sponse	was	characteristic	of	these	rats.	Major	cellular	infiltrations	were	found	in	COL-EL,	COL-
mfEL	and	COL-ligament	scaffolds	at	day	21.	Van	Wachem	et	al.	observed	a	huge	infiltration	of	
lymphocytes,	including	numerous	plasma	cells,	after	subcutaneous	implantation	of	porcine	heart	
valve cusps and walls into young Sprague Dawley rats31.	However,	in	our	scaffolds,	we	found	substan-
tially	less	mononuclear	cells	in	both	young	and	adult	Sprague	Dawley	rats.	Adult	Wistar	rats	showed	
an	even	milder	tissue	response	to	the	implanted	scaffolds.	Elastin	without	microfibrils	resulted	in	less	
infiltration	of	mononuclear	cells	compared	to	microfibril-containing	elastin.	For	tissue	engineering	
purposes,	fibres	of	highly	purified	elastin	are	thus	preferred	to	microfibril-containing	elastic	fibres.
51
Tissue	response	of	defined	collagen–elastin	scaffolds
	in	young	and	adult	rats	with	special	attention	to	calcification
3Scaffolds	showed	to	be	biodegradable	by	all	hosts,	as	expected,	but	none	of	the	scaffolds	was	
fully	resorbed	at	day	21.	Degradation	was	associated	withph	agocytic	cells,	and	calcified	elastic	
fibres	were	found	in	macrophages	and	to	a	certain	extent	in	giant	cells.	More	degradation	was	
found	in	Sprague	Dawley	rats,	which	was	underlined	by	the	higher	numbers	of	phagocytic	cells	in	
these	scaffolds.	Minor	collagen	degradation	of	crosslinked	collagen	scaffolds	took	place	in	Wistar	
rats, which was comparable with results described by Pieper et al.32.	In	this	rat	strain,	elastin	was	
only	locally	degraded.	Collagen–elastin	scaffolds	may	thus	function	as	a	temporary	elastic	matrix	
here16.	Type	 I	and	type	 III	collagens	were	made	by	all	hosts.	Generally,	with	a	more	extensive	
tissue	response,	new	matrix	formation	and	vascularisation	occurred	bothearlier	in	time	and	to	
a	larger	extent.	This	means	that	in	both	young	and	adult	Sprague	Dawley	rats	more	new	matrix	
components	were	produced	than	 in	Wistar	rats.	 In	most	cases,	 the	presence	of	elastin	 in	 the	 
scaffold	was	associated	with	a	higher	degree	of	vascularisation.
Conclusions
Elastin-containing	scaffolds	did	not	calcify	in	adult	rats.	In	young	rats,	however,	calcification	of	
scaffolds	containing	elastin	or	elastic	fibres	was	observed	and	removal	of	microfibrils	from	the	
elastic	fibre	did	not	prevent	or	reduce	this.	Absence	of	microfibrils	reduced	the	tissue	response	
in	adult	Wistar	rats.	Tissue	response	to	and	calcification	of	scaffolds	differed	withage,	strain	and	
purity of the materials and therefore the choice of animal model is of key importance when 
evaluating	biomaterials	for	their	capacity	to	function	as	a	temporary	matrix	for	tissue	engineering	
and	matrix	remodelling.
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Abstract
Elastin	is	the	prime	protein	in	elastic	tissues	that	contributes	to	elasticity	of,	for	example,	lung,	
aorta,	and	skin.	Upon	injury,	elastic	fibers	are	not	readily	replaced,	which	hampers	tissue	regen-
eration.	 Incorporation	of	solubilized	elastin	 (hydrolyzed	 insoluble	elastin	fibers	or	elastin	pep-
tides)	in	biomaterials	may	improve	regeneration,	because	solubilized	elastin	is	able	to	promote	
proliferation	as	well	as	elastin	synthesis.	Porous	biomaterials	composed	of	highly	purified	col-
lagen	without	and	without	elastin	fibers	or	 solubilized	elastin	were	prepared	by	 freezing	and	
lyophilization.	Solubilized	elastin	formed	spherical	structures	that	were	incorporated	in	the	col-
lagenous	part	of	 the	scaffolds	and	 that	persisted	after	chemical	 cross-linking	of	 the	scaffolds.	
Crosslinked	scaffolds	were	subcutaneously	 implanted	in	young	Sprague	Dawley	rats.	Collagen-
solubilized	elastin	and	 collagen	 scaffolds	 showed	no	 calcification	 in	 this	 sensitive	 calcification	
model,	in	contrast	to	scaffolds	containing	elastin	fibers.	Collagen-solubilized	elastin	scaffolds	also	
induced	angiogenesis,	as	revealed	by	type	IV	collagen	staining,	and	promoted	elastic	fiber	syn-
thesis,	as	shown	with	antibodies	against	rat	elastin	and	fibrillin-1.	It	is	concluded	that	scaffolds	
produced	from	collagen	and	solubilized	elastin	present	a	non-calcifying	biomaterial	with	a	capac-
ity	for	soft-tissue	regeneration,	especially	in	relation	to	elastic	fiber	synthesis.
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Elastin	 is	 the	major	 insoluble	protein	present	 in	elastic	tissue,	contributing	to	the	elasticity	of	
lung,	 aorta,	 ligaments,	 and	 skin.	 Elastic	fibers	 are	not	 readily	 replaced	upon	 injury,1 probably 
because	of	difficulties	in	recapitulating	normal	developmental	expression	patterns	of	tropoelas-
tin	and	associated	molecules.2, 3	This	seriously	hampers	tissue	regeneration.	Solubilized	elastin	
(obtained	by	hydrolyzing	insoluble	elastin)	may	markedly	improve	tissue	regeneration,	because	
it	exhibits	multiple		biological	effects.	These	include	enhanced	cell	migration,4	cell	proliferation,5 
and	elastin	synthesis.6, 7	Solubilized	elastin	interacts	with	the	elastin-laminin	receptor,	which	is	
composed	of	3	subunits:	2	transmembrane	subunits	of	61	and	55	kDa	and	1	extracellular	subunit	
of	67	kDa,	the	latter	binding	tropoelastin	and	other	elastin-like	molecules.	The	receptor	is	pres-
ent	on	a	large	number	of	cells,	including	fibroblasts,	vascular	smooth	muscle	cells,	endothelial	
cells, chondrocytes, monocytes, lymphocytes, and polymorphonuclear leukocytes, and its signal 
transduction	pathway	is	mediated	through	a	pertussis	toxin–sensitive	G-protein.8-11	In	addition	
to	the	elastin-laminin	receptor,	other	receptors	may	play	a	role	as	well	(e.g.,	integrins).12 Bioma-
terials	containing	solubilized	elastin	may	thus	exert	biological	effects	on	a	wide	variety	of	cell	
types.	We	have	previously	prepared	biomaterials	 composed	of	highly	purified	 type	 I	 collagen	
and	elastin	fibers	and	studied	their	tissue	reaction.13, 14  In young Sprague Dawley rats (but not 
in	adult	rats),	implantation	of	these	scaffolds	resulted	in	calcification	of	elastin	fibers.	Although	
initiation	of	tissue	calcification	does	not	require	a	cellular	response,15 the in vivo milieu can accel-
erate the process16	(e.g.,	through	the	extracellular	release	of	enzymes	by	macrophages	and	giant	
cells	involved	in	elastin	degradation).17-20	We	here	hypothesize	that	porous	scaffolds	containing	
solubilized	 elastin	may	 improve	 synthesis	 of	 elastin	 through	 interaction	with	 the	 elastin-lam-
inin receptor.6	Furthermore,	if	enzymes	involved	in	elastin	degradation	play	a	role	in	increasing	 
calcification,	application	of	solubilized	elastin	may	reduce	the	presence	of	macrophages	and	giant	
cells	and	thus	reduce	calcification.	In	addition,	solubilized	elastin	is	less	hydrophobic	and	more	
charged	than	insoluble	elastin.	Negative	charges	from	C-terminal	carboxylic	groups	may	prevent	
positively	charged	calcium	ions	from	precipitating	in	the	same	way,	because	negatively	charged	
sulfate	groups	have	been	shown	to	suppress	calcium	binding	to,	for	example,		polyurethane.21 
In	 this	 study,	 we	 therefore	 prepared	 and	 characterized	 collagen,	 collagen–elastin	 fibers,	 and	 
collagen-solubilized	elastin	scaffolds	and	studied	calcification,	angiogenesis,	and	elastin	synthesis	
after	subcutaneous	implantation.
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Material and methods
Materials
Mouse	anti-bovine	elastin	immunoglobulin	(Ig)G	clone	BA-4	was	purchased	from	Sigma	Chemical	
Co.	(St	Louis,	MO);	goat	anti-rat	alpha-elastin	from	Elastin	Products	Co.	(Owensville,	MO);	rabbit	
anti-bovine	type	 I	collagen,	 rabbit	anti-rat	 type	 I	collagen,	and	rabbit	anti-rat	 type	 III	collagen	
IgGs	from	Chemicon	(Temecula,	CA);	and	goat	anti-human	type	IV	collagen	IgG	from	Southern	
Biotechnology	 Inc.	 (Birmingham,	AL).	Rabbit	anti-human	fibrillin-1	(pAb-rF6H)	and	rabbit	anti- 
human	fibrillin-2	(anti-rFBN2-1)	anti-sera	were	prepared	as	described	previously.22, 23	Alexa488-	
and	Alexa594-labeled	secondary	antibodies	were	 from	Molecular	Probes	Europe	 (Leiden,	The	
Netherlands),	 and	 rabbit	 anti-goat	 peroxidase	 and	 3,3-di-aminobenzidine	 tetrahydrochloride	
(DAB)	were	from	DAKO	(Glostrup,	Denmark).
Isolation of scaffolds components
Insoluble	type	I	collagen	was	purified	from	bovine	Achilles	tendon.	Briefly,	tendons	were	cleaned	
from	noncollagenous	tissue,	pulverized	under	liquid	nitrogen	conditions	using	a	Pulverisette	19	
with	 a	 0.5-mm	 sieve	 (Fritsch,	 Idar-Oberstein,	Germany),	 and	 consecutively	 rinsed	 extensively	
with 0.1M sodium chloride (NaCl) in 50mM Tris-hydrochloric acid (HCl) pH 7.2, 1.0M NaCl in 
50mM	Tris-HCl	pH	7.2,	4M	urea	in	0.5M	acetic	acid,	0.5M	acetic	acid,	acetone,	and	demineralized	
water.24	 Insoluble	elastin	fibers	 (ELfiber)	were	 isolated	from	equine	 ligamentum	nuchae.	Non-
elastinous	tissue	was	removed,	and	ligaments	were	pulverized	under	liquid	nitrogen	conditions	
through a 1.0mm sieve. The pulverized ligament was then washed and treated with 1M NaCl in 
10mM	phosphate	buffer	pH	7.4	(PB),	various	organic	solvents,	formic	acid	with	cyanogen	trypsin	
bromide, 4M urea plus 1M 2-mercaptoethanol in 0.1M PB, trypsin, and 1M NaCl in 10mM PB.25 
Solubilized	elastin	(ELsol)	was	prepared	from	insoluble	elastin	fibers	using	oxalic	acid	hydroly-
sis.26	Briefly,	10	g	of	elastin	was	hydrolyzed	for	1	h	with	75mL	0.25	Moxalic	acid	at	95oC. Then the 
preparation	was	quickly	cooled	on	ice	and	centrifuged,	and	the	supernatant	was	collected.	The	
pellet	was	hydrolyzed	again	for	1	h	with	oxalic	acid,	followed	by	cooling	and	centrifuging.	This	
procedure	was	repeated	until	all	insoluble	material	was	solubilized	(generally	after	a	total	of	14	
steps).	Supernatants	were	pooled,	dialyzed	against	10mM	PB,	and	subsequently	dialyzed	against	
MilliQ	water	using	Amicon	Ultra-15	10	kDa	MWCO	filter	tubes	(Millipore,	Billerica,	MA).	Charac-
terization	of	solubilized	elastin	preparation	The	amount	of	solubilized	elastin	in	the	elastin	pool	
was determined according to the method develop by Lowry,27	size	of	elastin	using	1-dimensional	
gel electrophoresis (4% polyacrylamide gel with silver staining),28	and	gel	permeation	chromatog-
raphy29	[column	material:	Sephacryl	S-500,	reference	samples:	ferritin	(0.88MDa),	dextran	blue	
(2MDa),	and	Helix	pomatia	hemocyanin	(9	MDa)],	size-charge	distribution	using	2-dimensional	
gel electrophoresis,30	 amine	 group	 content	 after	 reaction	 with	 2,4,6-trinitrobenzene	 sulfonic	
acid,31	and	amino	acid	composition	using	a	Biochrom	20	amino	acid	analyser	(Amersham	Phar-
macia Biotech, Uppsala, Sweden).32
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Various	scaffolds	were	prepared	composed	of	collagen	only	(COL);	collagen	plus	insoluble	elastin	
fibers	in	a	1:1	ratio	(COL-ELfiber);	and	collagen	with	solubilized	elastin	in	97:3,	9:1,	and	1:1	ratios	
(COL-ELsol).	Briefly,	a	2%	(w/v)	protein	suspension	 (collagen	without	or	with	elastin	fibers)	was	
shaken	overnight	in	0.5M	acetic	acid	at	4oC. If appropriate, ELsol was added and the suspension
diluted	to	1%	(w/v)	with	cold	MilliQ	water	and	homogenized	on	ice	using	a	Potter-Elvehjem	homog-
enizer. Air-bubbles were removed by centrifuging at 250 g for 10 min at 4oC. The suspension was 
then	slowly	poured	into	a	plastic	mould,	frozen	in	a	bath	of	ethanol	and	solid	carbon	dioxide	(CO2)	
(–80oC)	and	lyophilized	 in	a	Zirbus	 lyophilizer	(Bad	Grund,	Germany).	For	scaffolds	composed	of	
collagen	plus	ELsol	in	a	1:1	ratio,	a	suspension	with	a	final	concentration	of	1.6%	was	used	as	well.
Scaffolds	were	applied	as	such	(non-crosslinked)	or	crosslinked.	For	crosslinking,	200	mg	of	scaffold	
was incubated for 4 h at 228C with 20mL 33mM 1-ethyl-3- (3-dimethyl aminopropyl)carbodiimide 
(EDC)	and	6mMNhydroxysuccinimide	(NHS)	in	50mM	2-morpholinoethane	sulfonic	acid	(pH	5.0)	
containing	40%	ethanol.	EDC/NHS	crosslinked	scaffolds	were	then	washed	with	0.1M	dibasic	so-
dium	phosphate	(twice	for	1	h),	1M	NaCl	(twice	for	2	h),	2M	NaCl	(once	overnight,	5	times	for	30	
min),	and	MilliQ	water	(6	times	for	30	min).	The	scaffolds	were	then	frozen	in	ethanol/CO2	again	
and lyophilized.13, 33	For	 in	vivo	experiments,	EDC/NHS-crosslinked	COL	and	COL-ELfiber	1:1	scaf-
folds	from	a	1.0%	suspension	were	used	along	with	COL-ELsol	1:1	scaffolds	from	a	1.6%	suspension.
Characterization of scaffolds
The amine group content was measured to evaluate the degree of crosslinking.31 The amount of 
Elsol	bound	to	collagen	was	established	by	estimating	the	protein	content	in	the	solution	after	
crosslinking.	Proteins	 in	 this	solution	were	precipitated	with	10%	2,4,6-trichloroanisole	on	 ice	
for	2	h	and	centrifuged.	The	pellet	was	then	dissolved	in	10mM	sodium	hydroxide	and	the	pro-
tein amount assayed according to the method developed by Lowry.27 The same procedure was 
applied	to	evaluate	the	in	vitro	release	of	ELsol	from	the	scaffolds.	Neither	non-crosslinked	nor	
EDC/NHS	crosslinked	collagen	scaffolds	gave	any	release	of	protein	from	the	scaffolds	after	24	h	
or	7	days	in	PBS,	and	therefore	the	protein	release	from	COL-ELsol	scaffolds	could	be	attributed
to	ELsol	only.	Water-binding	capacity	of	scaffolds	was	determined	as	previously	described.13 Scan-
ning	electron	microscopy	was	used	to	analyze	the	morphology	of	the	scaffolds,13   transmission 
electron	microscopy	to	determine	the	ultrastructure	of	the	scaffolds,25	and	immunofluorescence
microscopy	 to	 study	 the	distribution	of	ELsol	 in	 the	scaffolds	using	mouse	anti-bovine	elastin	
(1:1000)	as	a	primary	antibody.14
In vivo evaluation of scaffolds
The	Ethics	Committee	of	the	Radboud	University	Nijmegen	Medical	Centre	approved	the	study.	
Sprague-Dawley rats (male, 3 weeks old) were purchased from Harlan (Zeist, The Netherlands) 
and	housed	2	per	cage.	The	animals	were	fed	pelleted	diet	and	water	ad	libitum.	Scaffolds	were	
washed	in	70%	(v/v)	ethanol	and	sterile	PBS.	Rats	were	anesthetized	with	isoflurane,	and	sub-
cutaneous	pockets	were	made	to	the	right	and	left	of	2	midline	incisions	on	the	back.	Punches	 
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(ø	6	mm)	of	the	scaffolds	were	 implanted	 in	the	pockets	at	a	distance	of	approximately	1	cm	
from	the	incisions	(4	implants/rat).	In	this	study,	6	COL,	6	COL-ELfiber,	and	12	COL-ELsol	scaffolds	
were	implanted	(2	COL,	2	COL-Elfiber,	and	4	COL-ELsol	per	time	point),	and	a	total	of	6	rats	was	
used.	Lower	numbers	of	COL	and	COL-ELfiber	scaffolds	were	used	because	these	were	compared	
with previous results.14	All	scaffolds	were	crosslinked	using	EDC/NHS.	Implants	with	surrounding	
tissue	were	harvested	at	3,	7,	and	21	days	after	implantation.	Immediately	after	explantation,	
scaffolds	were	divided	in	half.	One	half	was	processed	for	conventional	histology	and	the	other	
half for immunohistochemistry.
For	conventional	histology,	explants	were	fixed	in	4%	(v/v)	formaldehyde	in	PB	for	at	least	24	h	
at 4oC	and	embedded	in	paraffin.	Five-mm	sections	were	stained	with	hematoxylin-eosin,	Elastin	
Van	Gieson	(visualization	of	elastin	and	collagen),	or	Von	Kossa	(visualization	of	calcium	depos-
its).34	The	total	area	of	calcification	in	the	scaffold	was	determined	using	Neurolucida	software	
(MBF	Bioscience,	Williston,	VT)	and	expressed	as	a	percentage	of	the	total	implant	size.	Values	
were	compared	using	the	Student	t-test,	and	p<0.05	was	considered	to	be	statistically	significant.	
At	 least	 two	persons	performed	histological	evaluation	 independently.	 Immunohistochemistry	
(immunofluorescence	and	DAB	staining)	was	used	to	study	the	biodegradation	of	scaffold	com-
ponents	and	the	 formation	of	extracellular	matrix	by	the	host.	Scaffolds	were	 frozen	 in	 liquid	
nitrogen,	and	5-mm	cryosections	were	mounted	on	superfrost	slides	and	air	dried.	Immunofluo-
rescence assay was performed as previously described.14	Primary	antibodies	used	were	mouse	
anti-bovine	elastin	(1:1000),	rabbit	anti-bovine	type	I	collagen,	goat	anti-rat	elastin,	rabbit	anti-rat	
type	I	collagen,	rabbit	anti-rat	type	III	collagen	(all	1:100),	rabbit	anti-human	fibrillin-1,	and	rabbit	
anti-human	fibrillin-2	(both	1:500).	Antibodies	were	visualized	with	Alexa488-	or	Alexa594-
conjugated	secondary	antibodies	diluted	in	PBS	containing	5%	normal	rat	serum.	The	antibody	
to	bovine	elastin	also	reacted	with	equine	elastin,	the	antibodies	against	human	fibrillin	also	re-
acted	with	rat	fibrillin,	and	the	antibody	to	bovine	type	I	collagen	did	not	substantially	cross-react	
with rat type I collagen or vice versa. 
For	 immunohistochemistry	 with	 the	 DAB-staining	 method,	 cryosections	 were	 fixed	 with	 4%	
paraformaldehyde	in	PBS	for	20	min.	Endogenous	peroxidase	was	inhibited	with	0.3%	hydrogen	
peroxide	 (H2O2)	 for	10	min.	After	blocking	 for	30	min	with	2%	bovine	serum	albumin	 in	PBS	
containing	0.1%	Tween	(PBST),	sections	were	incubated	with	goat	anti-human	type	IV	collagen
(1:50)	for	1	h,	washed,	incubated	for	1	h	with	rabbit	anti-goat	IgG	peroxidase	(1:100),	and	washed.	
Antibodies	were	diluted	in	PBST	containing	5%	normal	rabbit	serum;	washings	were	with	PBST.	
Sections	were	washed	with	50mM	Tris-HCl	(pH	7.6)	and	incubated	for	10	min	with	DAB	(0.5	mg/
mL)	and	ammonium	nickel	 sulfate	 (7.5	mg/mL)	 in	Tris-HCl.	Finally,	 the	 reaction	substrate	was	
added	(0.2	ml	30%	H2O2/mL).	Sections	were	washed,	counterstained	with	hematoxylin,	dehy-
drated,	and	embedded.	The	antibody	to	human	type	IV	collagen	cross-reacted	with	rat	type	IV	
collagen.	The	total	area	of	blood	vessels	(including	the	lumen)	in	the	scaffold	was	determined	
and	expressed	as	a	percentage	of	the	total	implant	size	using	Neurolucida	software.	Values	were	
compared	using	the	Student	t-test,	and	p<0.05	was	considered	to	be	statistically	significant.
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Analysis of solubilized elastin preparation 
The	solubilized	elastin	preparation	was	analyzed	using	sodium	dodecyl	sulfate	polyacrylamide	
gel	electrophoresis,	which	revealed	that	the	molecular	mass	range	of	the	solubilized	elastin	was	
between	70	and	880	kDa.	Gel	permeation	chromatography	gave	a	mean	molecular	mass	of	the	
solubilized	elastin	of	approximately	1100	kDa.	Two-dimensional	gel	electrophoresis	showed	that	
the	elastin	peptides	had	an	isoelectric	point	of	approximately	6.	The	mean	amine	group	content	
± standard	deviation	of	the	solubilized	elastin	was	292± 5 nmol amine groups per mg of protein. 
Amino	acid	composition	of	solubilized	elastin	was	similar	to	that	of	elastin	fibers	for	all	amino	
acid residues, including desmosine and isodesmosine (both 0.5± 0.0 per 1000 amino acid
residues).
Analysis of scaffolds containing solubilized elastin
Porous	scaffolds	were	prepared	using	various	ratios	of	collagen	with	ELsol.	After	4	h	of	crosslink-
ing,	less	than	5%	of	ELsol	could	be	retrieved	from	the	remaining	crosslinking	solution.	Hence,	the	
crosslinking	efficiency	of	ELsol	to	the	scaffolds	was	at	least	95%.	The	biochemical	characteristics
of	the	scaffolds	are	summarized	in	Table	1.	
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EDC/NHS	crosslinking	coupled	ELsol	firmly	to	the	scaffolds,	because	the	in	vitro	release	was	only	
2%	after	7	days	in	the	case	of	EDC/NHS-crosslinked	collagen	plus	ELsol	scaffolds,	whereas	it	was	
60%	after	only	24	h	when	crosslinking	was	omitted.	Collagen	and	ELsol	each	possessed	approxi-
mately	300	nmol	amine	groups	per	mg.	Therefore,	scaffolds	made	from	these	components	had	
the	same	amount	of	amine	groups	for	all	ratios	before	crosslinking.	After	EDC/NHS	crosslinking,	
approximately	60%	of	the	amine	groups	remained	for	all	scaffolds,	indicating	that	40%	of	the	amine	
groups	was	used	in	the	crosslinking	reaction.	ELsol	did	not	contribute	to	the	water-binding	activity	
of	scaffolds.	At	a	higher	percentage	of	ELsol,	the	waterbinding	capacity	of	COL-ELsol	scaffolds	was	
lower.	Under	scanning	electron	microscopy	 (Fig.	1),	non-crosslinked	COL-ELsol	 scaffolds	showed	
spherical	 structures	attached	to	collagenous	fibrils	or	sheets.	Spheres	of	different	sizes	 (ranging	
from±200	nm	to	10	mm)	were	found	throughout	the	scaffolds.	After	crosslinking,	these	spheres	
deformed	to	some	extent.	COL	and	COL-ELfiber	scaffolds	 	did	not	show	this	 spherical	organiza-
tion.	Immunofluorescence	staining	using	an	antibody	against	bovine	elastin	demonstrated	that	the	
spheres	in	COL-ELsol	scaffolds	were	composed	of	ELsol	(Fig.	2A).	The	same	was	found	based		on	the	
autofluorescence	of	elastin	(Fig.	2B).	Transmission	electron	microscopy	showed	that	ELsol	spheres	
in	EDC/NHS-crosslinked	COL-ELsol	scaffolds	had	a	wide	size	distribution	and	were	mostly	incorpo-
rated	into	the	collagen	network	(Fig.	2C,	D).	The	latter	figure	also	shows	a	sphere	with	a	less-dense	
outer	core.	Crosslinking	does	not	occur	instantaneously,	which	may	cause	this	effect.	
Tissue response to implanted scaffolds 
All	animals	remained	in	good	condition,	and	no	infections	were	observed.	Macroscopically,	a	thin	
capsule	was	 	 seen	around	 the	 scaffolds	at	explantation.	 In	Table	2,	an	overview	of	 calcification	
behavior and cellular response is given 
for	 the	3	different	 scaffolds.	 Tissue	 re-
sponse	to	COL	and	COL-ELfiber	scaffolds	
was consistent with previous results.14
Fig 1. Morphology of scaffolds as analysed 
by scanning electron microscopy. (A, B) 
non-crosslinked (NX) COL-ELsol; (C, D) EDC/
NHS-crosslinked (X) COL-ELsol; (E) COL and (F) 
COL-EL
fiber 
scaffolds. A and C represent cross-
sectional views, whereas B , D, E and F are en-
larged to views. Arrowheads indicate insoluble 
elastin fibres en COL-EL
fiber
, whereas arrows 
indicate spherical structures that are only 
present in the COL-ELsol. Spherical structures in 
EDC/NHS-crosslinked COL-ELsol are somewhat 
deformed compared to non-crosslinked COL-
ELsol (inserts in B and D). Bar is 100 µm in A 
and C, and 10 µm in other images.
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Fig.2 Microscopical evaluation 
of spherical structures in collagen 
with solubilized elastin (COL-ELsol) 
scaffolds. (A) Immunofluorescence 
staining for elastin and (B) auto-
fluorescence visualization using ul-
traviolet optics in 1-ethyl-3-(3-de-
methylaminopropyl)carbodiimide/ 
6 mM N-hydrocysuccinimide (EDC/
NHS)-crosslinked scaffolds show 
hat spherical structures are com-
posed of ELsol. (C, D) Transmis-
sion electron microscopy images 
display that ELsol spheres (White 
arrowheads) are incorporated in 
the collagenous structures (white 
arrows) of EDC/NHS crosslinked 
scaffolds. Bar is 50 µm in A, B and 
0,25 µm in C, D.
Calcification of scaffolds
In	young	Sprague-Dawley	rats,	COL-ELsol	and	COL	did	not	calcify	at	all	in	the	time	span	investi-
gated,	in	contrast	to	COL-ELfiber	(Fig.	3).	In	COL-ELfiber	especially,	elastin	fibers	calcified	from	day	
7 on. At day 7, 3.5% ±	0.1%	of	the	total	scaffold	surface	had	calcified,	whereas	at	day	21,	it	was	
11.5%± 0.7%,	which	was	statistically	significant	(	p<0.05).
Fig. 3 Light microscopy evaluation of calcification of scaffolds 21 days after implantation in young Sprague-Dawley 
rats. (A) Collagen Alone (COL), (B) collagen plus insoluble elastin fibre (COL-EL
fiber
), (C) collagen with solubilised 
elastin (COL-ELsol) scaffolds. Calcium deposits have an intense black colour due to Von Kossa staining and are only 
found in COL-EL
fiber
. Bar is 50 µm.
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Cellular response to scaffolds
At	day	3,	cellular	response	to	COL-ELsol	showed	moderate	infiltration	of	neutrophilic	granulocytes	
throughout	the	scaffold,	whereas	at	day	7,	fibroblasts	and	other	mononuclear	cells	and	few	giant	
cells	were	found.	At	day	21,	a	greater	number	of	phagocytic	cells	was	observed,	with	strong	prolif-
eration	of	fibroblasts.	Cellular	reactions	to	COL	and	COL-ELfiber	were	considerably	less.	COL	gave	
the	mildest	reaction;	after	21	days,	some	macrophages	and	giant	cells	were	present,	mainly	at	the	
periphery	of	the	scaffolds.	At	day	3,	cellular	response	to	COL-ELfiber	included	some	neutrophilic	
granulocytes	that	had	entered	the	outer	part	of	the	scaffold.	At	day	7,	fibroblasts	and	other		mono-
nuclear	cells	were	found	in	the	scaffold,	with	some	giant	cells	at	the	periphery	of	the	scaffold,	and	
at	day	21,	phagocytic	cells	like	macrophages	and	giant	cells	dominated	the	scaffold,	whereas	the	
number	of	non-phagocytic	cells	had	increased	at	the	periphery.	Although	more	macrophages	were	
found	in	COL-ELsol,	the	number	of	giant	cells	in	COL-ELsol	and	COL-ELfiber	was	similar.
Vascularization of scaffolds
Type IV collagen (present in endothelial basement membranes) was used as a marker for blood 
vessels	(Fig.	4).	At	day	3,	no	blood	vessels	were	observed	in	the	scaffolds,	although	they	were	
found	in	the	surrounding	tissue.	At	day	7,	COL-ELsol	showed	more	blood	vessels	than	COL-Elfiber	
and	COL,	but	differences	were	not	 statistically	 significant.	At	day	21,	blood	vessels	were	also	
most	abundant	in	COLELsol,	both	at	the	periphery	and	within	the	scaffold,	accompanied	by	more	
large	blood	vessels.	COL-ELsol	now	contained	a	significantly	 larger	area	of	blood	vessels	 than	
COL-Elfiber	and	COL.	At	this	time,	COL-ELfiber	also	had	statistically	significantly	more	blood	ves-
sels	than	COL.	In	this	scaffold,	vascularization	was	also	present	at	the	periphery,	but	considerably	
fewer	vessels	were	found	within	the	scaffold.	 In	COL,	blood	vessels	were	found	mainly	at	the	
periphery	of	the	scaffolds.
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Fig. 4 Light microscopical 
evaluation of angiogen-
esis in scaffolds 21 days 
after implantation in young 
Sprague-Dawley rats. Sec-
tions were stained for type 
IV collagen as a marker for 
blood vessels. (A) Collagen 
alone (COL), (B) collagen 
plus insoluble elastin fibre 
(COL-EL
fiber
), (C) periphery 
of collagen with solubilised 
elastin (COL-ELsol), (D) with-
in COL-ELsol scaffold. Bar is 
50 µm. (E) Quantification 
of blood vessels in the scaf-
fold using type IV collagen 
and expressed as a per-
centage of the total area. 
At day 21, COL-ELsol had 
significantly more blood 
vessel than COL an COL-
EL
fiber
. *p<0.05.
Scaffold degradation and new matrix synthesis
Table	3	gives	an	overview	of	 the	 immunostaining	 for	 scaffold	components	and	newly	 formed	
extracellular	matrix	molecules	at	different	times.
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Scaffold degradation
Scaffold	degradation	was	studied	using	conventional	histology	and	immunohistochemistry	with	
antibodies	for	scaffold	elastin	and	collagen.	From	day	7,	elastin	staining	in	COL-ELsol	decreased,	
and	after	21	days,	elastin	 staining	was	 reduced	even	more.	Elastin	 spheres	were	 still	 present	
at	this	time,	especially	 in	the	central	part	of	the	scaffolds	(Fig.	5A,	B).	At	the	periphery	of	the	 
scaffolds,	 staining	 intensity	 was	 less,	 and	 spheres	 were	 smaller,	 suggesting	 resorption	 and	 
degradation.	Collagen	gradually	decreased	with	time.	Elastin	fiber	fragments	(smaller	than	the	
implanted	elastin	fibers)	were	found	from	day	7	on	in	COL-ELfiber.	At	day	21,	less	elastin	staining	
and	more	elastin	fragments	were	observed	in	these	scaffolds.	In	the	same	scaffold,	thinner	and	
fragmented	collagen	structures	were	visible	mainly	at	the	periphery	of	the	scaffolds	from	day	7	
on. At day 21, degraded collagen was also found more centrally, whereas only minor amounts of 
fragmented	collagen	were	found	in	COL.	Elastin	and	collagen	degradation	in	COL-ELfiber	and	COL	
was consistent with that found in previous studies.14
Fig. 5. Elastin Van Gieson-stained paraffin sections of collagen with solubilised elastin (COL-ELsol) scaffolds shows 
that Elsol Spheres from the scaffold are still present 21 days after implanting in Young Sprague-Dawley rats. Within 
the scaffolds, elastin spheres (arrows) are still quite large (A), but at the periphery of the scaffolds, the elastin 
spheres are smaller (B). Elastin Von Gieson stains elastin black and collagen pink or red. Bars represent 20 µm. (C) 
Semi-thin epon sections of crosslinked COL-ELsol scaffolds that were implanted for 7 days in young Sprague-Dawley 
rats stained with toluidine blue and basic fuchsin. Flattened cells aligned with the scaffold lamellar structure and 
were accompanied by extracellular matrix formation. Cells stain Blue, new extracellular matrix stains light pink and 
scaffold material stains dark pink. Bars represent 10 µm. 
Collagen formation
Generally,	most	staining	for	rat	type	I	and	type	III	collagen	was	found	in	COL-ELsol,	somewhat	less	in	
COLELfiber,	and	least	in	COL.	In	all	scaffolds,	staining	for	type	I	and	III	collagen	started	in	the	fibrous	
capsule	and	at	the	periphery	of	the	scaffolds	from	day	7	on	(results	not	shown).	In	general,	new	rat	
collagen	fibers	aligned	with	original	scaffold	components.	In	COL-ELsol,	flattened	cells	aligned	with	
the	lamellar	scaffold	structures,	and	this	was	accompanied	by	extracellular	matrix	formation	(Fig.	
5C).	Type	IV	collagen	staining	was	present	in	blood	vessels	as	shown	under	vascularisation	(Fig.	4).	 
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At	day	21,	COL-ELsol	showed	most	new	rat	elastin,	not	only	in	blood	vessels,	but	also	as	thread-
like	structures	within	the	scaffold	(Fig.	6).	In	COL-ELfiber,	rat	elastin	was	found	mainly	in	blood	
vessels	present	in	the	capsule	around	the	implant,	and	small	amounts	of	thin	elastic	fibers	were	
found	sporadically	at	the	periphery	of	the	scaffolds.	In	COL,	rat	elastin	was	present	only	in	blood	
vessels	in	the	capsule.	In	blood	vessels,	rat	elastin	colocalized	with	fibrillin-1	and	fibrillin-2	stain-
ing.	Fibrillin-2	staining	was	mainly	present	in	blood	vessels	(Fig.	6J–L),	but	not	all	blood	vessels	
contained	newly	 formed	elastin	 (Fig.	6G–I).	 Thin	fibrillin-1	fibers	were	 formed	mainly	 in	COL-
ELsol,	to	a	lesser	extent	in	COL-ELfiber,	and	scarcely	in	COL	(Fig.	6D–F).	To	some	extent,	these	thin	
fibers	showed	colocalization	with	rat	elastin	(Fig.	6C,	F).	Fibrillin-1	staining	was	found	earlier	in	
time	than	newly	synthesized	elastin	(results	not	shown)	and	was	more	abundant	than	rat	elastin	
staining (Fig. 6C, F).
Fig. 6 Fluorescence microscopy evaluation of newly formed elastic fibres in scaffolds, 21 days after implantation in 
young Sprague-Dawley rats. Sections were stained for rat elastin (A-C, G-I), fibrillin-1 (D-F) and fibrillin-2 (J-L). Espe-
cially in collagen with solubilised elastin (COL-ELsol) scaffolds, threadlike structures (arrows) positive for rat elastin 
and fibrillin-1 were observed. Blood vessels mainly colocalized with fibrillin-2 and to a lesser extend with fibrillin-1. 
Insert in F shows an example of colocalized rat elastin and fibrillin-1 in blood vessels; insert in L shows that thin rat 
elastin fibers do not colocalize with fibrillin-2. C, capsule; S, scaffold. Bar is 50 µm.
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Discussion
In	biomaterials,	 some	principal	difficulties	are	observed,	 including	 limited	vascularization	and	
poor elastogenesis.3, 35	With	regard	to	the	application	of	elastin	as	a	biomaterial,	another	diffi-
culty	arises	because	elastin	tends	to	calcify.14, 36	To	induce	vascularization	and	tissue	formation,	an	
initial	tissue	reaction	seems	to	be	necessary.	COL	scaffolds	show	less	reaction	than	COL-ELfiber	or	
COL-ELsol,	and	little	tissue	formation	was	observed	after	3	weeks.	Tissue	reaction	is	also	depen-
dent on the animal model used. In a previous study, we showed that (young and adult) Sprague- 
Dawley	 rats	 showed	more	tissue	 reaction	 to	 subcutaneously	 implanted	 scaffolds	 than	 (adult)	
Wistar rats.14	As	a	consequence,	more	vascularization	and	collagen	production	was	observed	in	
the Sprague-Dawley rats.14, 37	In	this	study,	COL-ELsol	gave	more	tissue	reaction	than	COLELfiber,	
and	vascularization	and	tissue	formation	was	even	better	in	COL-ELsol	scaffolds.	For	example,	in	
normal	wound	healing	of	the	skin,	chemotactic	signals	recruit	inflammatory	cells	to	the	wound	
site,	initiating	the	process	of	reepithelialization	and	connective	tissue	contraction	and	stimulat-
ing	the	angiogenic	response.	It	is	important	that	this	tissue	reaction,	including	the	presence	of	
neutrophiles,	does	not	persist	over	time,	because	it	is	an	indication	of	a	grossly	infected	wound.38 
In	COL-ELsol,	neutrophiles	were	 found	only	sporadically	at	day	7.	Soluble	elastin	seems	to	be	
able	to	trigger	a	cascade	for	angiogenesis	and	tissue	regeneration.	Robinet	et	al.39 recently dem-
onstrated	that	k-elastin	(solubilized	elastin	prepared	using	potassium	hydroxide	treatment)	trig-
gered	angiogenesis	by	promoting	cell	migration	and	tubulogenesis	of	human	vascular	endothe-
lial	cells	through	the	elastin	receptor.	Elastin	synthesis	is	often	an	obstacle	in	tissue	engineering	
(e.g.,	dermal	substitutes).40	In	this	study,	COL-ELsol	scaffolds	were,	in	particular,	able	to	stimulate	
the	synthesis	of	elastic	fibers	in	vivo,	especially	as	thread-like	structures	to	which	fibrillin-1	stain-
ing	colocalized.	Additional	fibrillin-1	staining	was	found	surrounding	these	structures,	suggesting	
that	fibrillin-1	synthesis	preceded	elastin	deposition	and	that	elastin	deposition	was	still	in	prog-
ress.	Fibrillin-2	colocalized	mainly	with	newly	formed	elastic	fibers	in	blood	vessels	and	not	with	
loose	thread-like	elastic	fibers	found	in	COL-ELsol.	From	mice	experiments,	it	has	been	suggested	
that	fibrillin-2	directs	elastogenesis	during	embryogenesis,	whereas	fibrillin-1	is	more	important	
in	tissue	homeostasis.	41, 42	Our	experimental	setup	may	resemble	tissue	regeneration	rather	than	
embryogenesis.	Furthermore,	our	results	indicate	that	fibrillin-2	may	be	more	involved	in	cardio-
vascular	aspects,	whereas	fibrillin-1	may	be	more	significant	in	skin.	Another	study	in	which	skin	
biopsies	were	taken	from	healthy	volunteers	suggests	a	similar	phenomenon;	fibrillin-1	was	the	
major	contributor	to	dermal	elastic	fiber	formation	during	acute	wound	repair,	whereas	fibril-
lin-2	was	expressed	only	in	wounds	of	the	aged,	and	expression	was	confined	to	areas	proximal	
to dermal blood vessels.43	Raghunath	et	al.	also	found	fibrillin-1	preceding	elastin	deposition	in	
new	skin	developing	from	keratinocyte	autografts.44	Fibrillin-1	may	be	the	template	for	elastic	
fiber	synthesis	in	thread-like	(skin-like)	elastic	fibers,	whereas	fibrillin-2	may	be	the	template	for	
elastogenesis	in	blood	vessels.	However,	time-resolved	expression	patterns	of	fibrillin-1	and	-2	
would	be	necessary	to	confirm	this.	Solubilized	elastin	may	be	a	means	to	enhance	elastic	fiber	
synthesis.	 It	has	been	 suggested	 that	elastin	peptides	 stimulate	elastin	 synthesis	 through	 the	
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(including	elastin	regeneration)	was	found	with	a	collagen–solubilized	elastin	dermal	substitute.45 
In	a	clinical	study,	such	a	matrix	was	used	in	10	patients	as	a	dermal	substitute	in	severe	burn	
injuries	of	the	hand;	full	range	of	hand	motion	was	regained	after	3	months.46 For a sustained ef-
fect	of	angiogenesis	and	tissue	formation	in	vivo,	a	depot	of	solubilized	elastin	is	recommended.	
EDC/NHScrosslinked	COL-ELsol	scaffolds	contained	solubilized	elastin	spheres	that	could	still	be	
detected	21	days	after	implantation	and	may	thus	accomplish	their	biological	effect	over	a	lon-
ger	period	of	time.	Calcification	is	an	undesirable	phenomenon	in	soft	biomaterial	application.	
Young	Sprague-Dawley	rats	have	proven	to	be	a	sensitive	model	for	studying	calcification.14 With 
COL-ELsol,	we	could	not	detect	any	calcification	in	the	time	frame	analyzed,	whereas	COL-ELfiber	
showed	calcification	starting	at	insoluble	elastin	fibers.	This	effect	was	not	due	to	the	presence	
of	fewer	macrophages	and	giant	cells	in	COL-ELsol	(and	therefore	a	diminished	release	of	extra-
cellular	enzymes	involved	in	elastin	degradation).	Negative	charges	from	C-terminal	carboxylic	
groups	may	be	involved	in	preventing	positively	charged	calcium	ions	from	precipitating,	but	other	
mechanisms	cannot	be	excluded	based	on	this	study	alone.	Others	have	observed	calcification	
of	solubilized	elastin	preparations.	In	a	similar	rat	model,	Singla	and	Lee	found	calcification	with	 
collagen–elastin	films	stabilized	using	glutaraldehyde	fixation,36 but this treatment increases cal-
cification	of	biomaterials.47	In	a	cranial	lesion	in	adult	rats,	a	polypentapeptide	based	on	elastin	
with	an	amino	acid	sequence	of	(Val-Pro-Gly-Val-Gly)n	was	also	able	to	 initiate	calcification	in	
vivo,48 but	 it	only	calcified	 in	a	rabbit	tibial	nonunion	model	with	n>200.49	 In	conclusion,	COL-
ELsol	scaffolds	provide	a	noncalcifying	biomaterial	that	stimulates	angiogenesis	and	extracellular	
matrix	formation	(collagens	and	elastic	fibers)	and	may	be	useful	in	soft	tissue	engineering.
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Abstract
An	 important	 issue	 in	 tissue	 engineering	 is	 the	 vascularisation	 of	 the	 implanted	 construct,	
which	often	takes	several	weeks.	In vivo, the growth factors VEGF and FGF2 show a combined 
effect	on	both	angiogenesis	and	maturation	of	blood	vessels.	Therefore,	we	hypothesise	 that	
the	addition	of	these	growth	factors	to	an	acellular	construct	increases	blood	vessel	formation	
and	maturation.	To	 systematically	evaluate	 the	contribution	of	each	scaffold	component	with	
respect	to	tissue	response	and	in	particular	to	blood	vessel	formation,	five	porous	scaffolds	were	
prepared and characterised viz.: collagen, collagen with heparin, and collagen with heparin plus 
one	or	two	growth	factors	(rrFGF2	and	rrVEGF).	Scaffolds	were	subcutaneously	implanted	in	3	
months	old	Wistar	 rats.	Of	all	 scaffolds	 tested,	 the	one	with	a	combination	of	growth	 factors	
displayed the highest density of blood vessels (type IV collagen) and most mature blood vessels 
(smooth	muscle	actin).	In	addition,	no	hypoxic	cells	were	found	in	this	scaffold	at	day	7	and	21	
(hypoxia	inducible	factor	1-α).	These	results	indicate	that	the	addition	of	both	FGF2	and	VEGF	to	
an acellular construct enhances an early mature vasculature. This opens prospects for (acellular) 
tissue-engineered	constructs	in	conditions	as	ischemic	heart	disease	or	diabetic	ulcers.
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51 Introduction
A	major	problem	in	tissue	engineered	devices	is	the	vascularisation	of	the	construct.	It	usually	
takes several weeks for a construct to become fully vascularised1.	Vascularisation	is	important	in	
several	pathological	conditions	including	ischemic	heart	disease2	and	diabetic	ulcers3. Impaired 
wound	healing	in	case	of	diabetic	ulcers	occurs	due	to	a	lack	of	oxygen	and	nutrition	to	the	cells	
and	inadequate	removal	of	waste	products	from	the	cells4.	Introduction	of	angiogenesis	results	
in	better	healing	of	affected	tissues5.
In	order	to	increase	the	vascularisation	of	tissue	engineered	constructs,	several	approaches	have	
been	employed.	For	instance,	the	pore	size	of	the	scaffold	has	been	varied	resulting	in	an	opti-
mum	diameter	for	cellular	adhesion	and	migration	(~100	µm)6. Furthermore, endothelial cells 
and	fibroblasts	have	been	included	in	gelatine-coated	polystyrene	scaffolds	in	order	to	initiate	
angiogenesis in vitro,	resulting	in	sprouts	prior	to	transplantation7.	The	addition	of	glycosamino-
glycans and growth factors also proved to increase angiogenesis in vivo1.	However,	it	still	takes	
about	four	weeks	to	develop	sufficient	vasculature.	
Angiogenesis	 is	a	multifactor	process,	which	 is	regulated	by	an	 interplay	of	a	 large	number	of	 
factors.	Angiogenesis	can	be	set	on	by	e.g.	hypoxia8.	An	important	stimulating	factor	in	angio-
genesis is vascular endothelial growth factor (VEGF) which acts on the VEGF receptors (VEGFR). 
VEGF	stimulates	cells	to	produce	matrix	metalloproteinases	(MMPs)	that	degrade	the	basement	
membrane	and	 surrounding	extracellular	matrix.	As	 a	 result,	 endothelial	 cells	 proliferate	 and	
migrate	towards	the	interstitium,	where	they	start	sprouting.	Subsequently,	pericytes	prolifer-
ate	and	migrate	towards	the	newly	formed	sprouts	and	induce	maturation	by	forming	a	single	
cell layer around the sprout9,10.	The	administration	or	overexpression	of	single	VEGF	isoforms	in	
animal models results in angiogenesis, but the newly formed blood vessels may be leaky and 
phenomena	such	as	oedema,	inflammation	and	hemorrhagic	ulcers	have	been	reported9.
Another	growth	factor	known	for	 its	angiogenic	potential	 is	fibroblast	growth	factor	2	(FGF2).	
This	growth	factor	stimulates	endothelial	cells	to	produce	both	MMPs	and	VEGF	and	increases	
VEGFR	expression.	FGF2	also	stimulates	endothelial	cell	migration,	pericyte	attraction	and	matrix	
deposition11.	Local	administration	of	this	growth	factor	in	a	rabbit	ear	chamber	model	induced	
angiogenesis,	although	some	animals	showed	bleeding	vessels	and	full	vascularisation	required	
at least three weeks12.
Clearly,	the	administration	of	one	growth	factor	is	not	sufficient	to	create	well-developed	ma-
ture	blood	vessels.	Few	authors	have	studied	the	combined	administration	of	growth	factors.	
Tumour cells, transfected with VEGF and/or FGF2, need both VEGF and FGF2 to form blood ves-
sels13.	Similar	synergistic	effects	were	found	by	local	administration	of	VEGF	and	FGF2	in	a	rabbit	
ischemic	hind	limb	resulting	in	a	higher	capillary	density	and	capillary	vs.	muscle	fibre	ratio	than	
either VEGF or FGF2 alone14. 
In	this	study,	we	tested	the	hypothesis	that	the	combined	application	of	recombinant	rat	VEGF-
164 (rrVEGF) and recombinant rat FGF2 (rrFGF2) increases angiogenesis in acellular collagen-
heparin	scaffolds	for	tissue	engineering.	For	that	purpose,	scaffolds	consisting	of	combinations	
of type I collagen, heparin, FGF2 and VEGF were constructed, characterised and evaluated for in 
vivo	tissue	response	after	subcutaneous	implantation	in	adult	Wistar	rats.
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2 Materials and methods
2.1  Materials
Unless stated otherwise all chemicals were purchased from Merck Chemicals (Darmstadt, 
Germany).	Type	I	collagen	was	purified	from	bovine	achilles	tendon	using	diluted	acetic	acid,	
NaCl,	 urea	 and	 acetone	 extractions15. Heparin was purchased from Sigma Chemical Co. (St 
Louis,	MO,	USA).	Recombinant	rat	FGF2	was	produced	in	E. coli M15 PQE16 and recombinant 
rat VEGF-164 in P. pastoris GS1151. 
2.2  Preparation of scaffolds
Five	different	scaffolds	were	prepared:
-	COL:	type	I	collagen	only,
-	COLH:	type	I	collagen	with	heparin,	
-	COLHF:	type	I	collagen	with	heparin	and	FGF2,
-	COLHV:	type	I	collagen	with	heparin	and	VEGF,
-	COLHFV:	type	I	collagen	with	heparin,	FGF2	and	VEGF.
The	 scaffolds	 were	 prepared	 by	 freezing	 a	 0.8%	 collagen	 suspension	 in	 diluted	 acetic	 acid	
at -20°C1,16	 and	 subsequently	 lyophilising	 in	 a	 Zirbus	 lyophiliser	 (Bad	 Grund,	 Germany).	 All	
scaffolds	were	 chemically	 crosslinked	with	 and	without	 2.75%	heparin	 for	 4	 h	with	 33	mM	
1-ethyl-3-dimethyl	 aminopropyl	 carbodiimide	 (EDC)	 and	6	mM	N-hydroxysuccinimide	 (NHS)	
in	50	mM	2-morpholinoethane	sulphonic	acid	(pH	5.0)	in	the	presence	of	40%	ethanol.	After	
reaction,	the	scaffolds	were	washed	in	0.1	M	Na2HPO4, 1 M NaCl, 2 M NaCl and demineralised 
water.	Scaffolds	(2	punches	per	ml,	±	1,5	mg	each)	were	incubated	for	60	min	in	7	µg	growth	
factor	(FGF2	or	VEGF)	per	ml	phosphate	buffered	saline	(PBS)	(pH	7.2)	and	washed	in	PBS1. For 
the	combination	of	both	growth	factors,	3.5	µg/ml	of	FGF2	and	3.5	µg/ml	VEGF	were	used.
2.3 Characterisation of scaffolds
Scanning electron microscopy (SEM)	was	used	to	analyse	the	ultrastructure	of	the	scaffolds.	
Scaffolds	were	mounted	on	stubs	and	sputtered	with	an	ultrathin	 layer	of	gold	 in	a	Polaron	
E5100	SEM	coating	system,	and	analysed	with	a	JEOL	JSM-6310	scanning	electron	microscope	
at 15 kV.
The amine group content	of	the	scaffolds	was	analysed	using	2,4,6-trinitrobenzene	sulphonic	
acid	to	determine	the	extent	of	crosslinking17.
The heparin content	of	the	scaffolds	was	determined	by	a	hexosamine	assay	using	p-dimethyl-
aminobenzoaldehyde15.
The amount of growth factor	bound	to	the	scaffold	was	determined	by	western	blotting18 with 
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5antibodies	against	FGF2	(1:2000)	and	rat	VEGF	(1:1000)	and	peroxidase-conjugated	secondary	
antibodies	 visualised	with	 a	 chemiluminescent	 detection	 kit	 (ECL)	 (Amersham	Biosciences).	
Gene Tools (Syngene, Cambridge, UK) was used to analyse the intensity of the bands. 0-100 
ng	growth	factor	was	used	as	a	standard	curve.	Scaffolds	without	growth	factors	were	taken	
as controls.
Immunofluorescence microscopy was	used	to	determine	the	distribution	of	 type	 I	collagen	 ,	
heparin,	FGF2		and	VEGF	in	the	scaffolds,	as	described20	(for	dilutions	see	Table	1).	Omission	of	
the	primary	antibody	was	taken	as	a	negative	control.
2.4 Implantation of scaffolds 
NIH	guidelines	for	the	care	and	use	of	 laboratory	animals	(NIH	publication	85-23	Rev.	1985)	
were	observed.	The	study	was	approved	by	the	Ethics	Committee	of	the	Radboud	University	
Nijmegen. Wistar rats (male, 3 months) were purchased from Harlan (Horst, The Netherlands). 
The rats were housed per 2, fed pelleted diet (RMH-B 10 mm) and water ad libitum. The rats 
were	 anaesthetized	with	 isoflurane.	 After	 disinfection,	 4	 subcutaneous	 pockets	were	made	
on	both	sides	of	 two	midline	 incisions	on	the	back.	Scaffolds	 (Æ 6 mm) were washed in 70% 
ethanol	(4x	30	min)	and	sterile	PBS	(8x	30	min)	and	placed	in	the	pockets	at	about	1	cm	of	the	
incision.	Each	rat	received	4	implants	(2	different	scaffolds).	At	day	3,	7	and	21,	the	implants	
with	 surrounding	 tissue	were	 removed.	 The	 explants	were	 divided	 in	 halves;	 one	 half	 was	
processed	for	conventional	histology	and	the	other	for	immunohistochemistry.
2.5 Processing of explants
Conventional histology:	 to	 study	 the	 cellular	 reaction,	 paraffin	 sections	 were	 cut	 and	
haematoxylin-eosin	 stained21.	 Histology	 of	 the	 scaffolds	was	 evaluated	 independently	 by	 at	
least	two	experienced	investigators.
Immunostaining:	To	study	formation,	maturation	and	functionality	of	blood	vessels,	sections	
were	 stained	 with	 specific	 antibodies.	 Type	 IV	 collagen	 (COL	 IV)	 was	 used	 to	 manually	
determine the total area of blood vessels22.	The	total	area	of	blood	vessels	was	expressed	as	a	
percentage	of	the	total	implant	size.	Smooth	muscle	actin	(SMA)	was	used	to	study	the	level	of	
maturation	of	the	newly	formed	blood	vessels23.	The	total	area	of	SMA-positive	blood	vessels	
was	expressed	as	a	percentage	of	the	total	area	of	blood	vessels.	Hypoxia	inducible	factor	1-α	
(HIF1-α)	was	used	to	determine	the	number	of	hypoxic	cells	in	the	scaffold24. The amount of 
HIF1-α-positive	cells	was	expressed	as	a	percentage	of	the	total	number	of	cells	(on	average,	
500	cells	were	counted).	Values	were	compared	using	 the	Student’s	 t-test	and	p<	0.05	was	
considered	to	be	statistically	significant.
Immunofluorescence assay, Frozen	 sections	 were	 cut	 and	 incubated	 with	 antibodies	 for	
collagen	type	IV		and	smooth	muscle	actin		as	described20	(for	dilutions	see	Table	1).
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Peroxidase-antiperoxidase method, the	 peroxidase-antiperoxidase	 method	 was	 used	 to	
immunolocalise	molecules	(hypoxia	inducible	factor	1-α	and	smooth	muscle	actin)	in	paraffin	
sections.	5	µm	sections	were	deparaffinised	and	 incubated	as	described21	 (for	dilutions	 see	
Table 1).
Figure 1. Microscopical evaluation 
of the different scaffolds. Scanning 
electron micrograph of a cross-
section of COL (A) and COLH scaf-
fold (B). Immunolocalisation of type 
I collagen (C), heparin (D), FGF2 (E) 
and VEGF (F) in a COLHFV scaffold. 
Bar (A, B) is 100 µm; bar (C-G) is 
50 µm.
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3.1 Scaffold characteristics
The	morphology	of	the	scaffolds	was	analysed	by	SEM	(Fig.	1A,	B).	Rounded	pores	were	in	the	
range	of	75	to	125	µm.	The	scaffold	was	chemically	crosslinked	with	EDC	and	NHS	to	covalently	
bind	heparin.	During	crosslinking,	an	amine	group	reacts	with	a	carboxylic	group	and	hence	the	
extent	of	crosslinking	was	evaluated	by	analysing	the	remaining	free	amine	groups.	About	50-	
60% of the amine groups were used for crosslinking (Table 2). The amount of heparin covalently 
bound	to	the	scaffold	was	~	68	µg/mg	scaffold,	as	determined	by	hexosamine	assay.
The	amount	of	FGF2	that	bound,	analysed	by	western	blotting	and	Gene	Tools,	was	1.6	±	0.2	µg/
mg	scaffold.	For	VEGF,	it	was	1.0	±	0.3	µg/mg	scaffold.	When	both	growth	factors	were	present	
in	the	dipping	solution,	1.0	±	0.2	µg	FGF2	and	0.7	±	0.3	µg	VEGF	bound	per	mg	scaffold	(Fig.	2	
and Table 2).
The	 distribution	 of	 the	 different	 components	 in	 the	 scaffolds	 was	 visualised	 using	
immunofluorescence	 and	 revealed	 that	 heparin,	 FGF2	 and	 VEGF	 were	 equally	 distributed	
throughout	the	scaffold	(Fig.	1C-G).	
Figure 2. Quantification of VEGF and 
FGF2 bound to collagen-heparin 
scaffolds using Western blotting.
A) Detection of VEGF and FGF2 in 
various collagen-heparin scaffolds.
B) Standard curve of VEGF after 
band analysis (0-100 ng).
COLHV= collagen-heparin-VEGF 
scaffold; COLHFV= collagen-heparin-
FGF2-VEGF scaffold; COLHF= colla-
gen-heparin-FGF2 scaffold.
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3.2 Cellular response to scaffolds
A	systematic	survey	using	five	different	types	of	scaffolds	allowed	us	to	evaluate	the	contribution	
of	the	different	components.	Cellular	events	are	summarised	in	Table	3.
At	day	3,	COL	and	COLH	scaffolds	showed	minor	infiltration	of	granulocytes	and	macrophages	
at	 the	outer	part	of	 the	 scaffold,	whereas	COLHF	and	COLHV	showed	a	moderate	amount	of	
macrophages,	 fibroblasts	 and	 some	 granulocytes	 further	 in	 the	 scaffold.	 COLHFV	 showed	 a	
moderate	amount	of	granulocytes,	macrophages	and	some	fibroblasts	throughout	the	scaffold	
(Fig. 3). A thin layer of capsule surrounded all implants.
At	day	7,	no	granulocytes	were	present	in	the	scaffolds	anymore.	Few	giant	cells	were	found	at	this	
time	point.	The	cellular	response	to	COL	and	COLH	included	a	moderate	amount	of	macrophages	
and	 some	fibroblasts	 further	 in	 the	 scaffold.	 COLHF	 and	COLHV	 showed	a	moderate	 amount	
of	macrophages	and	fibroblasts	 throughout	 the	 scaffold	and	 some	non-phagocytic	 cells	were	
present.	A	larger	amount	of	macrophages	and	fibroblasts	accompanied	by	some	non-phagocytic	
cells	were	found	throughout	the	COLHFV	scaffold.	All	scaffolds	contained	a	thin	layer	of	capsule	
around the implants.
At	 day	 21,	 macrophages	 and	 non-phagocytic	 cells	 were	 present	 throughout	 COL	 and	 COLH	
scaffolds.	A	larger	amount	of	macrophages,	giant	cells,	fibroblasts	and	non-phagocytic	cells	was	
found	 throughout	 the	COLHF,	COLHV	and	COLHFV	 scaffolds.	All	 scaffolds	 contained	a	 capsule	
layer around the implants. 
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3.3 Blood vessels
At	day	3,	no	blood	vessels	were	observed	in	the	scaffolds,	but	blood	vessels	were	found	in	the	
surrounding	tissue.	More	blood	vessels	were	found	near	COLHF,	COLHV	and	COLHFV	scaffolds	
compared	to	COL	and	COLH.	This	observation	could	also	be	made	macroscopically	from	the	red	
colour	of	the	scaffolds	at	explantation.
At	day	7,	 no	blood	 vessels	were	present	 in	COL,	whereas	 all	 other	 scaffolds	 contained	blood	
vessels	as	shown	by	COL	IV	staining	(Fig.	4	and	5).	COLHFV	showed	the	largest	blood	vessel	area	
(5.9%	±	1.6),	COLHF	(2.6%	±	1.9)	and	COLHV	(2.3%	±	0.7)	somewhat	lower	and	COLH	the	least	
(0.9%	±	0.2).	No	significant	differences	were	found	between	COLHV-COLHF	and	COLHF-COLH.
SMA-staining	was	used	as	a	marker	for	maturated	blood	vessels.	The	total	area	of	SMA-positive	
blood	vessels	was	expressed	as	a	percentage	of	the	total	area	of	blood	vessels	(determined	by	
COL	 IV	 staining)	 (Fig.	 4	and	5).	 	COLHFV	 showed	most	 SMA-positive	blood	vessels	 (35%	±	4),	
more	than	COLHF	(18.3%	±	7.4),	COLH	(17.2%	±	0.9)	and	COLHV	(16.9%	±	2.2).	No	significant	
differences	were	found	between	COLHV-COLHF,	COLHV-COLH	and	COLHF-COLH.
Figure 3. Histological evaluation of scaffolds explanted at day 3. 
Haematoxylin-eosin staining of  COL (A), COLH (B), COLHF (C), COLHV (D) 
and COLHFV (E). COL and COLH only showed some cells in the outer part of 
the scaffold, whereas the scaffolds with growth factors (COLHF, COLHV and 
COLHFV) also revealed cells in the centre of the scaffold. Bar is 100 µm.
82
Ch
ap
te
r
5
Figure 4. Macroscopical (A) 
and immunohistochemical 
evaluation of the scaffolds 
explanted at day 7 (B, C).
A)  Macroscopical evaluation 
of a non-implanted scaf-
fold at day 0 and explants 
at day 7 (COL, COLHV and 
COLHFV). Note the red ap-
pearance of the COLHFV 
scaffold.
B)  Immunohistochemical evaluation using type IV collagen staining of the scaffolds explanted at day 7. COLHFV 
showed the most and largest area of blood vessels compared to COLHV, COLHF and COLH. No blood vessels were 
found in COL at this time point. 
C)  Immunohistochemical evaluation using smooth muscle actin staining of scaffolds explanted at day 7. COLHFV 
displayed the largest percentage of mature blood vessels compared to COLHV, COLHF and COLH. Arrows indicate 
SMA-positive blood vessels. Bar is 50 µm.
Figure 5. Analysis of the blood vessels present in the scaffolds using COL IV and SMA staining. Scaffolds containing 
two growth factors showed both a larger total area of blood vessels and more mature blood vessels.
A)  The total area of blood vessels per scaffold was calculated from COL IV staining.  At day 7, COLHFV had significantly 
more blood vessel area than all the other scaffolds.  At day 21, COLHV had a significantly larger blood vessel area 
than all the other scaffolds with the exception of COLHV. * p<0.05.
B)  The total area of mature blood vessels (staining positive for SMA) was expressed as a percentage of the total area 
of blood vessels. At day 7 and at day 21, COLHFV had a significantly higher percentage of SMA positive blood 
vessels than all the other scaffolds. * p<0.05.
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1.8)	and	COLHFV	(6.1%	±	1.2)	had	a	significantly	larger	blood	vessel	area	than	COL	(1.7%	±	0.8).	
COLHFV	more	 than	COLH	 and	COLHF	 (3.2%	±	 0.9),	 but	 no	 significant	 differences	were	 found	
between	COLHFV-COLHV,	COLHV-COLHF,	COLHV-COLH,	COLHF-COLH	and	COLHF-COL.	
COLHFV	(83.4%	±	4.9)	showed	a	significant	higher	percentage	of	SMA-positive	blood	vessels	than	
all	other	 scaffolds	 (Fig.	6):	COL	 (34.7%	±	10.5),	COLH	 (32.3%	±	5.9),	COLHF	 (34.2%	±	3.5)	and	
COLHV	(58.2%	±	12).	No	significant	differences	were	found	between	COLHF-COLH,	COLHF-COL	
and	COLH-COL.
3.4 Hypoxia
At	day	3,	all	scaffolds	contained	97-98%	HIF1-α-positive	cells	(hypoxic	cells).	The	cells	in	the	most	outer	
region	of	the	scaffolds,	especially	the	scaffolds	with	one	or	two	growth	factors,	stained	less	intense	for	
HIF1-α,	probably	due	to	a	partial	supply	of	oxygen	and	nutrients	from	the	surrounding	tissue.
At	day	7,	all	scaffolds	showed	both	HIF1-α	positive	and	negative	cells	in	the	scaffold	centre	(Fig.	
6).	COLHFV	(2.2%	±	0.9)	had	significantly	less	hypoxic	cells	than	COL	(36.6%	±	9.9),	COLH	(35%	
±	13.5),	COLHF	(16%	±	9.2)	and	COLHV	(10.4%	±	2.2).	COLHF	and	COLHV	had	significantly	less	
hypoxic	cells	than	COL	and	COLH.
	At	day	21,	COLHFV	(0.2%	±	0.04)	had	significantly	less	HIF1-α	positive	cells	than	COL	(21.2%	±	
3.6),	COLH	(14.7%	±	2.6),	COLHF	(4.9%	±	1.4)	and	COLHV	(4.0%	±	1.8)	(Fig.	6).	COLHF	and	COLHV	
had	significantly	less	hypoxic	cells	than	COL	and	COLH.
Figure 6. Immunohistochemical analysis of HIF1-α staining of cells in the scaffolds at day 3, 7 and 21.
A)  Photographs of COLHFV scaffold at day 3 and 7. COLHFV showed many hypoxic cells at day 3 and few at day 7. 
Inserts show that HIF1-α predominantly stains the nuclei of cells. Positive cells stain black and negative cells stain 
blue. Bar is 10 µm.
B)  Statistical analysis of the percentages of HIF1-α positive cells. At day 7 and 21, COLHFV had significantly less 
hypoxic cells than all other scaffolds. *p<0.05.
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4 Discussion
In	 tissue	 engineering,	 vascularisation	 of	 the	 transplanted	 constructs	 is	 often	 limited	 at	 early	
time	 points	 and	 this	 seriously	 hampers	 the	 survival	 of	 cells.	 Cells	 die	 due	 to	 lack	 of	 oxygen,	
nutrients	and	inadequate	removal	of	waste	products.	This	confines	the	size	of	tissue-engineered	
constructs	 to	 a	maximum	of	 a	 few	 cm2 4. Generally, it takes several weeks for a construct to 
become fully vascularised. This slow development of blood vessels hampers wound healing or 
tissue	regeneration	in	certain	pathological	conditions3,5. A means to increase angiogenesis is to 
administer	growth	factors	either	by	 injection	or	preferably	 in	a	slow-release	system	such	as	a	
bioscaffold.	Scaffolds	can	be	built	up	from	several	components	and	in	this	study,	we	used	highly	
purified	 type	 I	 collagen,	 heparin,	 recombinant	 rat	 FGF2	 and	 recombinant	 rat	 VEGF.	We	 have	
previously	shown	that	collagen-heparin	scaffolds	can	give	sustained	release	of	FGF21. Therefore, 
five	 different,	molecularly-defined,	 scaffolds	were	made,	 including	 collagen-heparin	with	 and	
without	one	or	two	growth	factors.	Porous	collagen	scaffolds	(containing	pores	of	about	100	µm)	
were	prepared	by	lyophilisation	and	heparin	was	covalently	attached	to	allow	coupling	of	one	
or two heparin-binding growth factors (FGF2 and VEGF). The amount of bound FGF2 resembled 
the amount found by Pieper et al., who used 125I-FGF2 to analyse the amount of bound growth 
factor1.	More	FGF2	than	VEGF	was	able	to	bind	to	collagen-heparin	scaffolds,	perhaps	due	to	
minor	 differences	 in	 their	 affinity	 for	 heparin25,26.	 Less	 FGF2	 and	 VEGF	 bound	 to	 the	 scaffold	
after	 incubation	 in	a	solution	containing	both	growth	factors,	which	 is	 likely	due	to	the	 lower	
concentration	of	each	growth	factor,	3.5	µg	instead	of	7µg/ml,	in	the	dipping	solution.	The	total	
amount	of	both	growth	factors	present	per	mg	scaffold	was	similar	to	the	amount	of	bound	FGF2	
alone.	This	systematic	approach	allowed	us	to	study	the	influence	of	single	components	on	tissue	
response	including	blood	vessel	formation	and	maturation.	
Many	 different	 factors,	 stimulators	 as	 well	 as	 inhibitors,	 are	 involved	 in	 angiogenesis,	 and	
they all have their own mechanism9. VEGF is found to be one of the most important factors 
in	 angiogenesis.	 It	 stimulates	 endothelial	 cells	 by	 binding	 to	 VEGFR-2,	 thus	 inducing	 MMP	
production,	proliferation	and	migration	of	the	endothelial	cells.	FGF2	upregulates	the	expression	
of VEGF25	and	attracts	pericytes,	which	form	a	single	cell	layer	around	the	newly	formed	capillary,	
necessary	 to	 mature	 the	 blood	 vessel	 and	 to	 protect	 it	 from	 degradation11.	 A	 HIF1-α/FGF2	
amplification	pathway	in	which	FGF2	upregulates	HIF1-α,	leading	to	an	angiogenic	response	has	
been reported27. The complete mechanism behind the angiogenic response of FGF2, however, is 
still	not	fully	understood11.
COL	and	COLH	scaffolds	showed	a	mild	cellular	response,	whereas	the	scaffold	with	growth	factors	
showed	a	higher	influx	of	cells,	mainly	macrophages	and	fibroblasts	and,	at	day	3,	granulocytes.	
COLHFV	attracted	the	largest	amount	of	cells	as	expected.	VEGF	attracts	macrophages,	which	on	
their	turn	produce	VEGF	as	well	as	MMPs	which	release	additional	VEGF	from	the	surrounding	
tissue28.	 FGF2	 stimulates	 proliferation	 and	 differentiation	 of	 granulocytes,	 endothelial	 cells,	
fibroblasts	and	many	other	cells.	Granulocytes	also	produce	MMPs	that	degrade	the	extracellular	
matrix	 and	 release	VEGF	and	FGF2.	Pieper	et al.1	 also	 found	 that	 FGF2	addition	 to	a	 scaffold	
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5attracted	more	cells.	An	increased	cellular	reaction	may	be	necessary	to	trigger	angiogenesis29.
We	found	that	the	presence	of	VEGF	or	FGF2	alone	gave	blood	vessel	formation.	The	administration	
of	a	single	growth	factor	(VEGF	or	FGF2)	seems	not	sufficient	to	develop	a	normal	vasculature9,12.
Indeed	we	show	that	a	combination	of	VEGF	and	FGF2	is	superior	with	respect	to	blood	vessel	
formation	and	reduction	of	hypoxic	conditions	at	early	time	points.	
Our	 results	 emphasise	 that	 the	 combination	 of	 two	 growth	 factors	 enhances	 angiogenesis	
resulting	in	a	higher	area	of	blood	vessels,	similar	to	the	findings	of	Ashara	et al.14	after	injection	
of	VEGF	and	FG2	in	a	hind	limb	ischemia	model.	The	need	for	multiple	growth	factors	was	further	
investigated	by	Lascke	et al.30,	who	found	that	angiogenesis	and	blood	vessel	maturation	could	
only	 be	 suppressed	by	 complete	 inhibition	of	VEGF,	 FGF2	 and	platelet	 derived	 growth	 factor	
(PDGF). We do not need PDGF to develop mature blood vessels, perhaps because VEGF and FGF2 
are	capable	to	upregulate	the	production	of	PDGF;	a	combined	administration	of	VEGF	and	FGF2	
has	been	reported	to	be	sufficient	to	develop	mature	blood	vessels	in	the	absence	of	PDGF9. 
To	 analyse	whether	 the	 formed	 blood	 vessel	were	 functional,	we	 used	 a	marker	 for	 hypoxia	
(HIF1-α).	Under	hypoxic	conditions	HIF1-α	is	accumulated	and	transported	to	the	nucleus	where	
it	dimerizes	with	HIF1-β	to	its	active	form31. The staining revealed that the formed blood vessels 
were	 capable	 of	 supplying	 the	 infiltrated	 cells	with	 sufficient	 oxygen.	 The	 scaffold	with	 both	
FGF2	and	VEGF	showed	almost	no	hypoxic	cells	from	day	7	on.	It	usually	takes	3	to	4	weeks	for	
a construct to become fully vascularised1,12.	We	show	a	huge	reduction	in	the	time	needed	to	
induce	angiogenesis.	This	benefits	tissue	regeneration,	especially	when	you	consider	that	this	
process	requires	sufficient	blood	vessels	to	be	present32.
The	 combination	of	VEGF	and	 FGF2	 is	 capable	of	 providing	 the	 scaffold	with	 enough	mature	
blood	vessels	to	supply	the	cells	of	oxygen	and	nutrients	at	a	very	early	time	point.	Bioscaffolds	
containing	 these	 several	 factors	 may	 be	 of	 use	 in	 several	 pathological	 conditions,	 including	
ischemic	heart	disease	or	diabetic	ulcers.	For	instance,	in	diabetic	ulcers	the	most	commonly	used	
tissue-engineered	construct	is	Integra	TM,	a	collagen	based	scaffold,	which	has	the	disadvantage	
that	it	takes	several	weeks	to	become	vascularised		which	increases	the	risk	of	infections3,33. We 
propose	 that	addition	of	appropriate	growth	 factors,	 like	FGF2	and	VEGF,	 that	 increase	blood	
vessel	formation,	could	contribute	to	improved	healing	and	reduction	of	hospitalization.
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5 Conclusion
Our	results	indicate	that	the	addition	of	both	FGF2	and	VEGF	to	collagen-heparin	scaffolds	leads	
to	an	early	and	well-developed	vasculature.	This	opens	new	opportunities	for	the	use	of	acellular	
scaffolds	for	tissue	engineering.
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Abstract
Skin	substitutes	are	of	great	benefit	in	the	treatment	of	patients	with	full-thickness	wounds,	but	
there	is	a	need	for	improvement	with	respect	to	wound	closure	with	minimal	contraction,	early	
vascularisation,	and	elastin	formation.	In	this	study,	we	designed	and	developed	an	acellular	dou-
ble-layered	skin	construct,	using	matrix	molecules	and	growth	factors	to	target	specific	biological	
processes.	The	epidermal	layer	was	prepared	using	type	I	collagen,	heparin	and	fibroblast	growth	
factor 7 (FGF7), whereas the porous dermal layer was prepared using type I collagen, solubilised 
elastin,	dermatan	 sulfate,	heparin,	fibroblast	 growth	 factor	2	 (FGF2)	 and	vascular	endothelial	
growth factor (VEGF). The construct was biochemically and morphologically characterised and 
evaluated in vivo using a rat full-thickness wound model. Results were compared with the com-
mercial	 skin	 substitute	 IntegraDRT	 and	 untreated	wounds.	 The	 double-layered	 construct	was	
prepared	according	to	the	design	specifications.	The	epidermal	layer	was	about	40	µm	in	thick-
ness,	containing	9%	heparin	and	0.2	µg	FGF7/mg	layer,	 localised	at	the	periphery.	The	dermal	
layer	was	2.5	mm	thick,	had	rounded	pores,	and	contained	10%	dermatan	sulfate	+	heparin,	and	
0.7	µg	FGF2	+	VEGF/mg	layer.	The	double-layered	skin	construct	was	implanted	in	a	skin	defect	
and	on	day	7,	14,	28	and	112,	the	(remaining)	wound	area	was	photographed,	excised	and	(im-
muno)histologically	evaluated.	The	double-layered	skin	construct	showed	more	cell	influx,	signif-
icantly	less	contraction	and	increased	blood	vessel	formation	at	early	time	points	in	comparison	
to IntegraDRT and/or the untreated wound. At day 14, the double-layered skin construct also had 
the	least	myofibroblasts	present.	At	day	112,	the	double-layered	skin	construct	contained	more	
elastic	fibres	than	IntegraDRT	and	the	untreated	wound.	Structures	resembling	hair	follicles	and	
sebaceous glands were found in the double-layered skin construct and the untreated wound, but 
hardly	any	were	found	in	IntegraDRT.	The	results	provide	new	opportunities	for	the	application	of	
acellular skin constructs in the treatment of surgical wounds.
93
Design	and	in	vivo	evaluation	of	a	molecularly-defined	acellular	skin	construct:
reduction	of	early	contraction	and	increase	in	early	blood	vessel	formation
6Introduction 
Skin	substitutes	are	of	major	importance	to	patients	whose	barrier	function	is	compromised	due	
to	trauma,	surgical	wounds	or	ulcera.	The	skin	is	the	major	organ	involved	in	thermoregulation	
and	hydration,	and	acts	as	a	barrier	against	infection1. Human full-thickness defects larger than 4 
cm	in	diameter	will	not	heal	well	without	a	graft2.	Currently,	autologous	grafts	present	the	most	
effective	treatment	modality,	but	their	availability	is	limited,	and	the	harvest	of	autologous	skin	
creates new wounds at the donor site. Therefore, intensive research is being conducted to the 
development	of	skin	substitutes	which	can	be	used	for	immediate	wound	closure,	without	the	
risk	of	infection,	necrosis,	tissue	hypertrophy	and	contraction3,4.
Several	skin	substitutes	have	been	developed	and	tested	 in vivo.	A	number	of	substitutes	ob-
tained FDA approval and are available for clinical use, including Apligraf and IntegraDRT2. Apligraf 
is	a	cell-based	construct	consisting	of	an	epidermal	layer	of	human	keratinocytes	and	a	dermal	
layer	composed	of	bovine	type	I	collagen	and	human	fibroblasts5. This construct is known to be a 
safe	and	effective	graft	for	use	in	chronic	wounds.	The	cellularity	of	constructs,	however,	makes	it	
expensive	to	produce	and	difficult	to	handle6. IntegraDRT is an acellular construct composed of a 
collagen-chondroitin	sulfate	dermal	layer	and	a	silicon	top	layer.	It	is	easy	to	handle	with	off-the-
shelf	availability,	but	requires	a	two	stage	operation,	in	which	the	dermal	layer	is	first	allowed	to	
become vascularised4.	In	acellular	constructs,	angiogenesis,	graft	take	and	elastic	fibre	formation	
still	need	to	be	improved,	whereas	contraction	needs	to	be	reduced1,2. In this study, we address 
these	issues	using	a	molecularly-defined	construct,	prepared	from	scratch.	
Using	a	subcutaneous	implantation	model,	we	have	previously	shown	that	a	scaffold	consisting	
of	type	I	collagen	supplemented	with	glycosaminoglycans	and	fibroblast	growth	factor	2	(FGF2)	
promotes angiogenesis7,8.	In	addition,	we	showed	that	a	scaffold	consisting	of	collagen	and	solu-
bilised	elastin	enhances	angiogenesis	and	elastic	fibre	formation9,	and	that	combined	addition	of	
two	growth	factors	(FGF2	and	vascular	endothelial	growth	factor	(VEGF))	reduced	the	time	span	
to	obtain	vasculature	from	a	period	of	3	weeks	to	~7	days10.	Next	to	its	role	in	angiogenesis,	FGF2	
may	also	reduce	wound	contraction	by	inhibiting	the	phenotypic	change	of	fibroblasts	to	myofi-
broblasts,	which	is	likely	involved	in	contraction11-13.	Also	Fournier	et	al	showed	that	FGF2	is	still	
present	in	a	fibrin	matrix	after	28	days,	indicating	that	the	binding	of	FGF2	gives	a	long	term	re-
lease14. Based on this knowledge, a double-layered skin construct was designed and constructed 
containing	specific	factors	to	stimulate	important	biological	processes	in	skin	regeneration	(Fig.	
1). The construct consisted of two layers: a collagenous epidermal layer harbouring heparin and 
FGF7	(which	stimulates	keratinocyte	proliferation),	and	a	porous	dermal	layer	consisting	of	type	
I	collagen	fibrils,	solubilised	elastin,	dermatan	sulfate,	heparin,	FGF2	and	VEGF.	This	molecularly-
defined	construct	was	characterised	and	evaluated	in vivo using a rat full-thickness wound mod-
el, suitable to evaluate skin constructs15,16. Results were compared with commercial IntegraDRT 
and untreated wounds.
94
Ch
ap
te
r
6
Materials and methods
Materials
Unless stated otherwise, all chemicals were purchased from Merck Chemicals (Darmstadt, 
Germany).	 Type	 I	 collagen	 fibrils	 were	 purified	 from	 bovine	 achilles	 tendon	 as	 described17. 
Solubilised	elastin	was	prepared	 from	equine	 ligamentum	nuchae	as	described9. Heparin and 
dermatan	sulfate	(DS)	were	purchased	from	Sigma	Chemical	Co.	(St	Louis,	MO,	USA).	Recombinant	 
rat FGF2 was produced in E. coli M15 PQE168 and recombinant rat VEGF-164 in P. pastoris GS11518. 
Recombinant rat FGF7 was purchased from QED Biosciences (San Diego, CA, USA). IntegraDRT 
(Integra®	dermal	regeneration	template)	was	purchased	from	Integra	Lifesciences	Corporation	
(Plainsboro,	NY,	USA).	Antibodies	against	bovine	type	I	collagen,	bovine	elastin	(cross-reacting	
with	equine	elastin),	rat	VEGF,	rat	elastin,	rat	type	I	collagen,	rat	type	III	collagen,	bovine	FGF2,	
human	type	IV	collagen	and	α-smooth	muscle	actin	(the	last	three	cross-reacting	with	rat	epi-
topes) were purchased and diluted as described9,10.	 Single	chain	variable	 fragment	antibodies	
against	heparin	 (antibody	HS4C319	Molecular,	DS	 (antibody	GD3A1220)	and	chondroitin	sulfate	
(CS;	antibody	IO3H1021	were	prepared	as	described.	Goat	anti-human	FGF7	(cross-reacting	with	
rat	FGF7)	was	purchased	from	R&D	Systems	(Minneapolis,	MN,	USA).
Preparation of the double-layered skin construct
The double-layered skin construct consisted of a dermal and epidermal layer. The dermal layer 
was prepared by freezing a suspension containing 0.64% (w/v) type I collagen and 0.16% (w/v) 
solubilised	elastin	in	0.25	M	acetic	acid	at	-20°C9,22, followed by lyophilising using a Zirbus lyophi-
liser	(Bad	Grund,	Germany).	The	resulting	scaffold	was	chemically	crosslinked	with	33	mM	1-eth-
yl-3-dimethyl	 aminopropyl	 carbodiimide	 (EDC)	 and	 6	mM	N-hydroxysuccinimide	 (NHS)	 in	 the	
presence of 0.375% (w/v) DS and 0.125% (w/v) heparin for 4 h in 50 mM 2-morpholinoethane 
sulphonic acid (pH 5.0) containing 40% ethanol, and washed with 0.1 M Na2HPO4, 1 M NaCl, 2 M 
NaCl, and demineralised water9.	Growth	factors	were	bound	to	the	dermal	layer	by	incubation	(1	
ml	per	8	mg	scaffold)	in	3.5	µg	FGF2/ml	and	3.5	µg	VEGF/ml	phosphate	buffered	saline	(PBS)	pH	
7.4	for	60	min,	followed	by	5x15	min	washings	with	PBS.
The epidermal layer was produced by air-drying a 0.8% type I collagen suspension in 0.25 M 
acetic	acid23, followed by EDC/NHS crosslinking in the presence of 0.5% heparin as described 
above.	The	epidermal	layer	(1	ml	solution	per	20	mg	scaffold)	was	incubated	in	0.5	µg	FGF7/ml	
PBS,	followed	by	5x15	min	washings	with	PBS.
The wet dermal and epidermal layer were glued to each other using a 0.5% collagen suspension 
in	0.25	M	acetic	acid.	The	total	construct	was	quickly	frozen	at	-80°C	and	lyophilised.
Characterisation of construct
A	number	of	morphological	and	biochemical	techniques	was	applied	to	characterise	the	double-
layered skin construct and commercial IntegraDRT.
95
Design	and	in	vivo	evaluation	of	a	molecularly-defined	acellular	skin	construct:
reduction	of	early	contraction	and	increase	in	early	blood	vessel	formation
6The ultrastructure of the constructs was analysed using scanning electron microscopy (SEM)10.
The extent of crosslinking	was	estimated	by	determination	of	the	amount	of	amine	groups,	which	
was analysed using 2,4,6-trinitrobenzene sulphonic acid24.
The glycosaminoglycan content (dermatan sulfate, chondroitin sulfate and heparin) of the epi-
dermal	layer,	dermal	layer	and	IntegraDRT,	was	determined	by	a	hexosamine	assay	using	p-di-
methyl-aminobenzoaldehyde17.	Because	the	standard	curves	of	heparin	and	chondroitin	sulfate	
/dermatan	sulfate	had	different	slopes,	two	calibration	curves	were	used.	The	total	glycosamino-
glycan content of the dermal layer was calculated by adding the numbers obtained for dermatan 
sulfate	and	heparin	(in	a	3:1	ratio).	
The amount of growth factor bound to the epidermal and dermal layer was determined by West-
ern	blotting25	using	antibodies	against	FGF2	(1:2000),	VEGF	(1:1000)	and	FGF7	(1:400).	Bound	
antibodies	were	 visualized	 using	 peroxidase-conjugated	 secondary	 antibodies	 and	 a	 chemilu-
minescent	detection	kit	 (ECL;	Amersham	Biosciences)	and	analysed	with	Gene	Tools	 software	
(Syngene,	Cambridge,	UK).	The	calibration	curves	ranged	from	0-100	ng	growth	factor.	Scaffolds	
without growth factors were taken as controls.
The distribution of type I collagen, elastin, dermatan sulfate, chondroitin sulfate, heparin, FGF7, 
FGF2 and VEGF	was	determined	by	an	immunofluorescence	assay	using	specific	antibodies	as	
described9,10.	For	DS	and	CS,	the	secondary	antibody	was	mouse	anti-VSV	tag	(1:5)19 Molecular 
and	the	tertiary	antibody	goat	anti-mouse	IgG	Alexa488	(1:200).	For	FGF7,	the	secondary	anti-
body	was	rabbit	anti-goat	IgG	Alexa488	(1:200).	Omission	of	the	primary	antibody	was	taken	as	
a	negative	control.
Figure 1 Design and rationale of the double-layered 
skin construct, consisting of an epidermal (film) layer 
and a dermal (porous) layer. The epidermal layer con-
tained type I collagen, heparin and recombinant rat 
FGF7. The dermal layer consisted of type I collagen, 
solubilised elastin, dermatan sulfate (DS), heparin and 
the recombinant rat growth factors FGF2 and VEGF. 
The construct was designed to resemble the architec-
ture of normal skin and to contain specific effector 
molecules. Heparin was added to the epidermal layer 
for hydration and growth factor binding, and FGF7 to 
stimulate keratinocyte migration and proliferation. 
Solubilised elastin was added to the dermal layer to in-
duce elastic fibre formation, DS and heparin to provide 
hydration and growth factor binding, VEGF to promote 
angiogenesis and FGF2 to enhance fibroblast prolifera-
tion and angiogenesis, and to decrease myofibroblast 
formation.
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Implantation of construct 
NIH	guidelines	for	the	care	and	use	of	laboratory	animals	(NIH	publication	85-23	Rev.	1985)	were	
observed.	The	study	was	approved	by	the	Ethics	Committee	of	the	Radboud	University	Nijme-
gen. Wistar rats (male, 3 months) were purchased from Harlan (Horst, The Netherlands). The 
rats were housed separately, fed pelleted diet (RMH-B 10 mm) and water ad libitum. The rats 
were	anaesthetized	with	isoflurane.	7	days	prior	to	the	operation,	the	wound	area	was	marked	
intradermally	with	8	dots	of	tattoo	ink	(Hauptner,	Germany).
Before	surgery,	analgesia	(injection	with	midazolam,	morphine	and	carprofen)	was	given.	Also	
postoperative	analgesia	was	given	 (injections	with	carprofen	 for	 two	days,	 twice	a	day).	Con-
structs	(1.5x1.5	cm)	were	disinfected	in	70%	ethanol	(3x30	min	and	one	overnight	incubation)	
and	washed	with	sterile	PBS	(6x60	min).	Two	full-thickness	wounds	of	1.5x1.5	cm,	including	the	
panniculus carnosus, were made on each side of the back of the rat and the constructs were 
placed in the wounds. The wounds were treated either with the double-layered skin construct, 
IntegraDRT	or	left	untreated.	The	double-layered	skin	construct	and	IntegraDRT	were	placed	in	
the	wound	in	such	a	way	that	they	fitted	exactly	and	touched	the	wound	edge,	without	overlap	
with the wound edge. The constructs were kept in place by 4 resorbable sutures (5-0 Vicryl). The 
wounds were dressed with a gauze, Tensoplast and Leukoplast. The bandage was applied for 14 
days.	Each	individual	rat	received	two	different	treatments	(double-layered	skin	construct	and/or	
IntegraDRT	and/or	no	treatment).	Per	time	point,	each	treatment	was	applied	four	times,	result-
ing	in	a	total	of	6	rats	per	time	point.	After	14	days,	the	silicon	layer	of	IntegraDRT	was	removed.	
At	day	7,	14,	28	and	112,	the	rats	were	sacrificed	and	the	implants	and	surrounding	tissues	were	
removed.	The	explants	were	divided	in	several	parts	and	processed	for	conventional	histology	
and immunohistochemistry.
Analysis of contraction 
At	day	7,	14,	28	and	112,	wound	contraction	was	evaluated	by	determination	of	the	remaining	wound	
area	using	photographs	and	a	ruler	at	each	time	point	(n=4).	Day	0	was	taken	as	100%	(no	wound	
contraction).	Results	were	represented	as	mean	±	SD.	The	effect	of	the	different	treatments	on	the	
size	of	the	wound	area	was	analysed	by	factorial	analysis	of	variance	(ANOVA)	followed	by	a	post-hoc	
test	(Duncan’s	multiple	range	test)	using	the	Statistica	software	package	(StatSoft,	Tulsa,	OK,	USA).
Processing of explants
Histology:	Paraffin	sections	were	cut	and	stained	with	haematoxylin-eosin	(HE),	Elastin	von	Gie-
son (EVG)26	and	a	Elastic	Masson’s	stain27. Phase contrast microscopy was used to study the lo-
cation	and	direction	of	newly-formed	collagen	fibres.	Histology	of	 the	explants	was	evaluated	
independently	 by	 at	 least	 two	experienced	 investigators.	 Sections	were	 scored	using	 a	 -	 (not	
present)	to	+++	(abundant)	scale.
Immunostaining:	 To	 study	 construct	 degradation,	 extracellular	matrix	 formation,	 presence	 of	
blood	vessels	and	amount	of	myofibroblasts,	cryosections	were	stained	with	specific	antibodies.	
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droitin	sulfate	were	used	to	evaluate	the	(remains	of)	the	construct.	No	major	cross-reactivity	
was	found	between	bovine	and	rat	collagen,	and	between	bovine	and	rat	elastin,	and	in	combi-
nation	with	the	size	and	the	position	of	the	collagen	fibres	and	elastin	material,	the	difference	
between	the	two	species	could	easily	be	distinguished.	Antibodies	against	rat	type	I	and	type	
III	collagen	were	used	to	analyse	the	presence	of	rat	collagen,	an	antibody	against	rat	elastin	to	
visualise	elastin	formation,	and	an	antibody	against	dermatan	sulfate	to	evaluate	glycosamino-
glycan	production.	An	anti-type	 IV	collagen	antibody	was	used	to	visualise	blood	vessels,	and	
an	anti-smooth	muscle	actin	(SMA)	antibody	to	analyse	the	presence	of	myofibroblasts	and	the	
maturity	of	blood	vessels.	Sections	were	scored	using	a	scale	ranging	from	-	(not	present)	to	+++	
(abundant).
Results 
Characterisation of the constructs
Double-layered skin construct
The morphology of the construct was analysed using SEM (Fig. 2A-D). The epidermal top layer 
was	a	thin	non-porous	collagen	layer	with	a	thickness	of	±	40	µm	(Fig.	2A	and	C,	Table	1).	The	
dermal	layer	was	approximately	2.5	mm	thick	with	rounded	pores	of	generally	75-125	µm	(Fig.	
2A	and	D,	Table	1).	The	glue	layer	of	collagen	had	a	thickness	of	25-30	µm	and	contained	pores	
of	±	10	µm	(Fig.	2B).	
The layers were individually crosslinked with EDC/NHS to covalently bind the glycosaminoglycans 
(94	µg	heparin/mg	epidermal	layer,	103	µg	dermatan	sulfate	+	heparin/mg	dermal	layer)	(Table	1).	
In the crosslinking process about 50% of the free amine groups were used (Table 1). The amount 
of	growth	factor	bound	to	each	layer	(0.2	µg	FGF7/mg	epidermal	layer	and	0.7	µg	FGF2	+	VEGF/
mg	dermal	layer)	was	determined	by	Western	Blotting	and	Gene	Tools	(Table	1).	
Table 1. Pore size and biochemical properties of the implanted constructs
Pore size and biochemical analysis of the epidermal layer, dermal layer and IntegraDRT. The amine group content 
was determined using 2,4,6-trinitrobenzene sulphonic acid24, the percentage crosslinking in comparison to non 
crosslinked scaffold is displayed between brackets. The glycosaminoglycan (heparin, DS and CS) content was deter-
mined using p-dimethyl-aminobenzoaldehyde17. Non-crosslinked collagen contained 298 ± 57 nmol amine groups/
mg scaffold Results are the mean ± SD of 3 independent experiments. Please note that no controls could be taken 
for the IntegraDRT construct.
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The	distribution	of	all	components	 in	the	construct	was	visualised	using	 immunostaining	 (Fig.	
2E-L), and was in accordance with the original design (Fig. 1). Both the epidermal and dermal 
layer	contained	type	I	collagen,	whereas	solubilised	elastin	was	only	present	in	the	dermal	layer.	
Heparin was distributed throughout the whole construct, with more intense staining of heparin 
in the epidermal layer. Dermatan sulfate, FGF2 and VEGF were found distributed throughout the 
dermal layer, the growth factors showing a more intense staining at the epidermal side. FGF7 was 
only present at the periphery of the epidermal layer. 
IntegraDRT
SEM	indicated	that	in	commercial	IntegraDRT	the	collagen	part	was	~750	µm	thick	with	50-100	
µm	pores,	and	that	the	silicon	layer	was	~300	µm	thick	(Fig.	2M-P,	Table	1).	 IntegraDRT	is	de-
hydrothermally crosslinked28. The analysis of the collagen layer indicated that 1 mg contained 
about	164	nmol	amine	groups	and	about	24	µg	chondroitin	sulphate	(Table	1,	note	that	a	control	
without	crosslinking	or	without	chondroitin	sulfate	was	not	available).	Immunostaining	was	used	
to	analyse	the	distribution	of	type	I	collagen	and	CS	and	both	were	equally	distributed	through-
out the collagen layer (data not shown).
Figure 2  Electron microscopical and immunological evaluation of the double-layered skin construct and Inte-
graDRT. A-D: Scanning electron micrographs of the double-layered skin construct: (A) cross-section, the arrow 
indicates the epidermal layer, (B) glue layer, indicated by a double-headed arrow, (C) top of epidermal layer, and (D) 
dermal layer. E-L: Immunolocalisation of (E) type I collagen, (F) heparin, (G) FGF7, (H) negative control, (I) elastin, 
(J) dermatan sulfate, (K) FGF2 and (L) VEGF. The epidermal (top) layer is indicated by a dashed line. M-P: Scanning 
electron micrographs of IntegraDRT: (M) cross-section, (N) close-up of M, (O) top of (silicon) layer and (P) top of 
dermal layer. In M and N, # indicates the silicon layer and * the dermal collagen layer. Bar is 100 µm in A, D, E-N 
and P; 10 µm in B and C, and 1 µm in O.
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No	infections	or	illnesses	were	observed	in	the	rats	and	they	stayed	healthy	without	considerable	
weight loss. Rats scratched more on IntegraDRT-covered wounds with the silicon layer present. 
Some	rats	even	removed	the	layer,	indicating	that	the	silicon	layer	caused	irritation.	The	tattoo	
ink	was	used	to	mark	the	wound	area,	but	the	dots	were	generally	too	large	and	too	unequal	in	
size	to	use	for	an	accurate	determination	of	the	remaining	wound	area.	
The	double-layered	skin	construct	was	constructed	from	two	layers,	an	epidermal	film	layer	and	
a	porous	dermal	layer.	The	two	layers	were	attached	to	each	other	by	a	thin	collagen	“glue”	layer,	
which	firmly	attached	both	layers	in	such	a	way	that	during	all	procedures	(e.g.	disinfection	and	
suturing)	the	construct	stayed	intact	and	was	easy	to	handle.	During	the	experiment,	we	noticed	
that	at	day	7	and	14	the	epidermal	layer	was	still	attached	to	the	dermal	layer,	but	that	at	later	
time	points,	the	layer	was	loosened	by	epidermal	cells	that	tended	to	migrate	between	the	two	
layers.
At day 40, the wounds of all groups were closed (data not shown). 
Wound contraction 
At	day	7,	a	significant	difference	in	wound	contraction	was	found	between	the	double-layered	
skin	construct	versus	the	untreated	wound	(p<0.05).	The	double-layered	skin	construct	occupied	
a larger area (90 ± 8% of the original wound area) in comparison to the untreated wound (65 ± 
23%). IntegraDRT had 84 ± 16% of the original wound area (Fig. 3B). 
At	day	14,	the	double-layered	skin	construct	had	significantly	less	contraction	than	IntegraDRT	
and	the	untreated	wound	(p<0.008	and p<0.002	respectively).	The	double-layered	skin	construct	
(80 ± 16%) occupied a larger area than IntegraDRT (47 ± 19%) and the untreated wound (39 ± 
22%) (Fig. 3A, B). 
At day 28 and 112, the remaining wound areas for all treatments ranged from 12-31% and no 
major	differences	were	observed	between	the	groups.
Figure 3 Degree of wound contraction as ana-
lysed by the remaining wound area. A) Mac-
roscopical images of the wound area at day 0 
and day 14. B) Quantitative data of remaining 
wound area. Values are mean ± SD (n=4). At 
day 7, a significant difference was found be-
tween the untreated wound versus the double-
layered skin construct (p < 0.05*). At day 14, 
the double layered skin construct was found 
to have significantly less contraction than In-
tegraDRT and the untreated wound (p<0.008^ 
and p<0.002#, respectively).
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Microscopical evaluation 
Cellular response
Table	2	presents	a	semi-quantitative	analysis	of	cells	present	in	the	wound	area.
At	day	7,	 little	epidermis	had	been	 formed	 in	all	 three	groups	 (data	not	shown).	The	double-
layered	skin	construct	had	the	largest	number	of	granulocytes.	The	numbers	of	phagocytic	cells	
and	fibroblasts	were	equal	for	all	three	groups.	
At	day	14,	partial	coverage	by	epidermal	tissue	was	observed	in	all	three	groups.	The	double-lay-
ered skin construct and the untreated wound showed some granulocytes, whereas larger num-
bers	were	observed	in	IntegraDRT.	No	differences	were	observed	with	respect	to	macrophages	
and	fibroblasts.
At day 28, all groups showed a further coverage, but complete wound closure was not yet seen. 
Keratinocytes	had	generally	migrated	under	the	epidermal	layer	of	the	double	layered	skin	con-
struct,	resulting	in	the	release	of	the	dense	layer	of	the	construct	(as	a	scab).	The	double-layered	
skin	construct	and	IntegraDRT	contained	more	granulocytes	and	phagocytic	cells	than	the	un-
treated	wound.	No	differences	in	fibroblasts	were	found	between	the	three	groups.
At day 112, all three groups had a fully developed epidermis, but no rete ridge structures were 
present in the newly-formed epidermis. The thickness of the epidermis (measured as number of 
cell-layers)	was	found	to	be	variable	within	each	group,	but	no	major	differences	were	observed.	
Granulocytes were absent. Compared to normal skin, slightly more macrophages appeared to be 
present in the healed area of all three groups (Table 2 and Fig. 4A). Structures resembling hair 
follicles and sebaceous glands were observed in the double-layered skin construct and the un-
treated wound, but hardly any were found in IntegraDRT. Most of these structures were located 
in	the	vicinity	of	the	wound	edges	in	the	newly	formed	matrix	(Fig.	4B-C).
None	of	the	groups	showed	newly-formed	skeletal	muscle	tissue	(replacing	the	excised	pannicu-
lus	carnosus)	at	any	time	point	examined.
Table 2. Cellular response in wound area after treatment, compared to normal skin.
The cells were scored from absent (-) to abundantly present (+++). The absolute numbers of granulocytes are much 
lower than for phagocytic cells. * Phagocytic cells include macrophages and giant cells. 
# The myofibroblasts were visualised using an antibody against smooth muscle actin. More myofibroblasts were 
found at the wound edges, indicated as 1moderate or 2abundant.
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At	day	7,	the	overall	score	for	myofibroblasts	was	comparable	between	the	treatments	(Table	2).	
Only	at	the	wound	edges,	the	double-layered	skin	construct	had	more	myofibroblasts	present	
than IntegraDRT and the untreated wound. At day 14, however, the double layered skin con-
struct	overall	contained	less	myofibroblasts	than	IntegraDRT	and	the	untreated	wound.	At	day	
28,	the	untreated	wound	showed	the	least	myofibroblasts.	In	general,	more	myofibroblasts	were	
observed	at	the	wound	edges	than	in	the	middle	of	the	wound	area.	No	myofibroblasts	were	
observed at day 112 and in normal skin.
Construct components
Collagen: Immunostaining for construct type I collagen showed that at day 7 most of the material 
of	the	double-layered	skin	construct	and	IntegraDRT	was	still	present	(Table	3).	At	day	14,	colla-
gen remnants were found in both the double-layered skin construct and in IntegraDRT, whereas 
at	day	28,	only	few	collagen	remnants	were	observed.	At	day	112,	no	scaffold	collagen	could	be	
observed.
Elastin:	At	day	7	and	14,	the	elastin	staining	of	the	double-layered	skin	construct	showed	small	
fragments,	indicating	degradation	of	the	scaffold	elastin.	No	scaffold	bound	elastin	staining	was	
seen at days 28 and 112.
Glycosaminoglycans: At day 7 and 14, heparin was mainly visible in the epidermal layer of the 
double-layered	skin	construct,	whereas	dermatan	sulfate	was	only	found	on	the	collagen	fibrils	
of the dermal layer (data not shown). At day 28, hardly any staining was observed of construct 
Figure 4 Histological images of the centre of the wound area at day 112. 
A) Haematoxylin & eosin staining (HE), B) Elastic Masson’s staining (EM), C) phase-contrast (PH) of the double-layered 
skin construct, IntegraDRT and untreated wound compared to normal skin. 
A) a closed epidermis was present in all cases and no differences were found in the number of cell layers. Rete ridge 
structures were absent. The dermis of the double-layered skin construct, IntegraDRT and the untreated wound showed 
higher numbers of cells than the normal skin (cells are blue). B) In the double-layered skin construct and the untreated 
wound, hair follicle-like and gland-like structures (arrows) were observed (also visible in C). Mature collagen fibres 
stain red, whereas the newly formed fibres are light blue. C) Phase contrast microscopy revealed that collagen fibres 
were more randomly oriented in the double-layered skin construct and untreated wound than in IntegraDRT. Bar in A 
is 25 µm, bar in B and C is 100 µm.
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glycosaminoglycan	remnants.	IntegraDRT	showed	staining	for	chondroitin	sulfate	on	the	collagen	
fibrils	at	day	7	and	14.
Newly-formed extracellular matrix components 
The	presence	of	rat	extracellular	matrix	components	is	summarized	in	Table	3.	Using	immunos-
taining,	it	was	shown	that	the	normal	skin	contained	randomly	oriented	type	I	collagen	fibres,	a	
small	amount	of	type	III	collagen,	a	moderate	amount	of	elastic	fibres	at	the	top	of	the	dermal	
layer,	and	an	ample	amount	of	DS	scattered	throughout	the	dermis.
Type I collagen:	The	amount	of	rat	type	I	collagen	increased	with	time,	being	abundant	for	all	
three groups at day 112. At day 7 and 14, the double-layered skin construct and the untreated 
wound contained more type I collagen than IntegraDRT, whereas at day 28, the untreated wound 
contained	most	type	I	collagen.	Phase	contrast	microscopy	was	used	to	analyse	the	location	and	
orientation	of	newly-formed	collagen	bundles	at	day	112.	The	double-layered	skin	construct	and	
the	untreated	wound	had	a	more	randomly	oriented	collagen	deposition,	whereas	the	collagen	
bundles in IntegraDRT were found to be more aligned (Fig. 4C). When comparing the results of 
the treatments with normal skin, the double-layered skin construct and the untreated wound 
resembled the normal skin at day 112 more closely than IntegraDRT. 
Type III collagen: At day 7, the double-layered skin construct contained a moderate amount of rat 
type III collagen, whereas IntegraDRT and the untreated wound contained less. From day 14 on, 
a moderate amount was found in all three groups.
Elastin:	The	amount	of	elastic	fibres	increased	with	time,	being	most	abundant	in	the	double-
layered skin construct at day 112 (Fig. 5). At day 7, 14 and 28, IntegraDRT contained the least 
elastic	fibres,	while	the	untreated	wound	had	the	same	or	more	elastic	fibres	than	the	double-
layered skin construct. 
At day 7, 14 and 28, the least dermatan sulfate was found in IntegraDRT. At day 28, the dou-
ble-layered skin construct contained most dermatan sulfate, whereas at day 112, the untreated 
wound contained most dermatan sulfate, similar to normal skin.
Table 3. Overview of immunostaining for matrix molecules in wound area after treatment, compared to normal skin.
The sections were scored from absent (-) to abundantly present (+++).
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At day 7 and 14, the double-layered skin construct and the untreated wound contained more 
blood vessels than IntegraDRT (Fig. 6). The blood vessels already invaded the double-layered 
skin construct at day 7, whereas hardly any blood vessels were found inside the collagen layer 
of	IntegraDRT.	At	day	28,	the	double-layered	skin	construct	still	had	many	blood	vessels	present,	
whereas the untreated wound and IntegraDRT contained a moderate amount. The blood ves-
sels were evenly distributed throughout the wound area. At day 112, all groups had moderate 
amounts of blood vessels present in the wound area. These were smaller, but more abundant 
than in normal skin.
Figure 5 (Immuno)histochemical evaluation 
of newly formed elastin at day 112, as anal-
ysed with (A) Immunostaining for elastin and 
(B) Elastin von Gieson staining with a magni-
fication of an area located directly under the 
epidermis. The double-layered skin construct 
showed elastin around blood vessels and hair 
follicle-like structures, and a large amount 
of elastic fibres throughout the upper der-
mis. IntegraDRT and the untreated wound 
contained a moderate amount of elastic fi-
bres that were mainly located in the upper 
part of the dermis. The untreated wound 
also showed elastic fibres surrounding hair 
follicle-like structures. Normal skin showed 
elastic fibres around blood vessels and hair 
follicles in the dermis. Arrows indicate elastic 
fibres. Bar (A) is 25 µm, Bar (B) is 1 µm. 
Figure 6 Presence of blood vessels in the wound 
area as visualised using an antibody against 
type IV collagen. The top of the dermis/epider-
mal layer is indicated by a dashed line. In the 
double-layered skin construct and untreated 
wound, more blood vessels were present on 
day 7 and 14, and they had penetrated more 
towards the epidermis in comparison to Inte-
graDRT. On day 28, the double-layered skin 
construct possessed more blood vessels than 
IntegraDRT and the untreated wound. On day 
112, all treatments showed a similar number 
of blood vessels, more abundant and with a 
smaller diameter compared to normal skin. 
Bar is 100 µm. 
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Discussion
In	this	study,	an	acellular	double-layered	skin	construct	was	prepared	from	purified	components,	
according	to	a	pre-defined	design.	The	biological	components	and	their	 location	were	chosen	
to	reflect	the	skin’s	extracellular	environment.	Growth	factors	were	positioned	in	such	a	way	to	
locally	exert	their	activity,	e.g.	FGF7	at	the	periphery	of	the	flat	epidermal	layer,	and	FGF2	and	
VEGF throughout the porous dermal layer. The double-layered skin construct was developed to 
accelerate and improve wound healing. In the clinic, acellular constructs may be preferred over 
cellular constructs for their ease of handling, transport and storage. 
The performance of the double-layered skin construct was compared to IntegraDRT and to an 
untreated	wound	(no	skin	construct).	The	double-layered	construct	had	significantly	less	contrac-
tion	at	the	first	two	time	points	(day	7	and	14)	compared	to	the	untreated	wound,	and	at	day	14,	
compared	to	IntegraDRT.	At	later	points,	no	significant	differences	were	found.	The	number	of	
smooth	muscle	actin-positive	myofibroblasts,	likely	involved	in	wound	contraction12, was also the 
least	in	the	double	layered	construct	at	day	14.	This	suggests	an	inhibition	of	the	differentiation	
of	fibroblasts	to	myofibroblasts	by	the	construct.	FGF2	is	known	to	inhibit	myofibroblast	forma-
tion	and	promote	a	fibroblast	phenotype29.	In	addition,	the	random	orientation	of	the	pores	in	
the	construct	may	have	prevented	 the	 remaining	myofibroblasts	 from	contracting	 the	wound	
area.	When	cells	are	randomly	bound	to	the	scaffold	the	sum	of	the	contracting	forces	is	near	
zero30. The FGF2 present in the double-layered skin construct (and not in IntegraDRT) may have 
been	 instrumental	 in	diminishing	 the	amount	of	myofibroblasts	present	on	day	14.	However,	
at	day	28	more	myofibroblasts	were	found	than	at	day	14	in	the	double-layered	skin	construct.	
FGF2 has a short life span which is increased by binding to heparin31,	but	after	28	days	most	of	
the	construct	was	degraded,	and	a	lack	of	FGF2	may	eventually	have	revoked	the	active	inhibi-
tion	of	differentiation	 into	myofibroblasts.	A	more	 sustained	 release	of	FGF2	may	 reduce	 the	
degree	of	contraction	for	a	longer	period	of	time.	The	decrease	in	mechanical	properties	of	the	
construct,	due	to	degradation,	may	have	added	to	this	effect.
The	addition	of	effector	molecules	to	a	scaffold	generally	results	in	an	increased	early	infiltration	
of cells8,10. This was also seen in the double-layered skin construct, whereas IntegraDRT and the 
untreated	wound	showed	less	influx	of	e.g.	granulocytes	at	day	7.	Whereas	at	day	14,	IntegraDRT	
displayed	 the	most	granulocyte	 influx.	 For	good	and	 rapid	wound	healing,	 infiltration	of	 cells	
is necessary in order to boost the wound healing process. Cytokines that are produced by the 
infiltrating	cells	promote	angiogenesis,	extracellular	matrix	production	and	remodelling32,33. Cur-
rently	used	acellular	scaffolds	such	as	IntegraDRT	lack	growth	factors,	but	our	study	suggests	that	
growth	factors	may	be	necessary	to	induce	early	angiogenesis	and	extracellular	matrix	produc-
tion.	
In	 commercially	 available	 acellular	 skin	 substitutes,	 it	 takes	 several	weeks	 to	 develop	 a	well-
developed	vasculature.	This	results	in	impaired	wound	healing,	due	to	a	lack	of	oxygen,	nutrients	
and the presence of waste products34.	Angiogenesis	can	be	promoted	by	the	 incorporation	of	
glycosaminoglycans	or	solubilised	elastin	to	a	scaffold,	as	we	have	previously	shown	in	a	subcu-
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and	VEGF)	in	an	acellular	collagen-heparin	scaffold	induced	a	mature	vasculature	already	at	day	
710. In the double-layered skin construct, many blood vessels were found on day 7, in contrast to 
IntegraDRT	which	did	not	develop	a	similar	amount	of	blood	vessels	on	any	of	the	time-points	
examined.	Moiemen	et	al.	 found	that	 IntegraDRT	was	only	 fully	vascularised	after	4	weeks	 in	
humans35.	This	is	in	line	with	our	findings	that	it	took	until	day	28	before	the	newly-formed	vas-
culature	in	IntegraDRT	had	reached	the	top	of	construct.	The	addition	of	growth	factors	 in	an	
acellular construct may thus greatly improve angiogenesis.
The	orientation	of	collagen	fibres	in	normal	skin	has	a	basket	weave	pattern,	whereas	in	scars	the	
fibres	are	very	much	aligned	in	a	parallel	way36. We and others have seen that the micro archi-
tecture	of	the	original	scaffold	influences	the	orientation	of	newly-formed	collagen	fibrils37,38. In 
the double-layered skin construct, the dermal layer had large randomly oriented pores to allow 
random	collagen	deposition,	which	indeed	occurred,	as	indicated	by	phase	contrast	microscopy.
An	 interesting	 feature	was	 the	presence	of	structures	 resembling	hair	 follicles	and	sebaceous	
glands in the double-layered skin construct and untreated wound at day 112. These structures 
were mainly found at the outer region of the healed wound, though some were present in the 
centre. Stem cells from the hair follicles in the vicinity of the wound edges probably migrate into 
the wound bed and proliferate to form a new hair follicle. This was not demonstrated by tech-
niques.	The	group	of	Ito	et	all	demonstrated	that	in	adult	mice,	de	novo	hair	follicle	formation	
was	found	after	an	excision	of	1	cm2	full-thickness	back	skin39. Growth factors (e.g. epidermal 
growth factor and FGF) are involved in hair follicle sebaceous gland development40. Further re-
search	will	 determine	whether	 the	addition	of	 (a	 combination	of)	 growth	 factors	 to	a	tissue-
engineered	skin	construct	can	indeed	induce	hair	follicle	formation.
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Conclusion
A double-layered skin construct was designed, developed and evaluated in a rat full-thickness 
wound	model.	The	construct	contained	positioned	growth	factors	and	resulted	in	a	reduction	of	
contraction	and	an	increase	in	angiogenesis	in	the	early	phase	of	skin	regeneration.
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Summary
Mimicking the cell’s natural environment using purified components
The	goal	of	tissue	engineering	is	to	restore/replace	damaged	tissues	or	organs.	Biomaterials	that	
are	developed	for	this	purpose	are	often	made	of	natural	materials,	such	as	collagen,	and	used	
with	or	without	cells.	It	is	preferable	to	have	an	off	the	shelf	product,	since	usage	of	cells	in	a	
construct	is	more	costly	and	autologous	cells	cannot	be	used	instantaneously	in	a	patient1. My 
aim	is	to	create	scaffolds	that	resemble	the	extracellular	composition	of	a	specific	tissue	such	
that	the	scaffold	attracts	sufficient	cells	and	induce	the	desired	regeneration	process,	for	instance	
angiogenesis.	In	developing	such	a	biomaterial,	it	is	of	great	importance	to	know	what	the	effect	
of	each	individual	component	in	the	biomaterial	is.	This	is	only	possible	when	the	compositional	
characteristics	of	biomaterials	can	be	fully	controlled	by	the	use	of	highly	purified	extracellular	
matrix	components.	 	The	aim	of	this	thesis	 is	to	design,	develop	and	analyze	a	novel	acellular	
biomaterial for skin replacement, mimicking the natural environment.  
In chapter 1,	an	overview	is	given	of	some	major	natural	components	and	their	application	for	
the	construction	of	molecularly	defined	scaffolds	for	tissue	engineering.		To	enhance	the	regen-
eration	process	growth	factors	are	needed.	In	chapter 2, the cloning of rat VEGF-164, its large 
scale	production	in	a	Pichia pastoris expression	system	is	described.	VEGF-164	was	purified	using	
a	heparin	column	and	shown	to	be	biologically	active.
Preparation and evaluation of collagen–based scaffolds for tissue engineering
Using	purified	components,	tailor-made	scaffolds	were	prepared	to	evaluate	the	effect	of	each	
component separately. In chapter 3,	scaffolds	made	from	highly	purified	type	I	collagen	fibrils	
and	elastin	fibres	(devoid	of	microfibrils)	were	characterized.	The	tissue	response	was	analyzed	
using	a	rat	subcutaneous	model.	The	scaffolds	did	not	calcify	in	adult	Sprague	Dawley	and	Wistar	
rats,	but	calcification	was	found	in	young	Sprague	Dawley	rats.	The	scaffolds	with	elastic	fibres	
attracted	more	cells	and	showed	more	angiogenesis	and	degradation	than	collagen	scaffolds.
To	create	a	scaffold	 that	does	not	calcify	 in vivo,	purified	elastin	fibres	were	solubilised	using	
oxalic	acid	hydrolysis.	Collagen-solubilised	elastin	scaffolds	did	indeed	not	calcify	 in	the	young	
rat model as described in chapter 4.	The	solubilised	elastin	was	mainly	present	in	the	scaffold	as	
globular	structures	that	were	incorporated	in	the	scaffold.	These	scaffolds	showed	more	elastic	
fibre	 formation	and	angiogenesis	 in	comparison	to	 the	collagen-elastic	fibre	scaffold.	Chapter 
5	describes	the	contribution	of	heparin	and	growth	factors	 in	 inducing	angiogenesis	 in	tissue-
engineered	constructs.	Five	scaffolds	composed	of	type	I	collagen,	collagen-heparin	and/or	FGF2	
and/or VEGF were made, characterized and implanted subcutaneously in a Wistar rat model. The 
scaffolds	with	heparin	and	both	growth	factors	gave	rise	to	mature	blood	vessels	after	just	7	days.
Molecularly defined constructs for skin tissue engineering
Taking	 into	account	the	results	above,	a	molecularly	defined	skin	construct	was	designed	and	
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7developed.	 The	 construct	was	 composed	of	 two	 layers;	 the	upper	 epidermal	 layer	 consisting	
of	a	type	I	collagen	film	with	heparin	and	FGF-7,	and	a	porous	dermal	layer	consisting	of	type	
I	collagen-solubilised	elastin,	heparin,	dermatan	sulphate,	VEGF-164	and	FGF2	as	described	in	
chapter 6. The construct was characterized and wound healing was compared in an acute full-
thickness	wound	rat	model	to	IntegraDRT	and	an	untreated	wound.	The	molecularly	defined	con-
struct	showed	less	contraction	and	more	blood	vessel	formation	at	early	time	points.	Also	more	
elastic	fibres	were	found	at	the	end	of	the	experiment	in	comparison	to	IntegraDRT.	Besides	less	
contraction	in	the	beginning,	few	differences	were	found	with	no	construct.
General conclusions
Highly	purified	components	were	prepared,	including	VEGF-164.	These	components	were	used	to	
construct	molecularly	defined	scaffolds.	To	prevent	calcification	and	induce	early	elastic	fibre	forma-
tion,	solubilised	elastin	should	be	used.	To	induce	early	blood	vessel	formation	in	scaffolds,	both	
FGF2	and	VEGF	should	be	added.	In	the	complex	molecularly	defined	skin	construct	prepared,	the	
effect	of	these	components	were	indeed	demonstrated	found.	The	construct	showed	many	blood	
vessels	at	an	early	time	point	and	increased	elastic	fiber	synthesis	at	later	time	points.	These	results	
are promising though it is not yet the ideal construct for an acute wound.
Generally,	this	thesis	indicates	that	it	is	possible	to	construct	complex	scaffolds	for	tissue	engineer-
ing	using	highly	purified	components,	and	that	such	scaffolds	induce	tissue	regeneration.	This	is	a	
starting	point	for	developing	all	kinds	of	tissue-engineered	constructs	that	resemble	the	extracellular	
matrix	of	specific	tissues,	and	may	contribute	to	the	replacement	or	regeneration	of	tissues/organs.
Future directions
Replacing	natural	tissue	is	the	ultimate	goal	in	tissue	engineering.	By	mimicking	nature,	we	hope	
to	create	a	construct	that	will	eventually	lead	to	complete	human	tissue	regeneration	without	 
issues	 of	 contraction,	 lack	 of	 functionality	 and	poor	 cosmetic	 appearance	 that	we	encounter	
today.		The	question	arises	how	far	should	you	go	in	mimicking	the	natural	tissue,	is	it	–from	a	
patient’s	perspective–	not	better	to	only	induce	a	number	of	crucial	processes?
To	know	how	far	you	should	take	the	mimicking	of	natural	tissues,	more	research	is	needed	on	
processes	in	wound	regeneration	and	the	role		of	matrix	components	in	regeneration.	Every	ma-
trix	component	has	it	contribution	to	the	functionality	and	structure	of	the	tissue,	though	only	
some	of	these	components	are	involved	in	regeneration.	Therefore	we	should	aim	for	a	construct	
that	induces	the	processes,	rather	than	exactly	mimick	new	tissue.	It	is	very	interesting	to	analyze	
the	regeneration	process	in	an	embryo,	since	an	early	embryonal	wound	heals	without	scarring2. 
The knowledge of this process could help to develop constructs that regenerate without scarring 
and	functional	problems.
Even	if	you	would	be	able	to	make	a	construct	that	exactly	resembles	natural	tissue,	it	will	be	very	
difficult	to	fulfill	demands	for	commercial	production,	and	this	will	make	the	step	from	research	
to	business	to	clinic	difficult.	For	the	manufacturer	it	is	better	to	keep	the	construct	as	simple	as	
possible (KIS principle).
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For	the	future	of	the	molecularly	defined	double-layered	skin	construct	it	would	interesting	to	
adapt	the	construct,	for	instance	by	adjusting	the	amount/ratio	of	growth	factors.	Evidence	exists	
that	FGF2	decreases	contraction	by	inhibiting	the	formation	of	myofibroblasts3. In the double-
layered	skin	construct	prepared	here,	FGF-2	may	be	released/degraded	too	quickly.	An	idea	is	to	
aim	for	a	sustained	release	of	the	FGF-2	and	study	if	this	decreases	the	contraction.	Also	it	was	
found that FGF-2 regulates the melanocyte viability4	and	a	sustained	release	might	lead	to	better	
skin	color.	In	literature	it	is	described	that	TGF-β2	induces	hair	follicle	morphogenesis	and	that	
TGF-β	decreases	contraction6. Adding these growth factors to the construct might lead to a 
better	outcome	for	the	patient.
For future study, it may be possible to incorporate biocapsules like lyophilisomes made from 
solubilised	 elastin	 in	 the	 skin	 construct7.	 For	 example,	 anti-bacterial	 compounds	 (silver	 or	
β-defensins)	can	be	 incorporated	 in	 these	capsules	 for	 scaffolds	used	 to	fight	 infections	 in	
chronic wounds8, 9.	The	molecules	are	released	in	the	wound	upon	elastase	digestion	of	the	
capsules.	This	does	not	mimick	the	natural	tissue,	but	may	lead	to	better	wound	healing.
Before	such	a	construct	can	be	made	available	for	use	in	the	clinic,	more	animal	testing	needs	
to	be	performed.	Rat	skin	is	different	from	humans,	e.g.	a	rat	has	a	muscle	layer	in	the	skin.	
Pig skin resembles human skin more. It is important to study how the developed construct 
behaves in such an animal model. A large amount of data can, however, be obtained using in 
vitro	experiments.
The	use	of	molecularly	defined	constructs	for	tissue	engineering	has	great	potential	for	the	fu-
ture,	since	it	allows	identification	of	the	functional	contribution	of	each	component.	Hopefully,	
future research will lead to novel (double-layered) skin constructs, which the physician can take 
off	the	shelf	to	immediately	help	patients	with	acute	burns	and	chronic	wounds	and	which	result	
in	less	contraction	and	a	better	clinical	and	visual	outcome	than	is	possible	today.	
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Samenvatting
Nabootsen van het natuurlijke weefsel met zuivere bestanddelen
Het	 doel	 van	tissue	 engineering	 is	 het	 herstellen/vervangen	 van	 beschadigde	weefsels	 of	 or-
ganen. Biomaterialen die ontwikkeld worden voor dit doel zijn vaak gebaseerd op natuurlijke 
moleculen	 (zoals	 collageen)	met	 of	 zonder	 cellen.	Het	 heeft	de	 voorkeur	 om	een	 product	 te	
maken	dat	direct	beschikbaar	is	voor	de	patiënt,	want	cellen	toevoegen	aan	een	biomateriaal	
is	een	kostbare	zaak	en	autologe	cellen	zijn	niet	direct	voorhanden	voor	een	patient1. Mijn doel 
is om acellulaire biomaterialen te maken die zo veel mogelijk overeenkomen met het vereiste 
weefsel	 en	 die	 cellen	 aantrekken	om	het	 gewenste	 regeneratieproces	 in	 gang	 te	 zetten,	 bijv.	
angiogenese.	Om	een	dergelijk	biomateriaal	te	ontwikkelen	is	het	nodig	om	te	weten	wat	het	
effect	 is	van	 iedere	component	afzonderlijk.	Dit	 is	alleen	mogelijk	als	deze	biomaterialen	qua	
samenstelling	goed	beheerst	kunnen	worden,	zoals	door	het	gebruik	van	gezuiverde	extracel-
lulaire	matrixbouwstenen.	Het	doel	van	deze	thesis	is	om	een	nieuw	biomateriaal		-zonder	cel-
len- te ontwerpen, te maken en te evalueren voor gebruik als huidvervanger, en gebaseerd op de 
natuurlijke cellulaire omgeving.
In hoofdstuk 1 staat een overzicht van alle zuivere natuurlijke componenten die gebruikt kunnen 
worden	bij	het	maken	van	een	construct	voor	tissue	engineering.	Om	regeneratieprocessen	op	
gang	te	brengen	zijn	groeifactoren	nodig.	Het	kloneren	van	rat	VEGF-164	en	de	productie	hiervan	
in het Pichia pastoris fermentor systeem wordt beschreven in hoofdstuk 2. De grote hoeveelheid 
aan	geproduceerd	VEGF-164	werd	gezuiverd	via	heparine-affiniteitschromatografie	en	bleek	bio-
logisch	actief.
Bereiding en evaluatie van op collageen gebaseerde biomaterialen voor tissue engineering
Met	de	gezuiverde	componenten	zijn	verschillende	biomaterialen	gemaakt	om	zo	het	effect	van	
de verschillende componenten te kunnen bestuderen. In hoofdstuk 3 staat een beschrijving van 
matrices	gemaakt	van	gezuiverd	 type	 I	 collageen	en	elastinevezels	 (zonder	microfibrillen).	Na	
analyse	zijn	deze	matrices	onderhuids	geïmplanteerd	in	een	rattenmodel	om	de	weefselreactie	
te	bestuderen.	De	matrices	verkalkten	niet	in	volwassen	Sprague	Dawley	en	Wistar	ratten,	maar	
wel	in	de	jonge	Sprague	Dawley	ratten.	De	matrices	met	elastinevezels	trokken	meer	cellen	aan	
en	vertoonden	ook	meer	angiogenese	en	matrixafbraak	dan	de	matrices	van	alleen	collageen.	
Om	een	biomateriaal	te	ontwikkelen	dat	in	het	lichaam	niet	verkalkt,	zijn	elastinevezels	gehydro-
lyseerd	met	oxaalzuur	en	gebruikt	om	-samen	met	collageen-	matrices	te	maken.	De	matrices	
met	collageen	en	oplosbaar	elastine	verkalkten	inderdaad	niet	in	het	rattenmodel	zoals	beschre-
ven in hoofdstuk 4.	Het	oplosbaar	elastine	vormde	ook	ronde	structuren	die	verbonden	waren	
aan	het	collageen	van	de	matrix.	Deze	matrices	 lieten	meer	angiogenese	en	nieuw	gevormde	
elastische	vezels	zien	dan	de	matrices	met	elastinevezels.	In	hoofdstuk 5 wordt de bijdrage van 
heparine	en	groeifactoren	in	het	stimuleren	van	angiogenese	in	tissue-engineered	constructen	
beschreven. Vijf verschillende matrices van gecrosslinkt type I collageen, en collageen-heparine 
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7en/of FGF-2 en/of VEGF-164 zijn gemaakt, geanalyseerd en onderhuids geïmplanteerd in Wistar 
ratten.	In	de	matrices	met	heparine	en	beide	groeifactoren	was	na	7	dagen	al	een	ontwikkeld	
vaatbed aanwezig.
Moleculair gedefinieerde constructen voor huid tissue engineering
Door	de	 resultaten	hierboven	 te	 combineren	 is	 er	een	moleculair	 gedefinieerd	huidconstruct	
ontworpen en ontwikkeld. Het construct dat beschreven is in hoofdstuk 6 bestaat uit twee lagen; 
de	bovenste	epidermale	laag	bestaat	uit	een	type	I	collageen	film	met	heparine	en	FGF-7	en	de	
poreuze	dermale	laag	bestaat	uit	een	type	I	collageen,	oplosbaar	elastine,	heparine,	dermatan	
sulfaat, FGF-2 en VEGF-164. Na analyse van het construct is het geïmplanteerd in een acuut 
wondmodel in rat en vergeleken met het commercieel verkrijgbare IntegraDRT en met een onbe-
handelde	wond.	Het	dubbel-laags	huidconstruct	liet	op	vroege	tijdstippen	minder	contractie	en	
meer	bloedvatformatie	zien.	Ook	werden	er	aan	het	einde	van	het	experiment	meer	elastische	
vezels	gevonden	in	vergelijking	met	IntegraDRT.	Naast	minder	contractie	in	het	begin,	werden	
weinig verschillen gevonden ten opzichte van de onbehandelde wond.
Algemene conclusie
Zuivere componenten werden geproduceerd, in het bijzonder VEGF-164. Deze componenten 
werden	 gebruikt	 om	 moleculair	 gedefinieerde	 matrices	 te	 maken	 waarbij	 de	 bijdrage	 van	 
individuele	componenten	 is	bestudeerd.	Om	verkalking	te	voorkomen	en	vroege	vorming	van	
elastische	vezels	 te	bewerkstelligen,	moet	oplosbaar	elastine	worden	toegevoegd.	Om	vroege	
bloedvatvorming te induceren, kunnen FGF-2 en VEGF aan een construct toegevoegd worden. In 
het	moleculair	gedefinieerde	huidconstruct	is	de	bijdrage	van	deze	componenten	aangetoond.	
Het	construct	liet	meer	bloedvaten	en	minder	contractie	op	een	vroeg	tijdstip	zien.	Deze	resul-
taten zijn veelbelovend, maar toch is dit nog niet het ideale construct voor de behandeling van 
een acute wond.
Het	onderzoek	in	deze	thesis	laat	zien	dat	het	mogelijk	is	om	complexe	tissue	engineered	ma-
trices te fabriceren, gebruik makend van hoog zuivere componenten, en dat deze componenten 
een	gewenste	weefselreactie	op	gang	kunnen	brengen.	Dit	 is	een	begin	van	een	groot	aantal	
verschillende	matrices	die	de	extracellulaire	matrix	van	een	benodigd	weefsel	kunnen	nabootsen	
en	die	kunnen	bijdragen	aan	de	vervanging	of	regeneratie	van	weefsels	of	organen.
Toekomstvisie
Het	vervangen	van	het	natuurlijke	weefsel	is	het	ultieme	doel	in	de	tissue	engineering.	Door	het	
natuurlijke weefsel na te bootsen, hopen we een construct te maken dat uiteindelijk leidt tot 
volledige	weefselregeneratie	zonder	problemen	zoals	contractie,	verminderde	functionaliteit	en	
slechte	cosmetische	resultaten	die	we	nu	nog	zien.	De	vraag	is	of	het	ook	echt	nodig	is	om	het	
weefsel	volledig	na	te	bootsen,	is	het	voor	de	patiënt	niet	beter	om	slechts	belangrijke	processen	
in	gang	te	zetten?
Om	te	weten	hoe	ver	je	in	het	nabootsen	zou	moeten	gaan,	is	nog	veel	onderzoek	nodig	naar	de	
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processen	die	optreden	in	wondregeneratie	en	de	bijdrage	van	matrixcomponenten	aan	het	weef-
selherstel.	Elke	matrixcomponent	levert	zijn	eigen	bijdrage	aan	de	functionaliteit	en	de	structuur	
van	het	weefsel,	maar	slechts	een	aantal	van	deze	componenten	zijn	betrokken	bij	de	regeneratie.	
Daarom zouden we moeten streven naar een construct dat de juiste processen opstart, waarna 
het lichaam het benodigde weefsel zelf gaat aanmaken. Het is erg interessant om het wondge-
nezingsproces in een embryo te analyseren, omdat een vroeg embryonale wond geneest zonder 
littekenvorming2. De kennis van dit proces zou een bijdrage kunnen leveren aan het ontwerpen van 
constructen	die	regeneratie	induceren	zonder	littekenweefsel	en	functionele	problemen.	
Zelfs	al	zou	een	construct	gemaakt	kunnen	worden	dat	het	natuurlijke	weefsel	exact	nabootst,	
dan	zou	een	dergelijk	 ingewikkeld	construct	moeilijk	aan	de	eisen	van	commerciële	productie	
kunnen voldoen. Dit maakt stap van de research naar het bedrijfsleven en de kliniek moeilijk. 
Voor	 commerciële	 haalbaarheid	 is	 het	 beter	 om	het	 construct	 zo	 simpel	mogelijk	 te	 houden	
(“keep	it	simple”	principe).
Voor	de	toekomst	van	het	moleculair	gedefinieerde	dubbel-laags	huidconstruct	zou	het	interes-
sant zijn om te zien hoe aanpassingen aan het construct de resultaten beïnvloeden, bijvoor-
beeld	door	de	hoeveelheid	en	de	ratio	van	de	groeifactoren	te	veranderen.	 In	de	 literatuur	 is	
beschreven	 dat	 FGF-2	 contractie	 vermindert	 door	myofibroblast	 vorming	 te	 remmen3. In het 
dubbel-laags construct kan het FGF-2 mogelijk te snel vrijkomen of afgebroken worden. Een con-
stante	afgifte	en	verdere	bescherming	van	FGF-2	zou	contractie	mogelijk	 langer	verminderen.	
Daarnaast is ook gebleken dat FGF-2 de levensvatbaarheid van melanocyten reguleert4 en zou 
een	vertraagde	afgifte	voor	een	verbeterde	huidskleur	 kunnen	 zorgen.	 In	de	 literatuur	wordt	
ook	beschreven	dat	TGF-β2	haarfollikel	vorming	induceert5	en	verminderd	wondcontractie6. Het 
toevoegen	van	deze	groeifactoren	zou	kunnen	 leiden	tot	een	beter	resultaat	voor	de	patiënt.	
Voor	toekomstige	studies	is	het	ook	mogelijk	om	biocapsules	zoals	lyophilisomen	van	oplosbaar	
elastine	toe	te	voegen	aan	het	huidconstruct7. Deze capsules kunnen gevuld worden met bijvoor-
beeld	antibacteriële	componenten	(zilver	of	β-defensines)	en	zo	zouden	infecties	kunnen	worden	
onderdrukt in chronische wonden8,9.	De	antibacteriële	componenten	worden	vrijgegeven	als	de	
microcapsules worden afgebroken. Dit is natuurlijk niet een nabootsing van natuurlijk weefsel, 
maar kan wel een bijdrage leveren aan een goede wondgenezing.
Voordat een dergelijk construct beschikbaar is voor gebruik in de kliniek, moeten er meer proef-
dierexperimenten	 uitgevoerd	worden.	 De	 rattenhuid	 verschilt	 van	 die	 van	 de	mens	 en	 bevat	 
bijvoorbeeld	een	spierlaag	die	de	mens	niet	heeft.	De	huid	van	een	varken	lijkt	meer	op	de	huid	
van de mens. Het is erg belangrijk om te zien hoe een construct reageert in een ander dier. Veel 
vooronderzoek kan al in vitro plaatsvinden.
Het	maken	van	moleculair	gedefinieerde	constructen	voor	tissue	engineering	heeft	een	grote	po-
tentie	voor	de	toekomst.	Door	de	kennis	van	de	bijdrage	van	iedere	component	kunnen	wondge-
nezingsprocessen	beïnvloed	worden.	Hopelijk	zal	toekomstig	onderzoek	leiden	tot	een	verbeterd	
(dubbel-laags)	huidconstruct,	dat	de	arts	van	de	plank	kan	nemen	om	een	patiënt	met		acute-,	
chronische-	of	brandwonden	te	behandelen,	zodanig	dat	het	construct	de	regeneratie	van	huid	
induceert	en	een	goed	klinisch	en	cosmetisch	resultaat	geeft.
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Het	is	af!!	Eindelijk	ligt	hier	voor	u	het	proefschrift	naar	aanleiding	van	mijn	promotieonderzoek.	
Ik wil de volgende personen bedanken voor hun interesse, hulp en bijdrage!
Als eerste en in het bijzonder wil ik mijn beide promotoren Prof. dr. Roland Brock en Prof. dr. Joost 
Schalkwijk en mijn copromotoren dr. Toin van Kuppevelt en dr. ir. Willeke Daamen bedanken. 
Beste	Roland,	hartelijk	dank	dat	 ik	binnen	jouw	afdeling	 	Biochemie,	mijn	promotieonderzoek	
mocht uitvoeren en jouw vertrouwen in mijn promoveren. 
Beste Joost, ik vind het een eer dat jij mijn promotor wil zijn. Dank je wel voor je bijdrage aan 
het	project	en	je	waardevolle	adviezen.	Van	jouw	grote	kennis	over	de	huid	en	statistiek	heb	ik	
veel  geleerd.
Beste Toin, heel erg bedankt voor het vertrouwen dat je in me had door me, na mijn stage, aan te 
nemen	voor	het	STW/ZONMW	project.	Gedurende	de	vier	jaar	heb	ik	veel	geleerd	van	de	moed	
erin	houden	tot		zelfstandig	je	onderzoek	te	verrichten	en	artikelen	te		schrijven.	Je	wist	met	jouw	
enthousiasme voor het onderzoek elke tegenslag weer om te buigen naar een nieuw interessant 
onderzoek.		Ik	waardeer	jouw	steun	tijdens	de	laatste	afrondende	loodjes	van	mijn	proefschrift!
Beste Willeke, Ik weet nog goed dat ik bij jou stage kwam lopen en dat je me zo enthousiast hebt 
gemaakt  voor het doen van onderzoek! We hebben in de eerste jaren veel onderzoek samen 
uitgevoerd	en	daar	heb	ik	heel	erg	veel	aan	gehad.	Na	jouw	promotie	heb	je	me	erg	fijn	begeleid,	
Je	wist	me	altijd	weer	te	stimuleren	tot	bedenken	van	nieuwe	experimenten.	Heel	erg	bedankt	
voor	jouw	hulp	met	de	analyses	en	het	grondige	nakijken	van	mijn	artikelen.	Daarnaast	wil	ik	ook	
jou	bedanken	voor	de	steun	tijdens	de	laatste	periode	van	mijn	promotie.	
Mijn paranimfen Gerwen en Margot, het is een eer voor mij dat jullie mij op deze belangrijke dag 
willen bijstaan. Gerwen, mede junior onderzoeker, bedankt voor je bijdrage aan het onderzoek 
en de vele gezellige momenten! Ik hoop dat we nog vaak gaan lunchen en veel succes met je on-
derzoek	bij	Fysiologie.		Margot,	fijne	collega	en	vriendin,	je	bent	in	de	moeilijke	tijden	een	grote	
steun voor me geweest. Je hebt me vaak genoeg een hart onder de riem gestoken. Ik hoop nog 
heel veel jaren met je te kunnen samenwerken!
Als	ik	aan	de	werkgroep	Matrixbiochemie	denk	dan	denk	ik	gelijk	aan	de	leuke	sfeer	op	het	lab	
en	onze	gezellige	kerstdiners	en	labuitjes!	Alle	medewerkers	wil	ik	bedanken	voor	de	fijne	samen-
werking, in het bijzonder;
Herman,	 	 jouw	goede	en	 innovatieve	 ideeën	hebben	me	vaak	de	goede	kant	op	geholpen	en	
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jouw	biochemie	kennis	was	van	onschatbare	waarde!	Tussen	de	experimenten	door	hebben	we	
vele	goed	gesprekken	gehad	over	allerlei	onderwerpen	van	het	nieuws	tot	de	thuis	situatie.	Deze	
gesprekken	heb	ik	erg	gewaardeerd	en	ook	dat	je	me	altijd	weer	wist	op	te	beuren	als	de	expe-
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me ook te pakken gekregen.
Theo,	Ronnie	en	Paul	Y,	heel	erg	bedankt	voor	jullie	hulp	en	kennis	van	de	TEM	en	histologie.	
Mijn	mede	junior	onderzoekers:	Paul	,	Nicole,	Tessa,		Mieke,	Joost,	Martin	en	Peter,	we	hebben	in	
die jaren veel gedeeld samen. Ik denk met veel plezier terug aan de leuke congressen en gezellige 
avondjes die we gedeeld hebben. Ik wens jullie heel veel succes in jullie verdere carrière! 
Natuurlijk wil ik ook alle andere labgenoten noemen en  bedanken voor hun bijdrage aan mijn 
proefschrift	en	de	gezelligheid	op	het	lab;		Kaeuis,	Elly,	Els	,	Cindy,	Marijke	en	Marianne,	Toon,	
Gerdy, Guido en Maartje. 
Ik	wil	de	studenten	die	hebben	bijgedragen	aan	dit	proefschrift;		Paulien	Smits,	Laura	van	Zelst	
en	Joost	Kreijtz	heel	hartelijk	danken	voor	hun	 inzet	en	 leuke	experimenten.	Heel	veel	succes	
toegewenst met jullie verdere carrière.
Ik	heb	de	vele	goede	samenwerking	met	andere	afdelingen	als	erg	prettig	ervaren	en	zeer	ge-
waardeerd, want samen kom je verder!
Van	het	CDL;	Geert,	Ilona	en	Debby	dank	jullie	wel	voor	alle	hulp	en	adviezen	tijdens	de	dierex-
perimenten.
Brandwonden Centrum Beverwijk; Esther, Magda, Anton, Neeltje en Michelle, dank jullie wel 
voor	de	fijne	samenwerking,	de	gezamenlijke	experimenten	en	de	gezellige	congressen.
Afdeling	Celbiologie,	Huib		wil	ik	bedanken	voor	de	fantastische	technische	ondersteuning!
Van	afdeling	nucleaire	geneeskunde	wil	ik	Otto	Boerman	bedanken	voor	zijn	hulp	met	de	groei-
factor	release	experimenten.	Helaas	hebben	de	experimenten	niet	tot	een	publicatie	geleid.
Van de afdeling Biomaterialen wil ik Frank en Jeroen bedanken.
Mijn	collega’s	van	de	stichting	Stamceldonorbank	Europdonor	Nijmegen,	Margot,	Dyonne,	Mona,	
Michel, Arnold, Brigit en onze vrijwilligers Willy, Theo en Bram wil ik bedanken voor hun steun, 
vertrouwen	en	geduld	bij	het	afronden	van	mijn	promotie.		
Ook	de	collega’s	van	de	afdeling	Hematologie	wil	ik	bedanken	voor	hun	belangstelling	en	enthou-
siasme, in het bijzonder Marianne, Emmy en Ingrid.
Brenda, Leonie, Sabrina, Elles en Corine, mijn lieve vriendinnen,  jullie wil ik bedanken voor  de 
interesse, de ondersteuning en vooral voor de gezellige uitjes. Hier kon ik veel energie uit halen! 
Ik hoop dat deze nog lang doorgaan.
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Familie en vrienden, die ik hier niet allemaal bij naam ga noemen, wil allemaal hartelijk bedanken 
voor hun interesse.
Pap en mam, dank jullie wel voor alle steun en kansen die jullie me gegeven hebben.  Jullie staan 
altijd	voor	me	klaar	en	dat	vind	ik	heel	erg	fijn.	Zonder	jullie	enthousiasme	en	bijdrage	was	het	
me niet gelukt om dit tot een goed einde te brengen.  Heel erg bedankt!
Irene, mijn zus, Gilbert en Liesanne, super bedankt voor het luisterend oor en interesse in mijn 
bezigheden. 
 Peter, mijn lief,  last but not least….   We hebben elkaar een paar jaar geleden mogen ontmoeten. 
Vanaf	die	tijd	heb	je	mij	de	ruimte	en	het	vertouwen	gegeven	om	mijn	proefschrift	af	te	ronden	
en	daar	ben	ik	je	heel	erg	dankbaar	voor.	Het	heeft	veel	van	onze	vrije	tijd	opgeslokt	maar	dat	is	
nu	voorbij.		Dank	je	wel	voor	je	vrolijkheid	en	spontaniteit,	dat	helpt	me	de	zaken	te	relativeren.	
Samen gaan we een mooie toekomst tegemoet!
Allemaal bedankt!
Suzan
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Figure 1. Macroscopic (A, B) and scanning electron microscopical images (C, D) of dense films (A, C) and porous 
scaffolds (B, D). Bar is 1 cm in A, B, and 100 µm in C, D 33. Figure reproduced from 33 with permission.
Chapter 1 Mimicking the micro-environment
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Figure 4. Macroscopical (A) and immunohistochemical evaluation of the scaffolds explanted at day 7 (B, C).
A)  Macroscopical evaluation of a non-implanted scaffold at day 0 and explants at day 7 (COL, COLHV and COLHFV). 
Note the red appearance of the COLHFV scaffold.
B)  Immunohistochemical evaluation using type IV collagen staining of the scaffolds explanted at day 7. COLHFV 
showed the most and largest area of blood vessels compared to COLHV, COLHF and COLH. No blood vessels were 
found in COL at this time point. 
C)  Immunohistochemical evaluation using smooth muscle actin staining of scaffolds explanted at day 7. COLHFV 
displayed the largest percentage of mature blood vessels compared to COLHV, COLHF and COLH. Arrows indicate 
SMA-positive blood vessels. Bar is 50 µm.
Figure 6. Immunohistochemical analysis of HIF1-α staining of cells in the scaffolds at day 3, 7 and 21.
A)  Photographs of COLHFV scaffold at day 3 and 7. COLHFV showed many hypoxic cells at day 3 and few at day 7. 
Inserts show that HIF1-α predominantly stains the nuclei of cells. Positive cells stain black and negative cells stain 
blue. Bar is 10 µm.
B)  Statistical analysis of the percentages of HIF1-α positive cells. At day 7 and 21, COLHFV had significantly less 
hypoxic cells than all other scaffolds. *p<0.05.
Chapter 5 Increased angiogenesis and blood vessel maturation in acellular 
collagen-heparin scaffolds containing both FGF2 and VEGF
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skin construct
Figure 3 Degree of wound contraction as analysed by the remaining wound area. A) Macroscopical images of the 
wound area at day 0 and day 14. B) Quantitative data of remaining wound area. Values are mean ± SD (n=4). At 
day 7, a significant difference was found between the untreated wound versus the double-layered skin construct 
(p < 0.05*). At day 14, the double layered skin construct was found to have significantly less contraction than Inte-
graDRT and the untreated wound (p<0.008^ and p<0.002#, respectively).
Figure 4 Histological images of the centre of the wound area at day 112. 
A) Haematoxylin & eosin staining (HE), B) Elastic Masson’s staining (EM), C) phase-contrast (PH) of the double-layered 
skin construct, IntegraDRT and untreated wound compared to normal skin. 
A) a closed epidermis was present in all cases and no differences were found in the number of cell layers. Rete ridge 
structures were absent. The dermis of the double-layered skin construct, IntegraDRT and the untreated wound showed 
higher numbers of cells than the normal skin (cells are blue). B) In the double-layered skin construct and the untreated 
wound, hair follicle-like and gland-like structures (arrows) were observed (also visible in C). Mature collagen fibres 
stain red, whereas the newly formed fibres are light blue. C) Phase contrast microscopy revealed that collagen fibres 
were more randomly oriented in the double-layered skin construct and untreated wound than in IntegraDRT. Bar in A 
is 25 µm, bar in B and C is 100 µm.
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